var title_f6_1_6160="Seldinger cricothyrotomy step 6";
var content_f6_1_6160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Seldinger cricothyrotomy technique: Step 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 446px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG+AdkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiigkDqaACimGRR3pPOSp5l3HZklFReetKJlPejnj3CzJKKQOD3pc07iCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU15FQcmknkEUMkjfdVSx/CuevNQMshWI5P16VjWqqmi4Q5jWmvAOh4qk98zHCjNU48sMucmnGRF6cn2rzpV5yN1BIm8+ZumKDI/rVcysfuqfxpu5u5ArPmfVlWJzK/rTRO4P3qi3H1FJnPpS5mFi2t46jnmpI9TAbDHH1rOK5+6SPpUTs6/6xA6+o61aqzXUOVM6a3vEk71bBzXHxSlPmgfI/uk1u6JdtcxSh/vI+MH0wP/AK9duHxDm+WRhUp21Rp0UmaM12GQtFJmlzQAUUZooAKKKKACiijNABRRmjNABRSZpc0AFFGaM0AFFJmjNAC0UmaXNABRRmkzQAtFGaM0AFFGaTJoAWikzRmgBaKbuPpS7qAFopM0ZoAWijNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBl+JbgQaVIv8UxES/j1/TNc9EVijUDlj+ZrR8blltLRwMqJcH64OKwo5vJQO/zOegrzcW252OmkvdNMKWGZDgegpQ6qMRrmq1uJJiGlOB/dFX0j4rkNSD943tR5RPUmrQTFGKNRFTyR6mgxmrezPamGOgZSdWB4Yionmkj+8Nw9RV94sVXkhzTAg+Sb5o22vV/w9JL/azR9B5Z3++OhrInRoTujOD6Vf8ADzvPrEDLkbVbf9Mf44rah/ERM/hZ2NLiiivWOMKKKKACijNGaACikzSZoAdmkpM0maAHZpM00mjNIdh2aM00GnUALSZoooAM0ZopKAFzS5ptLTAKKKKAFopKKQC0U3NLTAWkoooAKKTNLSAKKTNGaAHClpmadTELQKSloAKKKKACiiigAooooAKKKKACiiigAooooA5nx0rfYrWQZ2JLz+RxXP6ZEZm8yTJ9Pauu8WyBNCnBAJcqgz9RXN6acRAV52L0kdNJ+6aEQAGBVpOlVouTVtR8orlsW2KRSAYpW4FNQ5qrCHYpDThSGlYBtNdARxSE4NSKaQzNu4sqeKpafetp1+suMp91x6rW3NHuFYuoWpJ3L1qoycXdD30Z3cUiyRq6EMrDII7inZrmPCmokf6DOeRkxE+ncV0pNetTmpxujklHldh1Jmm5oqhDs0hNJmkzQFh2aTNNyKaXFK47D6QmozIKYZRRcdibNANVzMPWm+ePWp5kPlZbzShqp/aB60faB60cyDlZd3UZql9oHrR9oHrT5kLlZdzSZqn9pHrR9pHrRzIOVl3NGapC5HrT1uB60cyDlZbzRVYTD1p4lHrTuKxNS1FvFKGoCxJRTQaWmIWm0v40hoASjNBpppDHZopuaXNAC05TTc0A0wJBS0gpaZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBheNF3aLu/uyof1x/WudsT8orqPFo/4p+69tp/8eFcjpz5UV5+LXvI6aPwm3b1cXpVG2PSrq8iuYpjZOhpkRycVI44qGL79AFkUhFPUdKUinYVys4pUPanOOKiT71TYZMeRVO5Uc1cFQXC5GRQxowZw9vOssZwysGU+hrstKv0v7NZlwG6Ov8AdNc5PEJFINQaXcNpt9lifJk+Vx/I1vQq8js9iZx5kdrupC9U2uFxkMCKhkuwO9dzmkZKDZfaXFRNOKypr4DvVKXUBz81ZuqkaRpNm61yB3qJ7sDvXOSaj71Wk1A/3qyeIRqqDOke9A71A9971zT3x/vVA96T3rJ4g1WHOla/96YdQ965g3Z9aabpvWoddlqgdMdQ96b/AGh71zJuSe9NNw3rU+3ZXsEdOdR96P7S965fz29aPPb1NL27D2COo/tL3pRqPvXLee3rSidvU0/bsPYI6oah71Kl/wC9ckLlh3qRbs+tNYhkugdct/71Ml+PWuPW7b1qRb0jvVrEEugdml6D3qwl2D3ri478j+KrUWof7VaxxBk8OdgtwD3qUTA1ysWof7VW474f3q1jWTMnRZ0QkFLvFYqXgPep0uge9aKomZum0am6iqST571Msme9UpXJcbE1KKYGp2aoQ6lpKUUxD1p1ItLTJCiiigAooooAK5bW9K8RQ6rJqfhzVo3Em3zdN1AEwNgAZR1G6M4HuCa6migDldI8a2dxqa6TrNvPoust922vMBZveKQfLIPoc+1dVVDXNG0/XdPex1e0iurZ+qOOh9VPVSOxGCK5Q2niLwfGraZJceI9FT71pOwN5AvrG/AkA/ut83AAJoA7qisfRPEml61pcl/Y3SmGLImWQFHhYdVdTypHoayW1+51GaRbJhb2wztfALsPU54H0xmqjFyA66ivNbLxreadqDR6nm6si2N4UCRPfjAI9uv8q9Dsbu3v7WO5s5UmhcZV1PH+fanOm4bgU/Eyb9BvR6Ju/I5/pXE2BwBivRLqJZ7aWKT7joVP0IrzvSv3kcbEckc/WvOxi2Z0UXo0bduDxWnHGdtUYQFxmtBJ124rmppPcqTZDIMCoY+HqaWQE1EuM9altJjRYU1MEJWoEZQRV1JE21rTSe5MilKuKrE4er85U9KouPmqJqz0HElU5FDKSKdCvQVa8viiMOZA3YxpF2tVW6h8xeOta13F3FU1Qk4NZyTTLTuZkV40CeU5OF+6fb0qKXUCe9X77TzIhK9a5a6EkMhSQEEVbnJLU3oqMtC7Lek96qvdEnrVNnJphY1i5tnUoJFlpye9RmUnvUJNFQ2VykhkPrTN5zSU3vSGPyfWlH1pFGakVapCGgU8LT1WnbaYhm2jbT6KBDNtNIqXFNIoGRUnSnMKZmkx3HBqXeajpc1IyQSGpEmPrVegGncLF5LgjvViO7I71lA04MRVKbRLgmbkd8R3q1Ff9Oa5sSGpFmI71qqrRnKkmddBfD1rQhvAe9cRHdkd6txagRjmuiFcwnQO6hnDd6tIwNcZa6ngjmtuy1BXxkiuqFRM5Z0WjdFLioYJQ44NWByK3RzvQcKWkpaZIUUUUAFFFFABRRRQAUUUUAeMfF+ybU9VePw+YrLU1CJcXcbFDICRlX2/f2gDGeh7jFTaYLbw7oFvp1rIXkVNm5my3uSfUnJrI8U381jr2pRSoRMLhyc9wSSD9MEVzaasxnzKTya9CFL3VYR3SWq3URJwSahsL/UvDN4ZrFi9uTmS3bOx/wDA+9U9I1IHGG4rfzHdRc4Joemj2A7Wy8R2WsaDdXVlKBLHCxeFjh4zg9R/XpXP6fbiKGMjgqNp9/Q1xzafJbanFNbu0eW2vtOMqeoPtXcWj7ht9q8XMYqEklsdFHZkzSNjApylvWlEJzUgjwK8zmsbjNzjvmnq/rUb8VHv5xRuBYaRu1N86Ud6RATUnl0r2ARZpM85qUPnk9aYFxSE80XuA/z2U8U8XrAc1CQT0ppBzyKpTa2FZMsfaQ/WggHkVAFHWnqSoNHM+oWLKMMYNYmu2SzxsQAG6qatvMytxVW5uMjBFac6asxRvF3RxzAqxVhgjg02tHWYQsqzL0fr9azq5noepCXNG4UopKcBUlCgU5Y/WlUVIoqkS2IqgU+nBaeFqrE3I8UoFShKcEp2FchwfSjFT7KNlOwiDFBHtUxSm7aVgK7pULJg1bZfWoXGKTRSZDikp7CmGoZaE70tFFIYnelzTaKAHE03dSE00niqHYUyYpPPI71G1ROapMdi2l2VxzzV+01MoRlq59n5phmK961jNomVNM9G0zXFwNzfrXRWGsQTELvGfrXjMV8yMOauWOrvHPwT1rojiXE46mEUtj3BJFcZUg0+uA0jxIg2q78111nqCToCCDXbCtGZ59SjKDNGimLIDTwc1qYhRRRQAUUUUAFFFFAHNeMPCNl4kh3SfuL1FxHOo/Rh3FeD+ItCvdFvntb+IxyDlW/hceqnuK+naz9b0ey1qya11CFZEP3Wx8yH1U9jXRRruno9hNHzNY3klrIAelddpWqblBDVB418E3vh+RpADcWBPyzqPu+zDsf0P6Vy1vPJaycE4ru92oroWx6dFOk+3+9mt7TDlzXnmg33n3cCBuS3SvRNKHzmvBzRWml5HVQ2ZuKg2ZqKTgVY6IKpztgGvKkjVFO4kxVeOTc1QXs+Cear6VcrdTSqmT5Z2k+9VbQZ0duPlFT4pkCEIKeazYEcjYqDdzSztUKHJppAXEoYChOlBpAMPHShc45pHOKVDk0wI5I+4qrLGG4IrRI4qnN8pNCAxtUgzZuP7vzCsCuouD5qunqpFcv2qZnZh3dNBTlptOFQdDJEqVRUS1KlWiGTKKkUVGhqUVZA4ClxTc0uRTEOAp22owaXdTuApFMYUpamFqQDHFQOKmY5qJqllIiNRkVKajaoZaG0Uh60VJQlITSmmmgYhNMY0rVGx5pjQMaic0MeaY54qkWkRMarytU0h61Vc5qkBGT3p1rlpqa/C1Y01MtmmyWPmmeG5XBxxmuk0LXpI2CscgVxurTbtTREP3Rg1paYhyDVRk4mM4KS1PYdK1MTouT1regO5N3Y15dot1IbqOGLLMxCgDua9ShTy4kT+6MV6WHqOaPJxNNU2PooorpOYKKKKACiiigAooooAbLGk0bRyorxuMMrDII9CK8m8cfDd0Ml74fTfFjc9rnLL/ueo9uvpmvW6KunUlTd0B8zeG0aLX7VGBGHIIPbg167phw/PrV3xX4U0+4mOsRIYL2H52MYGJf94evv/Osywf5x9a48yqKpOLXY6KPws6FzhKy7yTCmr8j/ALkVi3z8GvNe5qjA1a78sMfQZq54ItyNOSVvvSsZD+J/wrn9dLPIkYOPMcJn6mu50C3+yQpanJjA/dseo9jWj2sN7G2oxHVeVsZqw5wmKpTtgGsZbiRTuZQDzSWrh24rM1KYqxxTPCFxLeNM8mNquVXHoKrl0GdQowKRulObimt0qGBUmbBpYGyaiuG5NJaPmTFOwGl0WqVx1NW3OBVC4brStqBRIxNXNyDEjjsCa6I583PpXOMdzE+pzSqdDqw3USlFFArNHUSLTwajBpwaqJsTqaeHqsGpd/vTuTylnfSb6rb/AHoL+9PmHylnf70u/wB6qb/ejzKOYOUt7s0mareb70ok96OYXKTE1Gw5pu+jfmlcfKIajapCaiY0hoYetGaQmkqShTTSRQxqMmgaFY1E3rSseaYxqi0hpqNqkNRP1plEMnSqrdasyd6rNxVITI5T2qWS8WygwOZCOB6VCg3yc9BVC9t55bosQfLY4Ddqdu5m2S6fE887SvyWPWuogVYIgfaqGmW6RR5P3VFdV4Q0Ntev/MmDLp8J+c9N5/uj+vtTUXUlyxM5yUFzS2Oi+HujNj+1LpcbgRCpH5t/QfjXdUiKqIqooVVGAAMAClr2KVNU48qPEq1HUlzMKKKK0MwooooAKKKKACiiigAooooApa0CdIvMDJ8pj+lcDYyfPXpMiCSNkYZVgQR7GvKZvM0vUJba6BDRnGfUdiK4sXG9mdFF7o6Uzgw4zWPfzDB5pFvEdPlcVmanchUYZ9zXElqbWM4wnUtZtrZCQFPmOR2x0/WvRLdS9pG7DEi8HHqK5TwVZMUlv5V+ac4TPZR0rsYcJEy++acpdAY6V81n3km1DVmV8VnXjgoRWa1YHOa3c+XbzSf3QcfWtvwNaGDS4iw5Ybj9TXMa/wDv7i0s0+9LJub6CvRNLgFvYovotbdAlsLKfmqvM+AamlPJrPu3wprDdgU7mfk80aDdJeMzRnIViv4is7UJvKtppT0RS35CpvAcJTTI2bqRuP41qloD2OjmOKz7l8Zq7cNgmsq8PWo6giB5MRTN/dUmudBrYuG26fcN7YrDD8VFTc7MMtGyalzUBlAqJ7gDvWZ0FssKYZQO9Zst8o71Sm1IDODVqLYG6ZwKja6UdxXMyamexqu9+x7mqUGI6o3i/wB4UC8U/wAVci125B5NOF23rT5BnVm7HrQLtf71cqbtvWgXbetHII60XAP8VSLL71yaXzDvVhNUIHJpcjA6hZfenhx61zKasO9WodSVu9S4sZvbvemtWfFdq3erCzg1IWJqKYsgNKWFIdhGphpWakNMZGRTDUpqJqaKQ01G1PNQyHFMogmbAqpI2BU0rZNVj8zhatENlm3jPklsda1QifY1UgdKigRBb7TUc0wRNuelS9SSXTbWfULyCxtV3SyNgeg9SfYda9w0bTodJ02Gztx8qDlscs3cmuX+GmhGysDqV0uLm6X5AeqR/wD1+v0xXbV6mFo8i5nuzyMZX55ci2QUUUV1nGFFFFABRRRQAUUUUAFFFFABRRRQAVR1XSrPVIvLvIQ+PusOGX6Gr1FJpPRgnbY4S88COjk6fdjZ/dm4I/ED+lUrrwbJDp9xNqFwu1V+7GSSecdT0r0iqesW7XemXMKDLsnyj1I5H8qxlQjZtI1jVlszmdLEYtkSLAVRgAdqtOcCudsrh7KcrICozgg8EGtsXMUyZRwa8mSaZ0kM79aybqQs2BVu8lAyAawNbvDa2TsvMr/Ig9zVRQIh0GM6l4nlm6xw/u1P869If5YgB6VzHgfTPsVgjOP3jfMxPqa6OduDVSYnqypM2M1l3jcVcuH5rOnbccVEUMwPEcuzTvKH352EY/Hr+ldX4cgEOnqMYwMVxt6ftviO3t15S3G5v94139soitAB6Vo9EDIJzljWbe8Ka0JDyaz705GBWaAyNVkEWkOTxuYD+v8ASuZe7C960vHNyLezs4AfmZi5H0GP61w8tyzd6HG7O6hpA2ptRA6Gs+fUWbODWazk9TTaagkbXJ5Ll3PWoixPU02jFWITdRuo2mnBaAEFOzRtpwWkA0GlpQDQaAGEmmFj608imkUwE3GnLIw70wiimIuRXjp0NXoNUYY3GsWlyalxTHc6mHUlPerSXisOCK45ZGHepkuWXuah0x3OxWYGniQetctBqDDGTV6PUAR1qHBjubRcUwsKzheA/wAVBuge9LlKuXmYVWlaoDcZ70hmBHWmkFxspwCaXS7G81G5KWNvJO6jcQi5wKq3U3GAa9l+E+kHT/DgupkAmvD5mcc7P4R/M/jXRRpe0lY58RW9lG557F4f8QTHbHpV2D/toUH5nFdV4Y+Hs5mhutddVVTu+zJyT7Men4CvTqK7YYSEXd6nnTxtSSstAAAAAGAKKKK6jjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwfEmhi/Qz2wUXI6joHH+Nefzx3NvKyjcjKcFTwRXr1UL/SbO/bdcRfOON6nBrmq0ObWO5tCry6M8taecKWkbCjkk1n2bnVtUSRh/okH3Sf4m9a9D8R+E7KXSJ/IjlMq4b755A6jH0rhJZltgscCBEXoBXLOm6ejN4TUtj0HT8LbKBRcvxXO6JrimMRzcY6Gtae4SRcqwNczT6jsV53rMu50gikmkOEQEmrU0nBrltXnbULsWMJ/cqQZmH8quKGXPCVs0skl5KPnncv9B2Fdq/EYFZOhwLHGijgAAVvvGCtN+8S3qZE7bap/fkq7fJtzWTJdR2sFxczNiKFC7H0AGalLoM4Dx1d/aNeeNT8kCiMfXqf5/pXO1NNcG9mkuSwbzWLkj3NMCH0qttGejBWikhmKMVJsNPWPNK5REFp4jJqdYvapBGQKVxlURU4R1ZKUCP2pXAr7fajbVkp7U1kouBX200rU5Sk2GncCApTSlWtntQUFFxFQrTSlWzHSGOncCmVNNq6YqjaKncCtRUpjpvl0XENzShiOlLso2GgByysO9SCZz3qMJUgFIZIsjdzUgn7VWY8VNZQPcTxxRjLyMFUepNKwXNzwfokviHXYbYA/Z1O+dhxtQHn8T0FfREMaQxJFEoSNFCqo6ADgCsbwj4ftfD2mLb243SvhppT1dv8AD0Fbh4FenQpezjrueNia3tZabIKKKK3OcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvOvHWl21tObmHaivy69gfUV6FM+yMmuK8VQfbLaVT3FcuJmkuVm1FO9zgFdCP3UqMPZqfHqD2/LXChfQtVPTrK1uA9tPGBdQ8EdNy9jWnBo9ohBWMbh681yuy3Okhl1G91LENmHjj/ilIwT9K09P09LS3wBljySepPrU0Maw4wuBVkygrUN9gKpvZLVwVJwK1bbX1dQHODWRdKrg1nNHhvlPNJahY6a6vBOvyHrXGfEDU0tNIGnK48+7+8AeQnf8AM8fnV24vRp1s0szf7q9ya8i1rUbq81m4ub4MJGbhT/CvYD2xXo5dhva1eZ7LUxrS5Y2Q6CSbTpd6AvCfvJ/h7109lJBewCWBty9x3U+hrAs5o51CsRzSvBcadcC4tDj1HZh6GvTxuAjiPejpL8xYbFOlo9UdEYuelPSH2o0m+g1KM7PkmX78Z6j/ABFaSQgHpXzFSMqcnGas0ezGUZrmi9CO1sDMp2Y3DoO5oa3IJBGDVnLxMrRg8c8daup5d7HuUgS/zrJtrUd9bGN9n9qUW/tWk8RRsOMU+KON8qzbX/hz0NHMMzDb+1MNt7Vrm2kBwYzQLWQ9QB9SKOYDHFt7Uv2X2rYNm4GSVx9aQWsh6AH6EUcwjINr7VE9vjtW8LUr802EQdeeaqTGF5CIg2B7E0KQGK0RFNWJmYBQST2FbBtsjL/Ivqf8KqysATHbqcnr3J/wqk77A3YqywGLG4qSewOcVCVFWfKccvjmkZKrYE7oqGMGmmKrRXHagrRcCgyYo21akSoiKdxEJFNJqQoWPFWYLJm5bpTAqJGXPTiuh8F2pm8U6XHjOZ1JA9Acn+VVPKVFwBW/8NUMnjmxwMhRIx9vkNVT96aRFV2g35HuqjFL9aKaCTIePlH617B4I6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAp374XFYd0gkRge9amoNliKxLqfYQB1NeTiZc0zqpqyPO/FFjJb3oubYlJkOVYfyPtVjSNTh1CPGRHdr9+M+vqPauv1K0huLf96BuNcPrPhoo3mxZV+q7eopRmpKzNdzZZmxgimbjXLJb69D8qXMxA/vfN/Okkg8QTcedNj/ZGP5U+VdwszpZX2qWkcIo6knFYd/4gtLclbUfaJfb7o/GoYvC+o3eDcNNIf8AbYmtnTfAjAgzAAVScI7u4WOTYXeq3AluDnHRV6LVjUPD0F5abJ0O4D5XH3lr1Gy8OW1tGFCAn1pl3oSsp2CiOIcZJx0sJpNWPnTVNMutGuB5nzRk/JIOjf4H2rS0rU0mTyrjBB/SvTdb8Ou0bpLCJIj1UjIry/xD4duNKkM9srvbdT3Mf19vevoMJjo11yT0Zx1KTjqtie7sZLaZbuycqy8qw/rW/oOspqGYZlEV2o5Tsw9R/hXK6TqpXEcxyp4INXL+yDhbmzYhlOQyHBU1eLwcMTG0tH0ZWHxEqLutux3A4II7c0kkTQyNPbjn7xX1/wDr0zwLd2Wvx/YL24Nrq6cAMBtnHqv+16j8R7dc/hi6QYjeKQAY6kGvmalGVGTp1Een7eE7SizCguIrpAj9+meoPpTX06MtlWIq7qHh29j3SxwMHPdBuB+oFVFS/iYoYw+0cndj+dcsqcl8JtGrFkksL+SihidvWmLB64H1NO+y3s7YZ0iXGeDuNH9ksYQzXDk+4FCoy6j9rFBO0TRiLzU3D9aZHCOMbfrml/sVSBmVuf8AZFIdJKkhbiQALngCn7Fh7VE08YMOGZfzrLZfs0ZBxjrmrLabNgEXJbIz8yCoxYgMPMZpDnjd0/LpTjSYe1SKaiS5KkkiInAPc1NFAsSybFAGTV8RbXRQOmTUW39031reKUdjFyctzPmjBaojFV505puysW9TqirJGe0FIIK0NlGylcZmPbk00WRJrV2D0pQuKOYCnFZogBPWpSoA4qY0xhxSuBRuOBXTfCFPN8YyOf8AlnbO36qP61zV0K7H4KoTrepSbeFgC7vTLf8A1q6cPrNGGJdqUj1+iiivXPDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFBoAxtUYKxrnC/m3uD0Fb+tArICehrmx8l6fcV49b42dlP4SWVw9wST8iD9apwt9puS55UHCio7iUpbTNnksan0pcKgqNkWatvaRsMsgqylrEvRBTosBalBqBCLGo6AVIFpKM1asSO2ijZSA06noIz4bzT726uLSK5hkuYDtlh3Den1Xrj3rO1Xw9FcAtGoBPavLvj/o7Werafr1pujM48mV0OCJF5U59SuR/wGub8IeNvGst9Dp+lXst/LJwsNwFkzj/AGm5Ax71j7fklytH1lDhh4vBxxmGqqzWqlpZrfX/ADS0Nbxn8Prmy8290qMtGuWkgXqvuvqPb8q5PR9UMEgWTlTwQa+kfD8OtSWIbxJ/Z4uSOEs0YBfqWJyfoMVwvxF+G6X4l1LQIxHffekgBwsvqR6N+h+tfQ4LM7pU6/3/AOZ8hiMP7ObUWnbtt8jzy+tRLsu7FykiEMCpwVI7ivV/hx41TXUTTdRIj1eNep4E4Hcf7XqPxHt4lp9/NYXDQXCsrKSrI4wQR1BFa0qEvHf6dI0VxEwkRkOCrDkEV6GKwsMRHll8mc0JuL0PpUsRwy1QvrW3uB+9TnpuHBFYPw78Yp4psHhvFSPVbYfvUUYDr2cf1HY/UV08i5yK+Wr0p0Z8kuh2wkmro5+bSpEJaFhIgGMd6pGMquGBBB5Bro5VZQSp5rLnvojJ5V7Hg9m6H86mM2aqbM1k+dR7GmunDf7tabWaSlXtZQw/utwapzxtGSsilTjoatNMtSuUNuAP9yquz5k/3qus37xB2KGocDKkf3jTHchI/ej6VUuJY7dSsmcluwzgepq9jLA/WsrUzusXk/imfA+g4FIZKVppWpB0A9qDXIdhCVppWpjTDQMjIplSNUZpgIaYx9KdTT0NMCjdV6F8EosQavNn7zxr+QY/1rz266V6Z8FowNF1CXP3rnbj6KP8a68Iv3iOXGO1JnolFFFeqeMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBXvbRLuIo5I9CO1clrGkX1oVnhT7TGp5Mf3gPp/hmu1orKpRjU1ZcZuOx5FcXKvFMoYHD5rTsZQMYNdpreg2erxkTqY5sYEseAw+vqK4G6t59LvmtrkfMvRh0cdiK4qtBwXkdEKikdLbTbgKtqeKwba4BAwa07ecEc1xtFl4GnioVbPSnA0JiaJqUVGDTga0TJscf8AGHTV1HwBqXy5ktgtwh9Cp5/8dLfnXnd/8LL6x8Kabq2jSTDXYIxPcQqSGJzuGz0ZeBjvjjnr7pKiSxtHKqujghlYZBHoadmonSjN3Z7eAz7E4CjGjR2UnJ32aaSs/Lc86+GPxEi8Roum6ttg1iNcAnhbjHUgdm9R+I9B6Ea8v+KHgA6hIdc8OKYdWiPmPHEdvnEc7lx0cfr9evSfDvU9Z1Hw1DN4htvIu8lVJG1pFHRmX+E9frjPGazjOSfLL7zTM8NhKtJY7BNRTdpQb1i/Luv68lR+IXgK18SRNd2ey21ZRxJjCy+z/wCP868Skj1DQb1rTUreW3lU8rIMZHqOxHuK+ot1Z+t6Pp+t2bWup20c8R6bh8yn1U9QfpXrYPM5UFyT1j+KPnZ0VLVbngWn302n38Gq6RJsuYjkr2cd1PqDXvnh7WbbXtKgv7Q4SQYZCeY2HVT7j/69eU698M9R0uR7jw/N9ttxz5EhAlA9AejfofaqvgHxI3h7XHt75ZILW4YJcRSKVML9nwenofb6V3YynTx1L2lF3kvv9DOm3TdpHugQN1FQ3OnxTxlZY1kX3HSpUfFSpIK8GNnudDucreaJcW7F9NmI/wCmch/kaqDWbi2Plavasq9NzrlT+NdzhHHIqCa1R1IIDKeoIyDVuL9QUu5yBj06+2PbXHksp4B5B9qjk024jBKBZVzkGM5/StW+8MWk7F4UNvJ6xHA/LpWa+matY5NvIlwg7Z2t/hU3NFIxLjzIoJFIKyglACMHJ4FUb8brq1gX7sfzEfSukOuxeYtvqtttcHgSp39QalfQ9PvJDc2srxSMuME7l/xok2kaRmr6nOZpKv6jpV1Y/NIgeP8AvpyP/rVn1znamnqhDTGanNUZoGMY0mKfto20xkVMc8VKwqGTgUxlK56GvVvg2gXwrMwHLXTk/wDfK15RcH5TXrPwdGPCT573L/yWu3B/GceO/hnc0UUV6Z44UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVleIdHi1e02H5J0yYpPQ+h9q1aKTSasxp21R5MRPYXT290hSRDgg/wAx7Vo293wMGu41jSLXVodlyhDr9yVeGX6H+lcRqXhvU9PYtApu4f70Q+YfVf8ADNcFXDtao6YVU9zRgusgc1ejlDCuSt7p1Yq+QynBB4INadreDIBNckoGh0CmnjmqcE4YDmrcbA1KEx4HNKw4py805x8ta8uhNyhcyBFJNYzamPO2pzUniad4bC5dD8yoSPyrmrZ2t7WCG3+a6mXO487B3aoUS0dNJqSxFVkYB26L3/KpEvge9YAgt7Nf306mY8tk7nP9agN2u790XP1XFPlQ7HVfaxjrWP4g0fS9fhZNRtkd9pVZl+WRPo364PHtVSO6k/iBxT/tJ9acbwd4uzE1fcg8Ha7cJJPoOsEf2nYABX6C5g6JKP5H0Oa6yO6B71574rglmhg1LT1zqunt5sIHWVf44j7MP1xWrpGuwanp8F5avmKVcj1U9wfcU5QT95CWmh2iXPoalFxmuYjv+etW470HvUWaHY31lpwZT1FZcVwoALOozwMnGTU6TAnrS5mKw3VNNtdQgaO4iV1Pr1H0rjb7Tr7w6/2i0eS5sB95Ty0Y/qK7tTmntEHQ8Zz2oUmO9jn9G1WDUIAUYHPUGodU8OxTq0tliKTrs/hP+FZ/iDQptPna/wBHUheskC9D7gf0q/4e11LyJQ5+boQaJRvqi4ycdYnJ3MEtvM0U6Mkg6g1GBXo9/YW+pwbJVBI+646r9K4jU9Nm06YpKMofuuBw3/16yaOynWU9OpQ20EU/FIRSNiBxVeXpVtxxVOfoapAULjlWr1z4Qbv+ER+bp9ofH0wK8hnbrXsXwjH/ABR0fvNJ/Ou3B/GceO/hnZ0UUV6Z5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnPxau2spNJaBUDyGQudvLAbcAn05NYWj6hHeYVfklAztJ6/SrfxmuN2qaZb/wDPOFpP++jj/wBlrjbFirBlJDDkEdq8rEytUZ61CipUVfc9CguGQ962LO5DYBNczpd19uhw+BcIOcfxD1rQtpdkgB4rHSWqMJRcXZnUxtmpzytZlrNuAq8rcVUJdDNoxNetzNBInZlIrhoGniMivlJPukjrgdh7V6XeoGQ1xOtwBZRIo6nBqZyaTsb0LOSUjMHByOtTJcMPvAMPeoaUVzptbHe4p6NFu3u0llePaylfxFW9iN/Fj8KxdPOb249MitgdK6lscUoK+gjWuejg1zEdp/wj/icKWC6bq7nYM8R3WMkfRwCfqDXVDe0kcUCeZPK2yNM4yfr2AAJJ7AGuW8aXGnXllNpcbG9ujjF1krFDIDkNGo5bB7sTnnjBroo0pT9DCrJQ9Tone2hbbJcwI3o0gBqeMoy7kmjZfUOCK53w9421a60uJ43gtJEzFLFDbxqFdeGH3fWr0mvyXPGpWVje56s8IRx9HTBB961+qeZj7fyNOY/ab2MI6skSA8HPOea04Lkg8mueMcQtG1DR5ZtkPNxbykM8IP8AED/EnY8ZHU1dsbtLodQso6p6+4rmqUnB2ZvFqSujqra4DAc1fikBrlopih61o2t3kgZrG1tUJo22UOK4rxBoEttcPqGljDfekhH8XuPeuuilyAamO2QYPWmnfYS0OV8Oa3HcoFY4YcEGuiuLeG+t2jkUOjDoa5PxXobWrPqemKRKvzTRjo47ke9X/Cmr/bIBk5xQ0tyvNGJrOizacxcAvbk8MOo+tZJr1S7SOeBlZQQwwQe9ed63YfYrkhM+U33fb2rKUbM7KFbn0luZbVUuBwatPVefoaSOkx7nvXsPwfff4Q2/3Lh1/kf615BdDrXrXwZ/5FSf/r7f/wBBSu3B/GceO/hneUUUV6Z5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHhXxOuxdeNLpVOVgVIR+Ayf1JrIsu1VdUuBd61fXAORLO8gPsWJqzZ9q8Wq+aTZ79KPLFRNqymaCVJIzhlOa6iR1lgSeLowzXJRdBW7otwATbSfdf7vsayg7MzxEOZXRuadc5GCea24pAyg5rlMNBKfStiwucgAmtJLqjiNKdvkNctqqb94PQ10sp3LxWDqcRwTjrSjruNaO5zNFbNj4fmv2kZb2KEKfuGEs2D3zuHvWing6Aj99f3bZ6hAij/wBBJ/Wqhg6k1dWsdMsZTjocloo3CST++xNa4rft/CWlwqFAuWHvcOv/AKCRVlfDuljrbFv9+V2/ma7FhJdzjeKXY5cti11lo/8Aj4j09jGB1CswDkfgB+deaRH96K9Z1Gzh0zxDbPp1vDGxgO5MYWVScMrexB/ke1c5qfg77Rdu+hHLnLfYJ2CTKP8AZJO119wf1rrpw5IqJzTlzSucXasbDxIYjgW+oR+Yn/XZOG/Ndp98Gt89Ky/Euia+ttFs8P6ibi1mWeMrCz5IPI+UHOVLDr3rodK0bWb8jfpN1Zx9Wlul8pEHqS2P0qyC/wCCS58R2qKNySbklU8hkKncD7VmxACNGiYlR9xs9R2Oa6TSoLSz8y0srgXN1OPLnuo/9WkZ+8sZ6kn+90x05rb0HRtMl0WyeXTrN2aJSS0Cknj6VlVpe0VrmlOp7N3ORttWMZCXYLL/AHx1H19a2ba4gMbTpKJEQZwp5J9K35PDmjSddNtl/wBxNn8sVWXwnpMcnmW8MsUnqszkH2IJIxXNLCPozb28X0DR76S4jYyxLHg8YOciteM5PFYsn7ifYOAO1ado+5RXC1rc0LE43DnkV57pP/Er8T3loPljD5Qf7J5FejuN0ea868XKbPxVaXPRJowp+oP/ANcVSWtu4RO9jfKe1YniC2Fyuzv1B9DVvT7pZIlIPantCZrncfu1n6jTs7o87uI3hkZJFKsOoqnL0r0fW9ChvYMj93MB8r/0PtXn2oWstnO8M67XX8j7ik1Y76VVVF5mPdjg16p8F5N3hq7TH3Ltv1Ra8suxwa9J+CUwOlanB3SdX/76XH/stdeE/iGWNX7o9Jooor1DxgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKw/GupnSfDF9dI2Jdnlx/7zcD8s5/CtyvJvjFqhmvLfTI2/dwr5sgB6uemfoP/QqyrT5INm2Hp+0qJHm8Iy1alpWdbjmtK34rx5Huo04TxVyJipDKcEcg1Rg6VcjrMTOiikF7ah/+Wi8OB/OlhkMTe1Y1pdG2lDqR6EHoRWmzpcR+dbHcn8S91NbQlfRnBVp8rutjftbkSKATU01usq1zkM5jYYNalrqK8bjQ46mRPFDJbTCWL7wGCD0Yela8MqzRh0PB/T2qj9ugKckZrN0/U1j1V4c5ikOD7Hsa6sNV5HyvYxqQ5lc6SiiivROc5jxCP+J9Zn/pif8A0IV0NtawXcKpcwxyoOQHUEA+vNZHiO3K3Fpff8sospL/ALKnBDfQEc/XPat7TuFXHpQBBd6dFEv7qa9jHol3KAPoN2BXJ6/bx7DvM0xHI8+Z5cfTcTiu41DkVyOsx7lYUAY3h/m+H1rsPDn/ACL+m+9tGf8Ax0Vx2nJL55itQTcyAqnH3f8AaPsOv6dTXe2kCW1rDBEMJEgRfoBgUAS0UUUAYmsRbZRIKWylxjmr+ow+bbtgcgVz9rP5b7HPQ4ryq8OWbR103eJ08TbkNcr46043empNGMy277x9O9bkE4xwaZfFZYXRwGRgQwPQg1hzaopaHI6PfvHGquCMcV0NvqaDqa81u7/VPCurGzvrc32nOS1vKeH2egbuR0INbtnrmi3oBF1Jauf4J4yuPxGR+tU7M0cWdtNqkZTqM1zXioJPpcdwwAkWTap9QQeP0pVvNJgTe98s2OiQgsT/AJ965/VtSl1GbJXyoE4ji9B6n3qJWNaFOXNcxbroa6z4M3yweIb2zdsfaYdyj1ZT/gTXJXR61BpGoS6TrVrf2+d8EgbH94dx+IyK0oy5JJnRWhzwcT6ZoqGzuYry0hubdg8MqB0b1BFTV7J4IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUhOKA1AC0UUUAFFFFABRRVLV9St9JsXubpsIvAUdWPYCk2krsaTbsiDxFrEOi6c9xLhpD8sSf32/w9a8I1qeW8uprm4bdLKxdj7mt/xBq9xrV6bi4wqgbUjHRB/j71gXiZU15Nev7WWmx7OGw/so67szrYc1oQdaow8PgVfh61jI6UX4OlW06cVUh6VbjrMTIJoZnJINMs5LzTp/OjOR/Ep6MPetFaJk3wuo6kU0yHFMtLcw3MEdwpNuZBuCy8A/Q9DTS8yc7SR2I5qtpfihdN0RNNv9PhuPK3KPMl2hgSTyCp9ayJda05M/ZdIsYcnOAsj/yIr0vZQaTUjyuaaduU6JHnfgBsepq/p0KIxKHz7luNsZzj6+lcSNdbObfTowexS3z/AOhk1MPEHiBl2xCZF7BSkeP++VqOWkvikVy1ZbRPZ4wWUZ4OKmWIdzXiH27xFL96eUD/AG7hz/Wq93/a4VWlljIJwSdxx+Zro+t0r2TM/qtS12j3eTyFBEkiAdwxFZaxW1ic6dqVtBH/AM8JWDRj/d5BX8Dj2rwy4S6GAZ493YCME02OC8LYe68s/wDXJcfyqvrERfV5Hus2ps6/PLpP1F9/9hWZK0V2SJtR0y3Xv5c4lY/TO0D8jXkv2C6cZ+3fki/4U1rK7jGTfNj/AHR/hS+sx7D+ry7nt2k2+kWan7LdQPI/35GlDM31P9OlayGB+EkRvowNfOgN2h/4+XA9TGv+FPEd6y7luYnHqUFH1mIvq8j6L8pT3FRvFjoa8CsTrB3GGaNQvGRuXn8DVxdT8SwH5biVh6LO4H86X1unezZX1Wo1dI9rkU4I9RXK6hHGtyUf91MegbgN9D/SuEPijxLCQd9x+DK//oSmnt441Vk8u8t/OU9RNbqQfyIqak6NZfEEaVWn0OzWSaHhlYfhSi9ZvlOTntiuIg8SsWwIRCD/AAQ+ag/mwqHzdfu7mWRNSlt7dm+RABkD6kZrkqU1BX5kzanGU3a1jrvFr28ljaQybTN5gaNe/Q5P0rnHtouvlr+VNtbHyZGlmlknnb70kjFifxNWH6VzNnfShyqzKxRV4UAVDJVh6rSUjUoXPes8LmWtCcVVjX97VoGeo/CjXkjhOjXbkNuLW5PTnqv58j6mvTK+ebXdG6SRsVdSGVgcEGvZPB/iKPWrXypflvolHmL2Yf3hXfha6fuSPLxmHs/aR+Z0VFFFdxwBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUh5paQdaAAAUtFFABRRRQAUUGsbX/ENnokX+kMZJ2GVhT7x+voKmUlFXZUYubtEvanf2+m2b3N3IEjUfix9B6mvINf1m51q8Ms7ERAny4geEH+PvTde1i51q8M9wcIOEjB4Qf571nqK8rEYl1NFsevhsMqS5pbgBUFymVNWwtRTLxXImdZiqNstXIu1RSJiTNSRVoxF6E1cjOKpQ9qtIagGWhTxUKGpVpEsHjR+WRSfcUwwx/3F/KpaQ0CItqjoAKKcabUsoKHRZEKOMqetFKKEBStdKSZXMbEOGIBP1q3HZTQKRLD5g9cVJp5xGcf3j/Or63EidCcehrtTOJozPsdmY8PbMGzn7pqXybZBiK3OfXZVuTUnXrGp/Cqk2qzYO1Av0FMRm3GnTS5LIIovU9cVTjsYhdrEjsFKkkjuauXF1NMfmJqvaE/bos+/8qmTdmVFJtGnHGsUYRBhRQaeaaa4zsWhGRSbQeoBpxoFNDYqov8AdH5VIKaKWqJGtUTmpGNQsaYyJzVeQ1M9QPQMqSjmoIl/e/jVmQc0RR/PVAXoF4FWbeaazuEntZGilQ5VlODUcC8VMV4rO9mFr6HqHhXxTb6xGsNwyw344KE4D+6/4V0teDYeKRZI2KupBVgcEH1r0fwl4vjvRHZ6mRHd/dWTosn+B/z7V6mHxSl7s9zy8ThOX3obHZUUUV3HAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSMyoMscCgBajuJo7eJpZ5FjjUZLMcAVk6vrDW8RFpHuk/vOOB+Fed63e3t/J/pk7yAHIToo+g6VzVsSqe2rOmjhnU3dkb/iDxwQ0kGkKCOn2hh/6CP6muEmkknmaWZ2kkY5ZmOSTUhTmgJXlVK0qjvI9alShSVoojC1Iq04LTwtZXNBm2mSrkVYAprikBkTpzTY1q5OvJqFV5rS4E0a1YWoohxUwqWBKhqVTUK1KtAmSrQaRTTjTJIzTDUhphqWUhKBRQKkCPT7hI55IZGCurEjPcHmthCjDqDXN3Fs13dOyJvC/KafBBLHws88WPXkV2x1SOOWjOiaJSDlRVK6iXHAFVFN2u0C+iOeu5ahmE5BLXkf/AVqrEjZlxmobNM3uQc7VJqvKk0hwJJnHf8AhFT6XE1vI6OAC4B49qifwsunrJGiaQ0ppprkOwSgUvagU0IcKKBSGqERvUTVK1RNQMheoWqwwqFxQMrFctU8aYNCLk1OgptgTRCp9tMiHFS1mwI2Womjyas4pQmaaA6jw14untfLttTzNbjgS9XX6+o/X616DbzRXEKywOskbDIZTkGvILe33N0rqNBa5smzA5CE8ofun8K9HDYiS92WqPOxOHi/ejozu6Kht5xNGGxhu61MDmvRTuea1YKKKKYBRRRQAUUUUAFFFFABRRRQAGgUUd6AA1HIuQakNJSBGJqNrvU4FcbqtiQ5OK9HmjDCsXUbEPk4rkr0eZHXQrcrPOJINpPFQlea6PULAqSQKxZ4Sp6V5c4OJ6kJqRVxS4pSMUVmWFIelLQaAKky1BtwauuuaiKU0xjIxUwFNVafigBy1ItRrTxQIkFSCogaeDTJA0w080xqGNDaKDRUjF0wkBiODvP861hKpH72NW/CudF6tldGORWKt8wKjOM1fi1S0kH+uVf97iupbHJLR2L87223IgGazbidBnZDirH2m3YfLPEf+BCq91LAF/1sefrVIkpPM/PGKZAxa6jz1wajnuYVyfMU/wC7zUmnFZi0y52j5Rn9amekWXBXki8aaaWkrlOsDQKDQKpCHCkNLSGmIjNMNSGmEUiiMionXNTsKYRQBGq4qSNacFzUqLQA9BgU+kFOC5qRABmrNvCWI4pYICx6Vt2FkTjitadNyZnOaiFhaZI4rpdPtcAcU2wswMcVswRBRXpUaVjzatW4+GPaBU6jFIoxTq7ErHI2FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABSUtJQAhGahljDdqnIppFJoaZkXdkrg8Vzmo6XjOFrt2UGq09uHHSuepRUjop1nE8wurRoyeKpMpFeg32lh8kCudvdKZSSBXnVMO47HoU8QpbnPUA1amtXQ8iqzKQa5mmjoTTGkU3FPopDGbaMU80lAxuKcKKBQA8U4UwU4UyR1NNLSGgBhooNFIZXW2S6lYyEqQcAjtVoaU4A2mOQf7Sio7YYkfJ/iq8CcYDYrqi9Ecst2V/wCz8D5raHd64qvcW4XgpAnHpVidJT0c1m3AbPzEmruQQyWsPV5N2OwGKn04KolSPhBggf5+lU5AcVa0xSPNz7f1qKnwmlL4kXTTSacaYeK5UdQtKKSlpgKaQ0maSmIDSYpaKQxpHFMxzUhFCrk0ACrUqinRxk9qtwWrORxQk2JySK8cZY8Cr9rZM5HFaNlppJBIres9PC44rpp0G9zmqV0tjOsdO6fLW9aWYXHFWoLcKBxVtFAr0KdFRPPqVXIbDEFHSrAFIop4roSMGwFLQKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkIpaKAGEU0ipCKaRSGQvGDVOezVweK0KTAqHFMpSaOcu9IVwcCsG90YqSQDXoBQHtUMtsr9QKwnhoyN4YiUTy2exeMng1VaNh1FekXelo4Pyj8qxbzRupC1xTwrWx2wxKe5xpFFbVxpbqThTVGSzdT901zOm0dCqJlPFFStCw7GmFCO1RZl3G04Gk2mjBoAdSUUGmA00UUUgKVxFK9x5kLOu1cZX/AAqRHuwABLEx/wBtSDVux6MT/eNaP7gr88ddUdEkcstWzKDXu3OLc/8AAjVS5NyG/eLAPfJNbhFn3iFUrp4BnyowDVEmHKJ2B2Mpb/ZWr2lgi1G/7+47vrTXlY9+KmsR+6b/AHjUVfhNKXxE9NNOIpNprmOkbiin7DQEJ7UwI6KmELHtUiWrHsaEmxXRVAp4UnpWjDp7t/Ca0LfSGJGVNWqcmQ6sUYaQFj0q5b2DMRwa6a00cDGVrXt9NVQPlFdEMK3uc88Slscva6UTjIratNKC4yK24rVV7VaSIDtXXDDpHJPENlCCzVAOKtpEB2qcLRiulRSOdybEUYp4FAFPAqrEtiAU6ilpkhRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApDS0UAMIpmMVKRTSKVh3GZpcg0Fab0pDFIBqKSEMOlSg0tKwLQzJrJX7VRm0pWzwK6AimlB6VDppmkajRyU2jj0qlLox7Cu3MQPaomt1PasZYaLNY4iSODk0hvSoG0tx2rv2tFPaomsUPasnhUarFM8/fT3HaoWsnHavQX05D2qB9LQ/w1m8IaLFHAtaP6Uw27jtXeNpSelRnSEP8ADUfVWWsUjz0O9pMyvGzITuBAzjNWVvIW4yR/vAiu1bQ42OWXmm/8I/Cf4f0rVUGZOsmzi3mixwyfnVWV1bpj8K74+HYP7g/KnJ4egB+4Pyp+xZPtUec+S7n5EYn6Vo2enypCNw5J3Gu8j0WFOiCphpiAdKUsO5aFRrqOpw62LntUqaa57V2w05B/DUiWCjtSWFG8UcamlOe1WY9HJI4rr0s1HapktlHatFhUZvFM5WHRvUVeh0hRjgV0KwqO1O2AVrGhFGTryZlQ6ci44FXI7RV7VaxSitVBIzc2xiRAdqlCigU4CrsRcQClpcUuKYhMUoFLilpiEApaKKYBS0CigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJS0UANIppWpKKVgIcUVNRRYdyKkqaiiwXIaMVNRRYLkWKQipqKLBcgK+1JtHpViiiwXK3lj0pPLHpVqilyj5iqIx6Uvlj0qzRRyi5it5Y9KNntVminYLlXZ7UbParVFLlC5U2e1OCe1WaKOUfMV9uO1Lip6KdhXIMUmKsUUWC5XxSgVPRRYLkQFKBUlFFguMpadRRYQlFLRTASilooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Remove the tissue dilator and guidewire as a unit, leaving the airway catheter in the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6160=[""].join("\n");
var outline_f6_1_6160=null;
var title_f6_1_6161="Distal radius central reference point";
var content_f6_1_6161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal radius central reference point",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The central reference point (CRP) lies midway between the palmar ulnar corner and the dorsal ulnar corner of the distal radius. Use of the CRP provides more accurate measurements of radial inclination, radial height, and ulnar variance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6161=[""].join("\n");
var outline_f6_1_6161=null;
var title_f6_1_6162="Radiograph osteitis pubis flamingo views";
var content_f6_1_6162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Radiograph of flamingo views showing pelvic instability",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flamingo stress views, obtained with the patient alternately weight-bearing on each leg, shows significant displacement at the symphysis pubis (&gt;2 mm). Note the underlying degenerative changes which include a prominent subchondral cyst superiorly on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Read JW. Groin disruption injury. Sports Medicine Imaging. For more information, visit",
"     <a href=\"file://www.sportsmedicineimaging.com/Home.html\" target=\"_blank\">",
"      file://www.sportsmedicineimaging.com/Home.html",
"     </a>",
"     . Copyright &copy; 2009 SportsMedicineImaging.com. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6162=[""].join("\n");
var outline_f6_1_6162=null;
var title_f6_1_6163="Fusobacterium nucleatum";
var content_f6_1_6163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusobacterium nucleatum morphology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD27VtWi0W5Q3e2OzkIUSeje9O1C4N3NDaWbg+YNzMp6LWJplg+o2E134jbfHIMrAeimq3g3Sr3wvdXlxqdwZ7K6kzCW6wr2XPpQB1WkTkmW0lOZYTjJ7j1rSIOelYOvajYaDe22p3VxHFbykRsxPBJ6VCPFsdy5XTreS5BOFKjg++aAOl2nI6bahlvLeDgtuf+6vJqi1tf38ai5m+zxnqqdadLbLZxFLNN0uOZH5xQBQ1DXr938iwssSHhS56++KszWjRRW82rzbi5A2nhQTVnQoHSCS6mAlmYnBP9K8/+PGo3T+GYIrW8NjO1wm0svv60AetBEEaCNAAOlc/428YWngrRpdQ1NXaFRhQoySewAqhaXesJ4VsntbqC6vWhXGOVJx1rlfEfh29n1PSL7xpeLc25lA+yoMRhu31oA0/APj+Xxdptzc20T2rnPMwxx2xWhM8Fn4Iuormdbm8u9wGDncx/pW3fWdneW/2Ox05I0ddpdRtwPwryz4gaNH8NtKj1bR7ye+1CE/u7KdjIGyew9qAONW01Lwsbea8lOk2RfE1v0Ewz1FfQnhbX9J1bTLcaG6SW4UDcnTNfOWg+KtV+IupND4ysEisVHzIqFWUe2a9s+Dmjado2kznQ383T5JDsDHLJ2oA7DWC5tvIjBLScEjtXH3ngu41rStunatc6fPDISNjfK3PQj0rvnAyxOCQDVDQyfs0zLnO89KAOE/4SHxn4avVs9U0uC7suAs9vkZ+orTPxA8P31q8F7dR2d32jlYKc12kqpcxlLhdwI71xnizwD4d1eXTk1GwjlcSZ3gbSfqRQB1GiXcGo6XDcWsySIw4KtkGrMxEcyoTy1c3Do+n+HLP+ztKUoyklEDcLXN+I5/G1klldWEFtcQrKA4JO4qaAPSXiYkZqK9kiW0lhLAu6lQBXJajrevR+Ukll80mAFiOTW5oun3U6G4uwYGxkhjk0Acp8NvDMPhWyu5o8eZPcs0hx2JrvnC7QR3Ga8i8PeNZtZ8bah4ctLcm3guDul9QDXsDpsUKRyoxQBH1GaFxg7j3pAuTT9mcEDkUANK88dKQqD34qQgYx3pBgHA64oAZt54pjcnipDTHBBx60AGOBTSOT608DCnvSY6etADSMdetJ9eaceaTHpQAA7j6UuOhxSjv0oHT2zQA327UvTrTj0xiheAc9uKAG+dFF99gK57xl4jttGtEv4I5LiaMjKRjJNdH5EDHLICfemrp9ozsWiRieORQB434x+Ier2nijQrp7RYNKuQQTKOTmqdxaeLPGmuN/YF9NZaawy5OQv4V1XxY8MWF7e6GmoXIVY5sxRjjPtXpOjRwW2lRJaW4hXaBgDGfegDmvBHgPS/CcTS8XGoScyTNySa6pyW7cU1iGb/aFO6j0NADTt7cmkY+opwGRikzuJHagBnNQXF5Bbo3mZJ9AKtEZPApDFFICrqGB9aAOWlutTgvkeyiDWEn3mY8ofYVu21khQTSSGVyM5NNm05dpMVw0an+E9K4afxLf+GPF0en6rsbSLgZjucH5T/dNAHoZHQDgUgGBzSpNFdRJJbOrow4IPWkx60AJg5Heqmq3S2tuSMiRhhcc81PNOYTtRCznp7VXFuzkzTgO4+6vYUAcbeXNw3iOG7vXEGjf6sRnoX7E+1c38RfH8/77SLNV2SDywyrljnuK9NvLG31XQTBHscOnytjOD61leFNIsoI2g1S2jl1CI485l5YdiKAPnO50nxhqKWumaybqSwaZTBLKTjGelfU3hrRLfQtFtreJRv2DJ75rK8SaOuoiKC0u2jeNw6jGQCK1F/tSOFUbypCoAznFAGooYnmsjxJq1rp0ccFxKqSTHGM8471z+q6l4ygV0tdNgkH8Lh65uxku4L1r3xTptxNfTfu4sfOIwepA7UAdLZ+LdQaSb+y9HnubKP5Y5BwGx6VX1LXZ9e0+W21bw+Y4+fmnTIB7V3mh3NkmlJHZPH8q/dHaodJmF1b3BkUON5GCKAOJ+Geg6lY6UtwLxXTJIi6qoz0FbfxLs7jU/CLRoVW/V1eLn+IHNdJbxxwJ5cCBFznC1ja5dWs2r2djK43DLsuewoAg0rxjY2vh1JLmRZLyFdkkUYywf0xWV4bi1HxVrD6rrWnC2tojiCKYZYj1NQwaMr+OkudItFj0xsm4bH3n7EV6IzknaOFHSgDz74y6LGfDclxodqF1jhY/JUZNM8AT2NvoNvYXbf2fqiLl0zt3N64rovFSLb3NtqL3IjNtkqhPDfWvPtQ8S6D4o12A6ray2TWrbkuEBwzfUdqAPS7OWe3uk+05aKcEBj2qxoKjy7lUPRzXKan4vsobJoGu4rgxjdGy9R9a0fBviC1m8LTau/yREk/UigDd1K+js2jV2VSxycnoK8w+KnxLeBrOx8GWj6rq4lGRGpKqO5JFW76O58a3aG2WWO3z80mcAj0Fd54W8OaVoEG23t0EuPmcryfxoA8w1TxbcaNa2ba1GBrd6QVjTLBR3FVfFHxc1CXQJYdN0K6aWFlDsUICjPWul0LRoLn4oX+qXwWWz2hLZX5EbDriua+K3iZm8QW9hoqxhJplt5mVe2aAOxtfE8knhhdRGl3odI/MZ3XB4FY2qfFVdY8KuNGhkW8cGMgjlTXS+PNdg0Lwjb6ag8y6u4hEigZ6jGa870zwxF8O5pddaOS/05od90n3vKbrkD0oAtfs+eGrmz1DUdT1Ig3c7kknqO9e1SsXLcV538K/FumalY3d3uSHz5SYlPy5HtmvQUdZU3IcqaAALjk9aXHOaMdOelGSTx2oAQrnvSbQSTinmme2cGgAUZJxxTGX5s8+9SR8DgYpe3WgCLuAOlDHOOOaeBxjGKaqnPNADMA8LnNAUjt+tOOVPA69KRn2t70AKVHHNV57y2tpFSaQKWPGanBD84PpxVXU9Lg1K3CyLhxyrelAFzaCAycqfegAjGfzrAtTd2jGDPK8AMeorZt7pZOJsRsBzuoAnCEvgDimXEq2y5f7386p3usW1vujSZPMPTmuA1Txbfx6r/Ztpp0l7cP8zSg8KvtQAeP9Ku9W1XSNVYl7eynDMo6CvVIG83T4HQcbR0rkbO61XUdLktX00W0YXq56mneG7++/s82l/NFFPCcYTnK9jQB1YX5STgfjUeVdTtYE/Wsb7Pc3j4WaUL3Y8ZrVtLVbWEKGJI65oAkQNj5qXHQ9BRySecUoz0NACDqRRt4xk4owM+9BGTg9KAIrjaICHGQfSue1OwsNRhNlqYSW3Y/Ix6oa35Lfd/y0IJ9Kw9a8IR6vA0YvJYWPIZDg5oAof2bqHhl4zY/6Rp/AIzyB7V09rcrdwiRAeeoPauT0SXX/AAy81prkovdOXiKcjkD3rqNHKyWfnADEnI+lAFggZ3EcmjnFL35HHpRyV9qAOQn1nTvCczRXcpjt5CSi7ScH0FOttRTxC0c0Eot4RyGPDEVrRaTbzQiS9Vbl2+YFhkD6VaNjabAvkJgccDFAD7G3t7ZMREMT1YnJJqcE5rPfTIScxPJGc9jVi2hlhbBlMie9AFv7QYgWPRaoadH9rvZLy6BIYbUB7CrUoVlKuCVPGBT0ARQqAYHFAHM3HhW0udQuWtbu5tJtpbMT4/Sn+C9GnstOlik1Ged1kbc0nfmtZXC+INgHDx8mrdnbi3abByJDnFAEyERqWY/dGSa4rTfD02reKLzWLmV1gPyRr6qK6nV9wsX2nGeCc9qhtdb0+ONLe3ZnZV6AZoA1kRIIhHEAqgVUnuy+6G1+eQ8Z9KzZtUF3KYcvBF3ZlwTV6e4stI0t5klTGMbu+TQBz2r+Hjrk8dnPMzKh3Stnr7Cums9F0mwt44I7OIqoxytJpSBLUSk5aTkmpbudYUweXPQUAc/4v07w/Dp0oksYvOlGAFXBNZPhT4eGy0aCC41Cc2m8yC3zxg84rphpX2rE91gyE5wewrXY5wq9AKAGWUEFlAILZAiKMcCkvX22MrA4bHFSnkVFLHHKmxnAA5wT1oA4/wATtFa+EbiytnEeryoTARw249DXB/DnQ3vvCesRatGH8Q2rFsuOd3UEGvRtTsIb3V7XV2AKWrbB6YNaWuQWdnpU8tnt+1SglSvU5oA85bUQfCg1bVU87VZ8QQRD5tmDj8K9GjWC08FONRXzDNATImMk8elct4K0SJdJa41RVG2Uttc989q7XWr+zt7FFZow0oCICRQB4D4C8HXfifT/ALfI72NjYXbNaRqMF8Hoa+gdMmSWwjjChJEGGWsTR7ixWSLTbWaJWhO+VVIrXjmguNVc2vRBhiOhNAF49qAevvSE/N0pM9+KAFyKbgZ44p1IUJoARSBkj+VOA465BpFAAwDR+eKABgcdaYcE8HPpTumfWo7bzNpMwAbPGKAHDO7B4NJsBGae2CM9/Sm5PfpQAuAp9Pb1pfm9gKRm6ED8xTs7hkigCGeFJ1AkGSOcjtTZbGC4/wBbuPHrUuTnIHHcU5nUZBOMUAVF0HTXbMkIOO7UtpbWceplreJAsa4yBVe/1JvJdbVDnpvNS6Nbvb2e6Y7pX5JoAPEE17cabdR2pEAKna+OazPAulw2+ns1wfOvF4eR+rGtfVZG8hIxjLsBUcCGy1L/AKZyqMD3oA0TkcAAD0AqPdnAByakIJbpzUNy0Nij3FzIqLjOSaAH4PHTFEjogG9wua5jUPG1lCuy2Illbpt5xS6TM+sEPtfAOWZulAHTc9uh70hOOW/SgYUBQOKGxgjtQA7IODTQ2WPqKQkrgH0poAwTnmgCDV5PMshC67t5xzUttEkFtHGmAoHSnkBgN45FH4ZAoATjv09BSADoMUvXtSYx1waAPO/hP4pl1SC80TVx5Wsac5jeNuCVHQj2ruTMgufI/jxk15f8TrOXQPGuj+K9OTbz5F0F43ofX6V3nhm9i1iObUI1OH4WgDZJCjJNKM4zVHWpfK02V84IGangnC21tk/fUYoAnBx3oBweBil68nrSE88UAU7sKupW0vTIK0+4sp5XLLdsinsBVXxLMbbTluxj9y4J+ladpMLi1imUDDgGgDP1DQhqVo9tJdzLlfvK2DWD4LlGiXkuk6vEvmRkmO4b+NfU+9dqgA+ZiAq8k15B8YPGdhqMMml+GJEudZjYLIsfJC55GfWgD1y+vNOhtzNcPF5XrxzXmF9P/wAJB4qtDYxS/wBi274uHB+Ut2xXP+D/AAprmpT2K3d68+mj5pYJDzH7V7dZ2NvYWn2aCKNLcDkAUAT/ALlY0WFgUwMYqsbZGuRKxyewNcxoAvLLVr6e4kabTpnxDxkx+1dbjcMr0IoAcZAOCcVUu7e53+dayYI5Knoamcxou+RgAO5NUpruS6IW3bZAeC570AT2WoJOTHMPKlHUHoTWF8TI72fw7Nb6DIY9WkXELL61tX0VtDaiPbvmP3cdTTtIsWtlWW4cyz9QW7CgDL8FWk48Jx6fq/8AyEfLAm56t6irMCww2c0cigzx/KMmr+p27GdL2HIkQ/Mo/iFcB4tv3g8eaQ8ErLbT8Tr246UAdNqGiQ3UdnZs77WYO6hsZrP1PTdNOoymaIuLWL92C3Q+tdTpi+bcyXbD92BhfpXMWTLqPiDU7m6+SwgHJ6DIoAo+DPDNppVnPeSRFtQvXJyTkgV2+mWMNhalEA3k5JrO8PXUOpq93CuYFO2I9sVsMAc9jQA7PWkJCjsKRTnpSOF2/NigBfTGPxpR79KQHJBqtqGp2mnrm4lAY8Bc8mgC5wqknpUMcqyk7CCtZ9s82pjzGPlwdl7mr8UaQptQcCgBxzn2pSPU03JxzjilZ/l6DNADsA/SmkrnBxQjA/WkkA9RQAobIzjpSnaRn1pu3C8Y/wAaMqoDMQAM0AMu5VtoGfOXPAFQW7Lbx7rghpX7VkS3s+p6wYbGMmGHq7DjNbVtZLE26U+Y/cmgCK4Cy3EMMa4XO5uK0WIGAORUOxI3aX2oR96BwevTmgBZIkkZSedpqvrcM0+nSG2IFxGNyZ9atqDt96ryXDLMsMfJ/i+lAHOp4nvjaJHJYTRSjh5CPlH41gWOjP4y1B59V1XfpsbfJFC+AxHrXoc6ia3eJ0Xa3B46is9PD2mm2a3t1NsCCf3fHNAFQaDpsDeVpluhYcFyK3bWBLW3WNFA9cVwuhC50zUrqza9mniRsh25Kg9jXaWnmsoYyh19aALByDntQRx6+lAJJwQDS5K49P5UANY8c9RSEYJ7Cg4LH1pWxjvxQAfd7nNIOh5/Wk+uaB0GKAAk5HP5Gk6dKAcZBH400dc9qAOZ8WpY+IPAd1KjiRHiLxMD3xxivN/2dfEVy/2rRNRcB4CSCx56102l6BcaRrEumX9476VPukgGcBW7rXmfw60SKL4t635LzGNJiQobqM0AfQWu3VnFpt2ZZkIRCSM+1cbb/EHQ500dDc+W7uI9rAjNdPeaXZ6laO1mqiUZU5559DXn/wARNGn1Xwjb29haw299bXCDeAAykHqKAO9ufECQ+JLKwkAWC5UmOQ9CfSugdPm/lXzv4js9W1CTSNNvpL5datpA0bqMBv8AarptF8b+LNK1q28P63pXm3EoPkXJO1WA/vUAejeO0ZvCl4sYw5Xg0/TNSgs9F09JnDymNchec8Vx/ifTfGt/ouoNPNZxW7KdscWc4+taXgqNrTR4hJAHlSIHfncBx60Ac5418c3mp61L4f0yKS3jVP3sx4J9hXFfDrwPt8VxTadI7XJctcO53Y9qvXV9Jc+Jr65RN8jsUXA61ZGr3Hww1/T7vVIJDZX52s6jOygD3iytY9NgMUSjceWb1NVtZ1CDTtNmmupFRcYBY9TT7bV9Pv7FL63vImgdQwO4VyXxktpNS+Ht1FYBXmlKqjg/d5HNAHT6DKtxpihFBTGSfWtAsOwwRWP4LsDovhKwtLicSTLEvmOTyTjk1qqyy5KsCBQAksSTLtkGRWf4su7XR/DN1dykIkCb/TOKvzzrbRPNICUUZOBXk3j3xWmp6LqMd1pl69uYz5ShPve9AHpXhvZqNhb6r87GdAy7uwxV+5vkhOyMGSY/wivPvh540XVfCmnWllaXEJjQRvI8eFUjiuzubuz0fRp7wyrLLtzknkn0oALDUnN9NHcTJ8i5KDtXMeK9EfUdIFzB/wAfXnF0NYHw5iv5dQ1S71gsLq8n/dRH+GPtXo/iC8tdNsYZJ5Y44o2BbcegoAxfBWvTX+lTadMNl5H8uD/OmeNbWXSPAWow2qlriZGJb6964bxr4i0/QPFFtqmmXkTrMAzKjA5Hfit/xX8UtBufCUzW8sU11JCR5QYbgcUAdn4EhS38F6WkYwfJUtgd8VsqcHFedfB7xvDrnhKJPs8iywfI3FdwupKZMG3lyPagC4WVXCDhj0pWKqCZGCj1Nchd61fTXVzdwwJFBANqmVsZNbllbDULaOa6lLFgCVB4FADptYtllNvCS8p6bahstBia6N5fkyy9VU9Fq7b2NvayFokXd645q0XyeaAFO1ThFCjsBTVP97rmmeYHXK84NKv3QD3oAcSAelIfmBwBSdufz9KQ9OeKADv6UrDjI603oeooyc0AOXPXn6U24LCBwi5J4FOB5yO1I2Scjp1oAi062FpBhQA7csRVjJ4wDSbuOetR3DOYsQEBj39KAINavY7LTZnOXcKcKOSTVXRRc3djDLcgxBhkR1Yls0SzmaQ+ZIR1NWbIk2US9CBQBKXEUbFsYA4qpp6EtJcP95jx9KjuH866FrGcgcuavlQqhFGB0oAM5pIRmSh+SNnUdaEOGzQByum24Tx9eKQfKeLkHoa6aG3W2kfy87PT0rz7UPG+l6P8S0sLsv5k0eFO3iuyi1yK8ci1UEH1OKANPPsaRiNvSooPM2EyYJ9qlU5O04wOtACBhnAHNGQOoOacEDdGGc9O9ZWnah9o1O7tV58o4J7UAanBPAph+lKeOBQPzoATGfrTSCafnrn6UYwDjpQBk61py6pp7xZKyAZRx1U+1eSfCdAfiFqUWC09uCsrHqea9S13xJpujWpae5jEjHaqg5JJ6Vx/hTR/7C8TatqLMHutTCug/u0AdvNCdP1F7qD/AI95D+9UdAfWvLPjJ4iNjrOnTaSZbmKNw9ykHI68ZxXa+I7hrPQrkXF029lOdnqe1HgTwxa2/hJo7mEPJdgs7PyTmgDB8dajcR6Rovi6K3KNbsheIcsyHrXZaL5HiPTo9TvIQTKoeLIwyCs62tlka00WRS6W53ncMjaOldaqJDGEhUJGOijigDNm0+8v9LubB7lkikQorj7wBrxjX/EGtfDfS4NDnuILqOVygkk++Fr3O+aRYGdJRGAOT6V5d440Cym8Mahf6kguL64yLdpfvL6Y9KAPO9A8U6xb6jJfv4edrLoJcZH1rU/4WvpHibxVHYeI4EWwgUhFZP4q1dAgurzwPbyTXUMFrAMSjPJI4xR4a8H+GtH1r+29V8m4MqGRI2AbB+lAHGpa6u3jGPBmTwxLKBHFG2Pl9cV7x4k0K1bw1b2lhcXBWR05EhJ61F4W0tNTu5NauLRYrRObeLGOPXFY/ij4o+HfD2vxWF2syFFL7QhIz7UAegR6fa2NpAJpGJ2gYZs5q7CFUARDAPtXF/DrX7Txmsup/aUI3EJATyg9xW54u1+DRLNkgdJL1wRFGG6mgCDxZq7QNFp1mvm3cxxtHO0epqa509F0KSO5VWmdNp46Vm+ANFkIl1fUrhZ9RuTlgDkIOwFSfEnXoNAtbQXUixCaUL7mgDoNHsrPS9JSCOONIguTxivLPGWgav4s8U2raS0lvpNo2+UBivmkV6Mxl1XT4mhUohAIDcbqSC41CyjKm0RlH/PM9aAOC8HXOoP8TdQguiFSCBFRJBgn3FR/E7xZa2mu2ek6vpTy2kjbppV5XHpXSa3fafp73WsajayxSeXtD7OQa4HwP4X1fXNWk1q+u1vdPdiVhnHUZoAk0jwxoHiw3RTSbmBYSfLcDqp6VuRfBjw1r+ixsVlgvI8r5iHaSfcVLrU2o+DtRS/0a0klspvknt+ye611/g/XLU6VNdzyLBuJfY7YIoA878H6HrPhzUB4eLxRqZTItwo+YpnjNW/in8SdR8B/Zba0gGpz3OVVVB3D3rU8N+IIfEHjm4ngBKRgplu4BrrBpun6nrpu7i2il+zjCFlBwaAPE/h9Z6l458ShNavbuC2ixO9qWKBmJ6EelfQ62cVnGscWFReMVzaaRaanf3t3Zlbe7J8sSx8EYqKx07U7OUx6tfSXceflccfyoA35b6BX8sPuc9hzTb+5+z2owfmc4Ap0NpBA4aNBuPOe9VbhXudUQFf3UYz+NAF2AeXAq/xHk1IMYGaaevoKTORz+dADt3FDc8U3JppcFyqt8w5IoAMHd81KfvYpM560vTvQA4Nj/Cn5yPao25xSDJGaAHqeCDS9MEUwgEEE/jVSWK6jz5MnmAc4agC9Iu6JkPRqa5FraEn+EcVTiv3Uhbq3ZAO45FM1ib7VCkFq37xzz7CgCxpcJSNp2AMkhyatHnPPNVkkjtbVUllG4DmozqDyZFrExPqeBQBcAPpzSq2H9u9V4PtDnMpA9hUrcD1NAGXqmhadd6pa38llC88R++yAkVeewtAdyQKpP93ii4uHhQMELoOuO1NtLyC5GI5MN3VuDQBZC4AVegFV7u4W3+RcmVugrN13xLbaa620ccs92/RI1LH8apNrcenJ5lzbyyXTDIU9fwoA6O33QQtLcHBxnmsDwejPd6ldvwJJTt+lQLqd9NBNeanFHb2yqSsZbJAx3o0zxNYW+lxvBDK5k5AVDzQB1LAlie9NViDisO31iS7bc6/Zl9D1rYjuImUASqzCgCY9f6UhoY45x1pATkc0AfI2t63BrniuCwtbh7jyX3DaP4q9w8OeF9XvbmC71C+IhCABQ3zYrn/hl4D/AOEcsJdQ1LS4JL+Yli7HJA9qXVtK8ZalqL6hYaiNJ0yAE+WDndj60AdD8UzaaPp+mwyzLDayXKCWR27H1rvdOlgn063eyZXg2Day9CK+atb8EeLPiPc2qXmou1hBLjdIuAR6jFeoabYeLvBWlRWemww6tZwLhVd9rgeg9aAPQbS0NvNNPgNJIevoKt5x1FctZ67rN3o4uoNOU3PRoC2CprDvvG2v2RlWfQsFELHDZNAHTayl3qd3DBaSpFEjbnDH7w9Kw/EnhW61vxDp/wDaOo7dOgBZoY+ATWbFqFnq2gx3Gpahc2t7J8wSFSrpntWNoeu3+g3cv9oibV7DftEo+aSMf7WKAGeNPDei2GvaWLW92adPOEuLVn+Un1xWJ8YdJs7jxromkeGZn+0zJgrE2VQepr1DUPD+g+P7WGZkAtkGflO1s/0ri/Bnw0ls/iPLq1ncTf2dbgxx+Ycnp/KgDqzpPiPTNLtoV1RZ5IlA+zhcBvqa5jwPpxv/ABfqOq+K9JjnaICONlUOqCvQPF+sWPhzTbmR51N9Ihxk5NZHgeSd/DsJXNtDMS8kkgwzZ9KAPO/jPpOleGXHibwhePZX0xCywQNhWHqVFcjoupzFxf6nPJdSum4yM+cD2r3rUoPBFpaPHfNazyT/AC7WIZmJ9q8F+KWm3HhrSbmGxmtRYTktD/fiB7ZoAseEvipew3N3b6aHlYviKNXzXbeG9A8QfELxbFqXjFfIs9NwYbYfxN1ya4H9mbwF9uu38R39wbcRErArD7/qfevpzw3byQxXEskokaVyQwGOO1AGq21AsaDAUYFIGwfXNByT603nPFAHN/EHSZ9d0pbSFgiMw3Y64ra0Kwi0jSILO3Xasa4471ZdgoJOSBRHcQMNxlUDvk0AQ6peWVtahb/btk+UAjqfSvONDsLfXH1WG4gJnhkZIIjxtXsTWf8AEbx/ollrFsfON09pPg26euOta9nr2n2CXusxG4WW6jDE7DgHHAoAb8HvDUukz6nJOMyByo56V6NZ24tLOct95ssa4z4fXGqDRTd3J+a6kL7XXaRk8V0dzeXr77dLcPx8xU0AZHw6leaPVGcbSLlsA+ldaTleTXJ+Hr2OHxTd6d9meB5IhLj17GurIweTzQApYBcnjFM8+JvuuufrSsoddp6Gq0mn2rNu2Yb1BoAtL0PIP40uMLmqX9nBRmOZ19Oc1ZgV44grMWx3NAEgIBqhp5aSe4mI+UtgGp7+TyrV2J+YjA+tJp8Rgs0QnJ6n8aALH8WKFPJzSd+KVj+dAAcnntSqMYyOKF5GKXnGKAEYgYI6UDPWkPPFO4H0oAZe3S20ALKGY8AetZNtZ3csjykrEH7960WgWS4EjnIX7oParJxtGOlAFSCyhjHz5dvU1bXCgcYqJgWI2ttwcn3qTP50ALjndzzTc9fWjP51F5ytcGEH5wM4NAEobaMYyKoanawfZ5Z8eXIikhl4q8uN3LAd65jXdQ/tG7XStPO8scTMvYUAY/hvU7yxglvL2Nb6SVzsdR8wX0NW9D0i48RapNrGryPEo+WKEHAAHetK+tksNKe10+LfIqZOKd4ZjvLvSYWusQpjlF60AXLyHT0ia3EZnduMdauWEUSWyBrdE2jAXFSQQRW6/u059e9PJOeaAGtFEx5iTH0pn2WHcSsY/CpuCe4NQNcD7X5KAtgc47UASnAOWOBSCWP/AJ6L+dMkhWZv3uQo96xdRVZFkt9Kh3znjexO1T70AZGjeLINVsftMVtPLIEyQRgLWBpd3rfi4XOmlorS18wmRlO5tueAK2PHesWnhLwxcEqiQ3A2xyAfdJrh/hhe+FtM0651O41t1nnf5vnOB+FAHtGm2a6bYQ2kOCEULnuasgP0HX1ry+XxLDqV7t8OXF9cykfK2CF/WsHxhrfxG0u0Wa3a1jjA4Rxl3oA7n4mapP4S0aTXNO2mVGG+EniQGuct/Ftnr+i2yWNxvvb8gTsBkxjuoFeQm88Z+PNZgi122uobGz+eTCkJ9TXexeDD4Ss4/FelTM6Ab3ixwB7CgDutU8L6rBpsr+H2jjfy+TOMluP0qx8KrrT/APhHXhuohHehytx5g6t3Oa429+NF3f6FGum6VL58reVuI6H1xWfo3iC8s9bOk3IMX29Mo9wm3Dd8UAavxHmv9O1FV8FrMsjEG4WMZTbXZ+FPG1hqOhCGNxBfxrseJ+GDVd8N+E4tFs8wXUkk8vzSM5yGNN1LwTpGoymaWHyrhvvPF8pJoATSvCVtO013q8i3lzK27LchB6Cte+ubaOIWFqiSTbdoQdh71yl34Y1KP/Q9E1a5t4Dw8jfMQPbNaumeG7Lw3ZNcNc3Fxc4y0krks5oApaR4E0HRZn1PVkjkuWYtuc5C57CvOf2gvs2taXDBptmjQI2S6jknsK2bm/vfFFwHupWh0pJtrOTgAVQt9Yi1bxs2iaHZG6tLcqWl/g496AO38AeHN3gDS7O9hFt5UQ2hDg59a7azj+z26xDooxUVslzhTPhABgIvQVZ6r8xxQBDc3cVvjzM89wKZFf2suAJgCeOag1TV9P02FpLyVMKMmuTj1O78TzNHp+nCCzP3bh+p9xQB3LzQQxF5ZUC+5rGvNMg15tqq8UQOTIrYzWfB4Ht32tf3VzO68geYQo/Cte4sfsGmTyW9xIoRDjPagD53k0mHSPirqFrZ2h1S0jYTSb/mZB3r36x1PRda0yOG0SJRwHjYYK+2K82+EcIh8cahd3Mnmtdrgs/c5ruviLY6NpmnSagzJbXYHybG27z6UAbviiVLHw3NPFsXyE3rjviq2kagLTw9FqVy3zTgOSfevDZNV8TXzPJcljoXSQlsiMV6HNrmlajpug6Nb6rbsd6s5Vhyo7UAddpmmmfW31yYnc8exV9FrbimScFkJIzisfxT4h0/w54cmuXuIyETaiKeWPYCo/A9xdXnhy3ubyHyZJhu2nrg0AbpOKOooHT3pHO1SxGcdhQA8H5ehxSLgio4JVlTcp4NKWCRsx6gZFAFK4c3GoJAv3E+Zqmv5mhuLdV+6xwaZpcZAknkHzyNnNRaiyHU7RHbk5I96ANI9jzVe9mEMaersAKnxk1m6q0Yv7KKSRVGS2CetAGmKR3C8scE1TutRQBlttssg9DwKz9MS6vLlprpt0an5QOlAG5nvSgd6YeAQKVScDIoAeTgDikz703rTuOeKAAc59aUD1oUY70g60ALnoCa5nxJq/8AYuu2cjQSSpONnyjgH3rbuYrh3zDKFPoRXOeJrXX5DYtaSWrMko3b17UAYPim7vtR8U6VBbapHbQS5DxqcEj3rsLO1sNKja3smV7l+r5yc15x4z8L6nc+L9Iu763+0WyZyIDsxXZ2eh6fcQtFYm5tpepbeSQfrQB08NoILGXJ3Oykk+tM0iPyrBF/GuVm07xPpsoFtfpdWh4KuvzAVt2DaskSmRYnT0xg0Abh60m0mo0dmi3SDY3oe1cF4g8U67ba6NJ02xSeSUZSXPy4+tAHa6rqlho9hNdahcRxRxqSS7YrykeNZdNW51yDUrW5t52LLa7vmUdsVw/i/RtT1bWjY+K5L3zZpAyRxH93tPpXe6BD4K8ORGwuNPkN3EABHJGWZvcUAdB4b+I9rrWlvcFFLDgwg/P+VT+GfG+n3F/eW5je1uEYBIZRhmqlBo2n6pqlvqNtpUlo0PMYVdob6iui0fRbOTWri9nt0+0D1HSgDz/+zbXXfAYm1q4M8O3ZHFJ13dB+NReDvhLbaXb2/wBpUSBv3iHGQp9CK4z4ya/HoHxV0e2gn/4lYKvNBGeN2fSvbNe8XLpmhwXhRVSRR5akjPIoAw/HGvnwXZWczWcORMqL5WBuz7U7RdP1PxHqyanqq7LYfMkbDjHbFYWpXNneQS3mupNfXDDzYIoV3BSOQMVd8E/E9PENkQ9jNZx23ySIw+YYoA7XxLdWmhaDfzRxL5jRNtVV5LY4rzK0/trSvBtpfeKZTJZMMm3iX5gD04rpPEXjSC+0qR7XTppbJCA02Bj6Cn2/iCDVNLMcUBnvpR5cVuwyEGOpoAy/h54MtnvD4i08/uZDuSBxlf8A9db/AIhu9Nu/F2l2Wu6ekRIJhmYfKW9AfWsLwrqd34N19NB1MySLdqZLdUX5VOeRXV+JdOn8TWa27232co4dJX+8uO4oA07ywltY92nXnlqo4Vzlawj42WwuUt9Ri8xmOPMg+YVPpfhO6tpUe81Se6iAx5Tn5a6GDT7KLGy2iUj/AGRQBzuteMLSLRmubVZNxcIqlSCTmuV8Z+N5rDRZnFq/2502xI/RQR1Nd9qdtBcarZWwiT5SZNu0dq8i+LG2LW7iC6cFpV2qvoKAMvw/oGp6/wCGLG1F4620s++Ujvk5xXq/h7StO8IaqllaRgSzRjnuxqj4efTvDfgnS4nk8yQMpwnLEmr1u82s+PIbk2skUFpDjL8ZJoA7cnIy3/6qyZ5f7U822t3Kxj5TIp/lVTxxrH9mWBjiYLLJxnPQetV/Dms2K3iaXHNG0xjDjb39aAM3UPh7DfTxCe+uTb5zIm/75rootDS0t0jsriSMIMKM8VrkHdVa8voLRQZX+Y9FHJNAFK6fU7WzeTzYPlXO5q4nXbrxZceFL+4W5s42ZTtQDPy11Wo6TLrzRm5nkhtRz5anBb61V8WWn2Pw1c2OlwMZJU2Bjztz3oA8Y0y01uy0qQbprnU5CHgaDop96o33hnxp40vI4tWlnRrYBnUnFfQXgnw1a6BpNuv+uudg3yPyav2ZD67dSqF2hQvA70AfLeqeCPiZbWl1Bp5ml0053QhvvCub+E3hHWdZ8TSWixyJLbsS4JIKGvt5JCAwHQivJfC9xZ6f8W9UkEIhllhAJXgM2aAMzXNFuk1TS9LTTJLieNlkkkd8rxXrdsb3yolaNIVAAK+lV9Os3fVJ9QuQdz8ID6VruSeetADO3vTh0INMRQM4z+JpIy+47wMdqAMs79N1HPLWs5/74Na5A288giormNZreVJBwQefSuc03xLa2kq2GqTJE54ikY8N+PrQB1CkADA4rz74i6lPoviXRbhpNtnJJsYkdCfeu3kv7SOIyCdHUD+E5rzT4tyQeINCiV7mGFLaVZShOGYA0AegQ6xNefLZW5df7/Y1zOseCb/XvEdve6hqEsdtEpAiibHJrovC+s6RJ4dtJbW4iEaxjoenFZK/EHSJZriCCVpXVii+WM5NAF3+xobSSKxsZJN3V2LZOK0ms7qBlFpOoQfwsK838I/EBotfvLDWrK6inlctBK0Z2uvYV6Idbt+qQzkn/YNAEvmX8SkyRLJ/u1PbXPnIN0bI3oagFzeTDfBCAno/WoItWkDulxauCvXbzQBq471WluLiOTCwbx7VBcahG9o0tux3LzsIwauWkwubeOVOQeaAK631yWYG0YY96hudUmhTLWUpA/u81pgtuJzTblpBC3lqHb0NABBKs8CyL0IzVXUIZ2UTWxzJHztPeuUstX1nTfEMlhc6eTZz/NDKDwD6GrPi/wAT3OhWG8rH57kBYxyeaAMrWfFcXiLWbLRNMkZbqOTN1jgoB1Fd/BClvGEVQMd68R1K5tfDOs2muWUEj6rOhkuEKkBhXb+Dfibo/iJGFzPFaXCnBR2xigDtby+gsbd5rqVUjUZJJrPtvEUN7b+bYRSSqeh28VLq8NpqOkz4aOZGXGQc0/SYY7PSoI441VVXsKAKs9vfakoMsnkR9Sq9SKvNp8IgXylHnIMqx61Ja3KXEe5OgOOKnU/MM0AcNezjUfHOmCRAZYVbf7VznxC1638O/EGwuZIlczARNuHQZ616DHpsH/CVveblDCPGM1xHx98OQ6po41K1lC3Nrzj1oA9NXUbcacl4MGLZu+X6VyNpe6zqWvGeziS20yRSNz/eJ9RWJ8L9cGt+GLfTGfM8QAce1emQxLBCkSqAFGBQB8h+KtLTxH8S9Uby5Lh4F+QR88jpXe+DtG1LSrq1fx8kk9iwAgycrH6bql8J3o8O2uvzafpcuo3igs9xtxzXo+g+JNNuvDFqPErJDK8YZlnXGPbmgDoBZWN3ZxNpQiUKMoygYryPWNbt7Txo/hm8s44jfn5rmMYAzx1rqZ/iH4Y0y4TStFnWeeY7VEQyqk+pq/No2hjRbq41CWCW8lXeZnxuU+xoAwNM8EWeiXpsJtVmfRseciu+Ru9Ca7LwfZWpmuL6KONUB2RkD+Ed68y8WQS+Horf+0LmSTw7eKC0hyTE+OOfSq+j+OGOmWeg27SW6XMu0Xj8Apn19aAOq8f3X9seKtNg0LbLf2wZy4PCY9a7zQb59R0uMzhVulG2RR2PevPV1Cy0LXki0O0lv5fK2yTxjcAT6mtzSUv7S9uJrC1lf7Ud7mbgK3sKAO0wehPPaqLTXsMjfuFdexBqKytL4zCa/uAT/wA806CrV7DJcjYsrIh4JXg0AeTX/jDUYPFOqXUySpHZxbUWOPcPxNc98O/Cf/Cf6vc+I/EWqySoZDsgBxj0r2u80a2i0ua0tYV3TcOxGSw75q3puladp9qtva2sUKgdEXGaAMDxRYad4d8J3FxalSIQGXODyDVrw3fFbOOV4s390gk2/hUviDwxp3iOwktJ3kVcgnY2OlZ3i23l0Dwdc3kdyTLYwkwsRzwOBQB5t44h1HV/F8q6jdbLaMACFG4z1r0LT9KtP7IW/sUBvLYBvMHU+orzDwnrEHiDw1c+I9WnjR4wQyA8s/sK9M+Hl9NN4Q3QWkjyTgkbxigDsYpGv7GKWNym9QfpTYbCGF95HmS/3m5rlvBmp3yW8llfiMXSSMBGv8K5712LMdqnHzd6AJOAv+FIQsi4dcj3qMEEHtT9w28UAPPyqSDgAVnadNZwCXM8Ykd8sN3NPudRtY28qUsc8HArBu9O0xrxb+wJiuV5ORw31oA6CTUY3LQwxySFh1A4FeReD2ltvizq2neICizSqJbRt2cjPT616bpHiK3n3wTQtDKgwW2/Kfoa8a+L+h3tjdWvjfQp2nlhkxKg54BoA+hipAAP6U3tXFfD3xxbeLNCFxbjE0KgTKeoPeu1Rg8auDwwzQAjMqIXYgKOpqG1uI7pC8Lhl9a5PxVdnW75NDsbnykk/wBbKjYI9hRrElx4K0KAANd2gdUaT+NQT1PrQB2cgzGwHUiuWfwrY67prLcqomVmAY9q6Oxure6tIZ45VZGXPWuLa9v7tNX+yTLbWsEhw56scdqAMu91C2+HWmNBqMH2kEkxyL8351na34n8I6n4TuL64jilvJkwsYHzA9qxfDHhDXfGesvdeJLyRrBCdqZ4I+lerX3gXw8fD89n/Z0AxEQrhBkcdc0AeKeGovEOgaKz61GsWiXB/dsuCwDdBXtOkeFNJj0G0OlRxxSKodJVAyT7mvOPAunweKrGfRL3UJ3s7JyhDt1I6flXd+C5ho97ceH7m7EptwHhZmGSlAEHiPWba0YQazY7JYvmjnRM5Psaf4d8eaTqUv2K6dbe5HClxtDj2qf4iPaXujPbxzxG9T51UnnFVYfCGieJ/Dts11bqk2wAyR8MCPegDtoQQAUYFT0IrI1lZbO9hv4ctHnbKvqPWsS08N63o0SRaXq7TQJwEuBk4+tdLG089hIt6iIwX5sGgBb77OyRFY13y9Kh01fsd09qThG+ZK4bwnrdxrGp3scwl/4l7mOMqvDj1rYk1a6eYTGCTELdChDEUAdhJIkMirISN3epSQF3dvWufHiOwuovLvEeEngb1IpLbWoLaRYzKstqxwGz0oAt6m8l/C0FpH+9H3ZD/CfWuB8O2kt74xkj8UjzJbfBic/6t/pXqS4aL92AFYcEVSubfT4rUi5C7l+bd3z60AJdaXa3N8rS20UkYTbkqDxXm3jb4R6Jrlw50VTYXhOXkjOF/KpvE3xMTR0az02F7u5bKx57fWuU03x9qgtGku5DHMx/1YXmgC3ongzxZ4GGX1UXunu4UxlzkDPavZbqTy9LjB4LgKPxrzuxlv8AxDYWlx9okMaSBnG3A+ldb4rm2x6Zbqx3PIuAKALmiobW4ltm7/OtaksZmQjcVA9KxLpbiHxHaFAWiaPDe1b5HPSgDg9V0SePxXDf2V9K6shV4Gfg/QV1UNnp+pWUsFxCCzKVZHqDX9DGomGa2ma3uom3JItV9RaezgN1crtkhXJkQZDAeooA4nwTo8nhf4h3VqY8Wtwu6M9hXrLj5utecXninTtT1LSr60mBmLbGQ8E16HE4mhWRehFAHKalpOzVDDaosdvdYEmzjGK05fDmmXG37XAtxsGAHGQK0jEC+/GWHQ09CefWgDLs/DGh2bbrbS7SNjyWWMA1X8VaXp7aDdFoI8beWAxir2tXy2NqrH77sFX61Bq9jb6voE1jJd+WJkIZg3IyKAOD+MlxaXvws/syxAnuZkVIgnO0+ua4eHTIdK8EaR4Z1rDXtyylXUfMF9qoajrln4embwz5wllic7Hzlj6V6J4Z8JW17ruk6vezTXV1FHlQ5yqemKAOk8L6FJpUMUGnApZFQWMgy5Nddv2hVGc4xSyNgDt2wKjIYY9TQBJj3qM88DOac2RilHTPrQA1g24Y59acq9yKQ8Pg96fynUdKAMUvNYeIV4/0W5GCfRhTPFkN3dWctr5UTwyIR859q1NUt/ttmQpxKp3KfcU+3C6jYtDcKQ20qaAPkvwZdRaZr19pq2YcRSEvATkE56ivqJtasdJ0CzKLseRAI4wMHPpivjXWnufCPxb1RInLPFcMwDHOR1Ga+oPhok3iqyg8Q6oqkMP3UfZccUAdboNj5SSXcyD7TOdzGtJX5wcVL1OOgFIVGSQBn1oAY4yhwOKIjkhe1OP3QCKiuHlijzbxhmPrQBN5ceSSin8KRjbRglxHjvWcba9ucmacRIOyVZttPhjzuy59WNAEbXdo7NHBbeYSOcLXnOp6Rqy6b4mtnnjs7Fo2lhicZHTPWvUXntrXHmskfueK4r4k6XceKbSG30lm2E7ZXRsbl9KAPC/hbBr+lWp1nToi8N5uikVeQcd69K0/4yW8PhdobuzmTVUJjEQUnJHHWpfB+ga9os1npHmRWlhuO0Bdx/OuktNO0HQ9Vu7K7s4p7qZvMDOnLA9eaAKvw6vtB11DdtKiai3LRscMpqr8dDcW3h62h02+kaaedUEa855ql4t+GS6yPt/hyL+zLtTvV43I3e2K811HWb238V29peNcSSaZhpwTkEg0AewWfw61S50y3mXXrq3uDGC0aEbDxXmnn+JbT4lxeHzdlrOd8SAj5SAOtezTfETQoPDwupL2GKYx5WMtyTiud8MaMjWFz4j1m6jE07ebEAR8i9QKAO8sYp9HgjgW2Dxgcsvc1m6t4uto47izjimNwyFSAhIXjuar6n44t4tLtHsFkuZ7ghECrnJrR05rgwFjp4WSTly3WgDyz4Vpa6N4vurC7kUfbAZAW4JOa7CTwlAfiP8A2pHkxGDawDcU7xno8PlQeIGhiEtj8zY44+tQeC/G9rqKGaW0uIvOYgPsJUD60Ade+g6czvJ9nQzFSobHNY3gWR4m1GydCoglO36VuXGr2kYVY50eaThUzz+VVNDSVNRvfOA3MQ2R34oA2d/zY6U10DoVf7p6+9PHPXrSHA4PSgDB8iGz11Z7JFRXXbKAOvpW/AQ6lnVTn2qF7aIsrsvfrU6jAwOlAEdxaWl0AJoEYD1FVH0TTzC0YgVQfStAMOlMGRnrQByfinU9b0e2jh0qyE6gffzyBXKW17d3iObt7sXsnyhdvyivWsAj5gMe9c7r/iHTNLYRgRtO5x8ozt+tAHDy+DLSzil1C/vooztyQ3Jqh4Si0m81nLIZI1HLCPINdNo2gxa14hnudTJubbaCiHIX8q7qy02xsRssreOJfRVoAzbu+0qx0hlhKwxrjtisXRrhNe8Rm5iYS2lsu1T23Vp+O7UahoVzp1pGpup1KqR/D70ngPw+nhvQIbQsXmIBdj1JoA0r8sNXtSOI8YJrQuZBFEXbjiuV+I+rPpGn2lxCpMnnKD9O9asdwNVFqUOYtodsetAGjbM7x7pOM9qW5ci2lVYhKSCNp708DGPQcUBgrcdaAPFb7Tr6+tNRsItCWHUIZS8UiMOO4IrX+GXiHWbGR9H8SW03nfeRz2HpXc6/HJbaha6jboMghZB6g96l1u2SW4tNRT5WjPJHcGgCvI2rWUvy7bqHv2YCtCxvEu/4GSQdVNQLrVnHETeyrDIvDBj0qo3izw+h3HUIAx4zkUATXX+l6zHE0e+KJdx+tWLy1sY18xoN744A71W0rVdJlaRrW7jdmOWOas3upWixrGlxGZpTsTmgD5qk0CDxD8cJ7qCBUtbRgbiMe3FfT0Fta20Ef2ONUjC8YryXw7pEPh/4v3sHmeZHqNuWYn+/nmvUNM8yLzrWZCBG2EPqKALeT1pC+DgDnvT24BqFpoYmBldU470APXLHpSjr6YpIJYZ8+VKjfQ1P5PFADMZ5Oafywx2qtNdJbsV2s7Y6LXMar4g1Oe9TTtNtPLnfne5ztFAHVz3NraruuJ4oh6swFY9x4p0yKCZ7OZJnGQNpyM1534l8J241+3m8W6jM9qYywXzCql/TiuG8EeHpfEeq39voTSx2cU5+dnJCL/8AXoAyNa0E6j8Qn1zUYg6XEuSg7jGK91+FqtZQXVpZlW0xWzEueUz1FcndW+oab4iszcaSbnS0/cGWM5+Y8Zrt/AUEdpq2qQRbguQ21hgjNAHZZBbA69aYTg4rL0q/jvNTvIlk+eJtu2tMjk56UAO9PbtQGHShsbRikUDqKAHHpimTzJBEZJTjHb1pk0ywxlzk+wqjbW8t3KZ7vAUfcT0oAgvtOTxFEyXyEWv8K9CaWy0abS7EQ6XMUVeiv83FbYGFAAAqJrqCKQrNKI/97igDMuLh5I4hdxbJ4mDBh0NcprduNd+IdjJDKUhtIv3pB+97U/4oeN7PTNKNlpjLdarcfJEiHofWqfw30PVre0N9qERa9m5becBaAPTJLlLO0ZyPlReB614ZrngvU7651jxTbzpA8oO+2K5LRj198V7N9kLbXvJchedvauR+IWuRW8It9GJmvmUh4kGQVx3oAwvC3gPwj4h0Kz1G7gHlRR/MS+Oe+a5fVbNW8RpH4TvLq60+2+U2xyybvao/hFouu61HqFvLcTWunLO26BuNueoFe5+HdDsdAslgtIVBHJYjkmgDyLwXrmtL4wGj6rpy2ltADIjsnAz6HpXrGqeKNL0m3b7Vew+ZjhdwyTWpJZ2tw7NLEpLDBOK8U+Kei6brmrJYWMaxm3BkmkU8jHagDprmW58S+C7pDOiC6kIjjVudueh/Ct63vtP8M+G7a2FqXZFCBET7xrx74OeF5dU1m78y5u4rWzfMQ8w4zXuAtF08pJqD+cobC5HCigDlrPRob7URql7pNxBcscqUk+6K6fT3EOqSvI7KrIMb63WkRYvNBGzGQazkjhv5mmePgcKfWgCSTUrRDzMKfDdQ3GfLJNOFpbgYEKflT0SNT8qgfQUAO6gcU/0FITjHFQ3l1HawGRwxI7AZoAnKlgcYHpmsLWtSk0y2eWa4iRV6DGSa5vVdS8UahPt0m2MUBOMsMcVLaeGNXmXdq7R3K9fLzjFAHK6x4g8QazdpBpjSPE55EQwQPc1peJdul6baadZaVNLqN2yh2PJ9zk1ueF7oaK1y0unEDecsnOPauVl+Itvd/EEB7JxDbjAz1zQB2mh3t5BrK2b6c8USwLl9w61vXurW9pZzTEjdHxtPXNchZ+L77UfFUq2WjyPbKgBk9DXO65qEl/8AFay0kpII5IxJKnQcUAek6A0lxbfbJkIeTkZ7CtbIZuRkjnNCosSLGigKBgUq9KAOV8d26X2lXoPLW8JcfXFZnwV1GXVPCSzSrhlcpz1wKuXuoLd6lcabAhaaQ4kOOAtbdtp8OhRJ9kVY4CPnUcDPrQBqnJOKBGC3NNDGWINEw+bkGs6/tZ/skryXDK+DtCnFAE1+0VyzWolUYGW56VDbXcDaXNFNMmIwRuzXF6F4SgMs11farcSzu3zxrIePatfWvDsD+HbhIS8Ee3kljuIoAu+JNLgmdbqWEOq8SJ/eWltfBnh24hjmj0+Ig8jita/vLW1tjJeOEjA5zXgPjj4z3drrL6T4TTfA3ymZ1OEb2oA9Q8eat4X8G6Q7T/Zo52GEiGNzfhXn+meKl8UTRmw0t2mjXbBt4wfWvPf+EU8ReJNfivLuGXUps5z/AALX0B4M0tvCmgzTtpqpcKheSR2GBx29qAOQ8D2N5fSXt7cRu2s6fOfNdz2HYV7Fp19DqVhHdQFWBHJHY1842nijxveHUNV0ext4dOvZzDvb+LJxkV618PbHWvDGnLZapGs8DjzRJH2J5INAHddqjlgjkKh4xIDxWc2tt52wafcNn+LbxS3GvCys5biSyuNsaliAtAHP+K30bRrwyyXBszHGZG2Ngt+Fcfo1l8QPEscupWOuLY2E3NujxhmK+tecafqep/En4p3N5dWU40eJtm0ghVUHv7mvquzhig0+CC2UJEigKAMcUAeX2Fn4z0nZbX10ZUY/vLtVDfpV+bStRstZ02bTtY3maTEolTJP+FeigkjDAEV598UNcbRjpr6Vaie+M4AHYD3oA0PiNd6dY6GW8QQxXLYxEp4+avO/g5rWnaPfaloVvgXl03ncHOFPap/FngvxV43SCW5njtoPMDsMHOPauk8P/D7R/BuuWOpJmS6mBikkkOaAOza6002q2rzJGUOfn45rkPHHjKz0EzXehrHfXojxKkZ6ADrXXa9ZW2q3K2LwqYmG6Q47Vl654Q0O20eeO2tY45pkMSsOuTQBw3wdlurm3/4SWe6WdLtysi5+5z0r2V8Ebuo6ivL9F8EronhlNIhuntroZYPn5ZCTmu28J3s09n9jvhtuoRtbJ+8PUUAasMqTRl1+70pyNzkCub8NXkt1qWoWykGK2lKk+ua6JcDd25oAUgEEsAfqKSJg6ExkY/lTnYiGQjOdprB0q4urawa6kVpId7blA5UZoA0J7S7YmQXexR/s1xN/4d1bxfqM1tql48OlRH5DF8rOfrXRaVqyeJbyUWcoNlAcNg9W9K6SNRGAqDAFAHk+m/C/SdK8TNdzXVxMkKDywzEkH613todTEwS3OLXpmTrWpDbqjyO4DMxzkipwwwQOMUAUV09nP+lTNJ3wDgVn6DY2z6ve3iRAAHyhkelbrAsjAHBYcVV0y2+xQshbLMxY5oAx9XhXQdS/tW1ytvIcToo4/wB6uhtriK8gSa3cOrjPHNOljS4gaGYBo36g9K8/1fVJPA1wz2sU15ZSHiJBkofb2oA6bxjriaHphZsGWT5VGea8J8J22oeI/GerCFnEDIS75r0UaLd+K4/7Z1i5KW7r+5to/wCD6+9dV4T0O00wXLWsQTzBszjrxQBkfCSwjs9PvGAHmeaUJ9cV1F/5cmofZ7lgInjPU03w9YiwjuE2gb5C3Suc1dZr/wAb2ltI223iUsSDgt7UALpV1dtrkukThv7PX5oZj/GPSu0jjWJAijAFQz2UDRxqqBTHypx0qbJwMc+tACjHcU0r3JpVORmlLAAnnigBCQBk4AFUhJLdz7VUC3Xqx70Mst5MOSkK/rV4KETYlAA6fu9qHb6EVUNnMW/4+n2nrU8IlGQ571LnkCgDm9O0NbLxDdNJcyyQXChvLY5AaprvwZoV3dtcNaKlwerrwatXbE67AucKVrVchPmY4A70AcPZ2Fx4NbU7yOUz2n3gr9VH1pvh7RRqGoJ4mkTF4/3eOielSeKLn+3L0aKhZI5h8zD0rovDaC105bINk2/yc9wKANE5bB6Cq2pyvbWE0inkDirLNhsHiqd7C87qG/1CDcc96AMXwhcaW7SMkyG9diZA33gfSuh1S1N3p1xAPvMpANeUeM720l0q4TRv3OpmQ7ZYx3B9RUvgzxB40g0UjUbATqvHnk8keuKAO38D3bS6Y9tcPm4tnMbZ68VZnMmqzGGOQokb8kd6848LaD4ki1u814XkctrcuS9vuIAruPDd9dwR30l3bjy0cnKHPFAFqTQYtNuGv7Lc0x/1qk53Cn+ILv7XogjtxkykKV7itDSdXtNUgE1rICp4w3B/Kob+yWKcXaEBR95exoAx/Ed6uoWM1lpsQuLiRSgbHypnuTXFeEPAixadd6PewxDUmJZ7hlGSp7ivU4I44FxDEi/QVna2ht7iDUkOGj+WT3WgC34b0xdG06O0RV/djBfHJrmPHd7Jq11HoFnJ8s5An2dQncVveJtft9H0hrkvlmX5AOcmsX4YWwubCfVrpC1zPIW3sOcUAW9b0Syj0rTNEtgsKK6EBR/d5rp9u2FIyc7RjNZw09pNbN9MSQq7I19PWptRvHtgBFA8zt0UUAXIweAB0rjvid4ht9L0OS0SZReXA2LGDk88VL4tudZt/Dd5dJLHayKh8tVGTntXlfw28IG71ltZ8Z6nJc3H3lidsgHtQB6H8MfDTWWhxNcQCIOd5XHLH1Nd4/HHpXL3d/qNoyro0MlxEP4XGAB7Vr6ZqguUC3UZgm7q3TNAF6V1jRmkOFxWRHp0WpXKTXEP7qJtyBhyT61szQiYDeMrTgABtHQdqAHMfkwBgY6VxvxVma08NRS2/NysysgzjnNdkoyDnoO9ePeNteTxF8RdN8M2zEoj75XHTA5IoA73wJey6raSXtxgSsdhX0xS38k194ogtlH7i3G5yPXtUF9qOn+F9SjzL5dvKu2RQOFPrS+DNUh1C9vnSRWMr7oyD1WgDpL62gu4vLmQMMdfSsDU7CawsLi6tnzLCpaIHqT6H1rpGHODVe+jEkSiVgsYOWzQBxXwmllmtdQlvYzFfSy75Yz/AAk13W35jmsjTfsn9r3DxMqSsoJGeo+la1zJHDA8jMoCj1oAV1Pkvj0Nc7peorc2JtLbLyM7K+P4ee9R/wDCTD7NLbqpa+fISP69DTfAulN4e024bUpENzPM0zNn1OcUAaGmeHrTR5TNpqeUX5kUdGPqfetZj06j1qKK8W5kIiRtv94jipyM0AIT/nNNcEDI49adt465pdw6E9aAGYbrTiQVz3FK2eg/OhR2x9aAKFzfsGEVrGZHPGewpbTT4zJ5t0ollPqOBSpPEb4w24HyjLEVdX72KAMqyW2/tG4tkwu07jGOn5VrIqoCF6VizeTZeJPOkITz48ZJ6kVrW8hkBYrhSeM0ASDO7iuPkn8/x3GFU5jQqWrrLtzBbvJnoOPrWJb262l3bXMoBlmyDnrQB0DdeDTec+1OYZ9jSdv50AKQKQc0DpxzR05FAARjp0pR14pFORnGKOnQUAPPTrSdcDvUF4zpAZE6ryafFMrW3nEgLjOaAOd1mWSLUReFtsMDAOfY1rOzakU8lv8AR8ZLD+KuetQ/imw1GMForVnKq44LYrotEYDS0hThohsP4UAUrHT4DrEl6q5kUeWDWokHl3bSpwHHI96LGHyYyD94nJqcnmgBCRglscVyfjLX5f7Mu7PR42mu2QrlR933rqLmIzQuisVJ7is5Y7XR9nmRjZJwZD6+9AGD4A8J2un6PbyXwM1yRvYuOhNdqpjACKoCdMAUyNV2DysFOoxSlcUAcuzzaTrE8cUbNbTAt5ajv7VyWj6/rMM2p2kekzlJ5iImbgYPrXpOrQNLaNLD/roxuX3qjo1wracs06AT5xt96AM62ge3tYfPhS1m7+X1zWvapc3YC3DfuV6E96kisGluBcXD5PXbWkccAACgDLl1KxhR3a7i2qMn5hUWo6rpg0V5bi4h2SIcAsOa4b4iXFnBoctvp1iHMzCMy4wBSaF4EN9bWs96xEYQbVbt70Ac8+pW8ml3FjqV8nmRuWDFs4U9BXrHhO4sxoVlBZsHAQfd9a89+I/hTQdD0WAiDfcXMypvJ5616doGnw6botpDDGq4jGSO/FAF5uM4qJriJHZT99RnFTHCqznOAM1j6RJFO1xeTSIFdiq7jjgUARpZtrTynUl/0bokfr7msqaDTfDh8q+QCJ2Pky45B9KueIPGek6Pst1uIpbx+EiRsmq9nZwas32jXbqB88xw7xhP/r0AJoEuvR3clxqSRyWD8QiPhlX3qprPirQ9HvfsWsz+T9oYCJjxgn3rpdMn+zy/ZXnjlhH+rYEHj0rlPi/4E0/xrZ2trI6295G3mRzLwVxQB1Ontd2sasH+1WhGUcHJxWpE6yLuWvmaDx/rnhq2fwvHNv1G3byo5vvBxXsHhbxdLbaVCmvW063ITLyCM4JoA1/iPr6+GvCN5fH74XCj3ryT4U+Gb27nTxTNJm9l3TKpOcL6VY+JHxK8M+ILiDRmuCIlkBlDKQDg9DWD4z+I2n+HvLXwtcAl41jaCMfKB7elAHoo1464l0klqswuSYWj6mHHBNVLhdP0DQ7a+0u5SK+059hjD/6xSeQRXGfDvWptY1CTV9Llhs3fEL2ztkv6mui8T6Xo3hTV5NRmEl7Bexnz4xljG3qKAOvPxJCT21rJp0n2q4A8rn5ST71rQaVrupzGbUbiOCJvuxR9vqa+e7iHxH4k0R7/AEKKX7HaSFkcnDjBr3Hwbf6pc+FbG51FpdzINzIdxoAhTwMtp4xtr2XVLltyEFN+AaT4m3emaPZWwF5I1y8qhYUkJL89MVq6lpUOqSW92L642wgk4bFcN4T8MG9+Ii6jqIkmRATD5pzgDvigDY+HtrqOq6rqOrXcQtt5EcSsMkAV36aZFkGd2lP+1UNndJBdXcaoBiTAArU/CgBFVUGFUCkAAbGaec9hyaCCMetADAwOQD044pvUcdaeABketNxtU9hQA0BgCCcmo7yf7NbZ/jPCj3qWaVIofMcjbjP1rFs5ZtT1EyzRmO3iPyA/xGgDQ0qzFvEZHH72Q7mNW5JFiUsxG0UlxKkKF3IC1nKr30oaUFIF5C+tAHC/ETU59P8AEmg6rfgpoySeWxHQFuAT7V6HqNzF/ZaXMDqY2AZSDwRUHiTSbHXvDV5YXsQeFoyBnsfWvIvhlq2oCzudFvt81lbM0NvMee+ADQB62szalPEsZ/coAXPqads+3agGYfurc/L9aqaC32LQ2hlGLlMg89a09Ki8q1G77zcmgC2c5o4/GjvSd6ADI7U0ofXNPON23vSZx1oATnPJ4pQ3PPSkByTTXkijHzuB9TQBIfnjZQOSMCvKda8bGz8VR+GrtTGznIwfvA16Rc61ZWEEs8sh2xjJIGa+afideX+t+NNM8TWmnSR28cyxo/dwDQB9M6RaJY6fFHGoVSM4qG2U2uoSoCSkp3D2qzpl2t7plrMBgmMZBGCOKm2hiCQMjoaAFPNKcAZJwBTZJEhXc7Ae1UMTXr5IKQA9O5oAtx3MckhVCTjvSX1rFf2b28wyrDHuKctuqEeXgL6VOB0oA5bSIr+wmktEmEnln5Vfrt7VsHUXjOLm3kXHUgZFSXdoJLiO5j4kTg+4q51Hz45oArxXtu6Ft4Ax0PWs/TrZTcSSsMoWJUGrU9iJrhCQBGOTiru1VAUAACgBCfelHXmmseQcZpaAPN/FF1BfeK7DSYxuhtyJHjQdT716JC3yKu0KAAMeleS+GfFXhjw5HLc61cEazcEtMzqS30HtXYaR8QdD1iJ20yYzuvUbSP50AZvxos4r3w/bxhj9rWYPAi9WYVY8N+Itdv8AQLeVdNUSRjy3Rm5BHFc94f1geJvHs11ejKWKlLaBTkE92Nd34dnEWr6jbzMiOxEgjz0BoAxvEOvX0GlSI0FylxL+7QImeTVK00mxjsYba6+1y3LJny2Y8mtb4hasbBrCK1VJbh5MqmeuKv8AhiwuUja91Uf6bNz/ALo9BQBw3h/4YD+07jUL4iMuTsXqQKi1X4JWGoTyynWdQjLnI2SYC160x6gmlUbuhoA8lt/gxdWKxnTvE+pKY+gd8iuT8VaJ4sl8SfY7DV2mkhi5ZmxgV7D4v8SrpQS2t3HnPwT/AHRWJ4D04ald6jqMhZ0OVRm/i9TQB5tofh/VZ/GGh3cmmRzx2Knz5I+dx9T6mvdrvW7SJQk1m+WGANlYfwtI+y6qCclLp0z9K65oYnlDsgLDpmgD5/8Ai5oGj2OoaOLfSYmv9RuCzKq84/Cut0f4RaZc2qS6lZxRO2GIA5+ldXqekjU/G9jdsiGOyUkE+prrJZFjQuzYUUAcdF8OvCulWu+KzSExnd5inBzU2gpperalKYLdJIIl2FiMgmpfEdyf7Fvb26z9njQ7E9TWL8M5NQt/D0a/2Y0RlJfcxxkE8UAbmmaM2g3t3FaKrabdZ/dgcIfauV8L/wDCRaC19Alot1py3DbFz8yKTngV21+dR+yPIJo4jj5RtzXA2UPj6TVZzYywx2chzvlX+QoA6PSr6PVdSK3Lx2SKeYSdrPWst/Yw+JkhjliO2PGQRxXnI8NTah4n+zeIbordOMhozjNLr3wvbSNVt7vRr2cmY7HWRyQPQigDqb65vU+KNtZqVGnywmUkd2rum+8c151pX2q5Zru9Ux3mnuIj7jua9DD74o3AyGANAC54JHagEkZpD82dtNkLrEdg+cDigBt1NFbpvlYD0GapPJLdWNw5Bjj2HGetEFizTedeHzG7DsK0ZY0mtnhYfKwxgUAcP4F8Rp4rWWDy2VbJzG27+Mg4rtgqrwFAHYVieFdPs9MjlitI0jPmMWwOfxrcYBj6UARTQJMyl+QO1TJgDbgcUjkqhIGSO1QWl3Fcq3lsN6nDA9jQA+4UvbyJH/ECDXn3gKwCavqFqqqLeKdmP1r0VTwfpzXN6ZYfZ2vZrXIM0pYmgBniC0mu9dsrq1lK29u2JlHR66pAuwbANpHFUbJYZbWSJOexPqaswgwW4WU/dFAEnPfpTIJUkdgp5U4IqlLrFskwjDbpPQVGVaG9jv14jkG2Rc/kaAHWtylzqswjfPljaR6VpHqc1x/g24kfxPr8UoHEoaP/AHcV15zzxzQAoIyahe3glfdIgJ96lpQcAk9BQBkeILWOS0W0iVQJTyAO1QQaNa3kIt3jQxQjCADofWr8REsstxJ9xAQuan0tNttnuxJoAh0qQbJICAJIjg+9XT096qSR+VqSyKDiQYar1AFRLXzJC853HqBVrGB8oA9qUnikXHPNACjnr0pCM0d+9LxigBB1puB70/AweaQEY+tADT0pe3SlPc0uegoAZxikJ54p2Dk0mMGgDzvQdD8FTywztJaXd2Vzl2BJ/CsD4iaxpMl9F4c8KWCz6rMR5ht1wI1/2iKsWvhfw/p583UtPktrsAETAnbn8Kv/AA+j0Oy1HVri2vLbz9wLzMOcelAEPwz0KDwz4jntbxs380Yc5OcD0rX8Y6loug+KLLUL+5WMzDyGAPb1rD8N6tpWv+OtV1B7rcIP3UQRuGx3ra8Rafa61C1tFpDTNuBEsg6fjQBwtxpGteJ/iLa67oMcy6RagqjTMcOfUD0r1+wfWA0YvvKZQOdtSaUJ7OzhtzCkSIoAVe1XmkJK8HmgBSGJz+dVdTeWK3xAVVj/ABn+H3q0ck8Zqnq+nJqdjJBK7pGwwdpxQB5Dd7/Ffjgabp4eS1gGJrjsx717JDaw6Lo/2e2QLHGmAPU1w3gfwfdaZqN9cLekQM22IBecV1U+k3NyPLmvpCuewxQBQ+H8BtLa9ikAWd5mlYZ55rqCck57VyOj6K2k+L5JPtM0qTxdGOQCK69hhqAMzS1P9oXkrHIJAA9KWdHv7nacrboeR61dWJY2YqOpyaeAB0FAGV4osft+jG0QfKzAEe2a0rRVgtIYVGAqhalblemT6U0gtwKAEkRZRhhkU5OBtHAFIWCOqkjJ6ZoKsGGOlAHnHxSB0zUbPWI32iH5nHsOtdXpeoxeI/D8N+jrtfDx5PSuU+PoceEiYhuZvkI74NJ8ILaLSfBtrDfkGB03ozN+lAFiDVbe71LVrbz0AZcMqn5lI71X+G/xBg1GW70fUnEd1ZSGMOejrng1xnizR7fSvGNn4ut42j02SYQzpuwGB4ziu08V/DPSNeaG+0aQ2N3NHkSxNjdxxmgD0lGR/uOrd+DSrnJ4rwT4HaxqmjeONZ8PeKbmVipC20kp+Vsen6V78UO8kcj9KAIzyMGobu4W2jwCDI3CiptwJIXnHWuX8bQTWsDalZzlbyJD5cZGVJ+lAFye+s/Dtq11qkwQzNyfc1aiuri+CSW8e23bkMe4ryC88RxS+H7q58U21wbxVJVVUlAfatP4f/Gjw1PpUVpqFybeeL5FDjqBQB6+DjGazb3Tis5u7PKy/wAS9mFQ+H/EOn69G82nzh4wce9aF9N5KRgMFJbAz3oArx3yT2cwHyTopyh4IrDj8TabDaCye4SG8dtgVzjJrd1e2tzbmQnZNj5SO5r5+g0Gfxj8TJ7O83rbwSEuyEigD3G51iz0PTRtYSynqE+Yk02xu/7TgSe5aTY3IjC4x9a57R9Gn8GeIxaFWvdKvPuM/LRsO2TXoKhAAVjVfbFAHDeLvEkWjKixaVNKTwHCcVix+Ir+6sZYrYNG8o4Vx9016hPCk5TeisAe4qGSxt2lz5EeO/y0AeWfC6+11/GN/FrdrsYIB5ijhgO9eutnOM81m/ZI7bVI54UwSu1sVpHk5NAB0+tB5BBHFAORmjr0oAqX+FtRFCp+c44q1EAkSKOgFLgHqORQwPYUAHUjrmlx+dID6GjmgB2Mmkx60p6dc0hoAB14NOqPnPvSgnGDQA49cCgfdNIMjNHYmgBecYycH0pBx0pc9KTNAC4HXNIcfjS5o4zQBnSxpOdsqKw9CK4+18F6Vf6pqcs8JAkbYVQ7QRiu03ZHIxTIYVjZmT+Lk0AZuieHdG8Pw+TptlFFjnIHJraRgRkDAqDaRznmpcZHPSgBR8zHPNA64PSmjLE4PPtQDgigCQDnHFNnYJCw7ngU4MCQO1UL25Ed/bQYyZO1AFqD91bjjHepo3LDJ7VGyHOBWfrmoQ6ZZfvplR5PlGTjrQBZhkW8vWZACsXAb3q6WG7GRn0rltK1i3njNhobrNMoy8v8INbmnWbW+XnkMkxHJPagC7jI/pSEnI45pOT1qGW7ghI3yZPpQBOMg5POacFOc9azpNYgU4SOVz7LTZNQu+WS3EcfUs9AFrULZpod8RxKnKmqVrrcEysiMHuoztkjU5IP0qvYvqOrwy73NvCThWHBIrAuPBM2jX76xot7L9pYgzrIchxQAarHd674vtYrpVTTrRS8qnvxXH6j410+38RT6LFbytZq22DauVDHrXcX+nz+Id0dlemOMr+/kj46fw5rnfB1pp9xbalZ3VsYLqKUqk7J6dCDQA74p3mhX/w8udO81obyOLzIV6HcOlcN4Z+M9nb/AAySC8Lx6/YJsQOCBIRwDXtGmaXpeq6cf7Zit5HhyrPx8wryD4xfCSLXIEu/CccURjz+6Uf6z6UAFwmpa34d0vxPqYS1jeQOZY+GXPcmtC/8S+LdFWMW0rXGly4VbthnBNZfwt1fU5PBt74e8VaRcSRWeY1ZUyAB6/St3QvE1r4hvjowhMWm2EeZ1b7wPtQBa1HxN4jtWttE8PNFqGpyKJZZSPljz60zWZ/Edjc6fD4imiM92QoWIHaD71D4M+JHg7w9faoJbgM6yFY325JA7ZrL1P4w6ZqfiN7gWTS20KkR7kySfagD07VdR0TSNLOl6qsUlxLCSiEAl+K8o8P/AAotLJI/ETRCaBpvMMJGdi5zWBdaD4u8YXMuv20UjxKSYInJBjHbFdt8JPE3iePSrzStZsfNktpCrK/B2n2oA9e0e10qWzjm02KNEYDPljFc78Vp3stOspo5jEFnXc3tVrQ4bvSLt5RasbOf59qHO0/SuX+JuvW19qdvpMisFYbmDDGKAOk0nUH8R3amzbdaxKB5nqe9U/DeljT/AIg6h5Q/dsm7Pcmtn4e2sNro5S2Xam6nWsElpr091LyszBQfSgDW1qEzWhkUfPF865qSwuBc2ccoHJHNN1CTCLGp+aT+VQaXbvYs9s53Rn5kNAGguc4NKetIBSgdeaAGEKXz3p3GPel6kmkbA+tAABgfWjGKVR+VIelAC0h4FKvIo7c0AJ+NH160uKT9aAFHINIRnpR1NOoATGKMUCjA7GgAzjNJ6YoPpmlTjjqKAIVlzcGPHQZzU3aqFozvqM7Y+QcCr3HfpQAhPHFJGxZcsMGlOOhNGMDAoArE/LlaE4JHrQuAPagsVyVAJFAEF8JxaubcAyAZA9ax/BWvpqxu7O5/d3UDkMjcHFaYk1GUMFEceehPNfP3x5g1LwvexatousTrqVwQkscPp60AfRcdxC8zRQsJGXgkdBT2GTjpXl/gHxDaaF4Ss7m5vHnkdQ06y/fDHrXUXnxG8M2+mfa7m+SMPwF/iz9KAOp+SFGeRgEXknNcJda/LP4xWWzCSWtvCchjjcfavPNU+JE1/rD6ZbXYmt7k4hVB8wz2avRfBnhKaC8XUtWHzGMKkXZR/jQBU1T4vaRZ3aWS2d59tc4CtEQCfrVrUPDU3jO4trzUGktrULkRBuT9a7K80jTb2PE9nCxxwSgyPpVNNPvrGE/2dPvRekcvQe2aALOkaJp+jW/l2ECRDuR1P1rQGD1rJ/tuG32Jqpjt5H4HzcE+1XYb2KQ4iyV9cUATOeQMUzyYDIWaNS3vUgG4Ais7xBrVnoVg9zfOqgDOO5oA0isaKXKqoAznFZ6htVlVkbFqp6f368h8V/GOS+s47Dw3YSz3UhxI204UV0mma74uutLtrXTtKigyoBllJ4oA9LZorfC7lUelVrvVtPtreU3F3EgCnILCuf0Tw/qkCvJqGofaJ5OSCOF9hVbxL4V0ubT7t7lWnu2jYAKe+O1AFSw8R+HvDulXNxbXyvbzszkBsnca5jwX410m/wBT1MTysLfcNsZTrWp8LfhrpdvokV1qkf2mZ8nZJyE9sV1uheGtCtb/AFIQ6fApLAn5B6UAczrNifEs1vBoby2tsT++aMlQRXTaR4Xl0lyYNRnl+XbtlO4D6VvW0UUJC2sSJHj+EVOcg5zQByvg2xubGTVP7QWJt8zEttxuFcP4i+HMHiHUrjUdEmewuJCUmeM7QyemO9et3MZmjaNPlDfeIptlapbW7xRYAIoA+W4P2d9TktHu11NS6yn5cdVz1+tey+AfhboXh6yje5iW8nODulGcGvRbRTb2vl8fhQ8a+WUUYoAkhSK3ULBGqRgcKBxWJq2gRXV0b6wIt73btZlHDj0NbCH92Aeo605fl6UAczoWt3VpfnTNXiKtn93Jj5Wql8R9GgupBeyJGu2I4fHIxXV6jaRX8DI6gOB8r9wa5LxNfG40ObTJiv22P5fm/iX1oA2PAKCPwzasrbi65z3rQ1YfvbU5AAfJqj4GRo/DtshXGFx+FZXizV2uNasNIsPnlZt0pX+FaAOktsXd00x5VPlWnyXBhu1SbG1uFY9jU9rbraW6RoAAOpNVNZt476wkjWRVlHKEHkEdKAL+COaPbpXMaN4jjvrd7eO4h+3W52SRswySKltvF1grNDfHyJVODu6E/WgDoe9HGaisb21v032k6SKfQ1OcBsY5oAYAd3Xg0/jp29aM4+lGeKAE6ZH60GlJ7dqQ9OKAAjgUAUdqF6YoAUZPTpR9aUHApjOqr87Kv1oAU+1IKpz6nbRSCMOHc9FWgy3Up+RAiepoAuD1oZgqOT2FMTKoAeT61U1u4Ntp0hQjzGGFHvQA7S3VkYlvnYkkVcOPpVDQbdo7NZLgZlYZNXyeRQAEdjSIDjmnggjpzTRmgCuQAMd6RVAbHrTipKKwPUZpkwKRN8wD9s0AZOs6qkd2un20yJOwy7E/cX1ry7xt4m0qPxBpmjaXANS1Hzg8kjLkA+5rur/TdMs45nndZ9QueASen/1qzNE8J2Oi2lzOXguppSZXkOAyn2NADb/wZdatZHzbWKOaT7zZ6fSubi+A8E9/5+oahKU7Rr0Feg+F/FP9q2JezKzrGxQgHnitO78WaXYITqU4tmA+7JwaAOd074YeH9Gsd9jaob2I71nbltw962dL8VW1wEguWCSj5CRyMjjk1lS+Lpdcili8NwPNFna0+MD8PWsrwZe6BYpqmlahOhuElLOHHzZNAHod1c+SgeJTKT0xVWN9QuSRIBAh6Y5NczP4x0jQFjV73zLRmx83VRXT6b4i0jUYkltL+CQN0w4oAxPFOjWrLYtMhlkE68t9a6sxIIVRVAGMHiuO+IfiOw0q40i3edDNc3Cqqk9vWtnxf4j0/QdFNxc3CBnX5AG5JoA5bxr47Hgy7SIwvdwydWTrH9a4e41RfHev2UP2geTK2GXPRfpWFvtPEGpy3d1q0gU9IAN24/SsrxVa3/h82uq6RYTwGGZT5qoQCM+lAH0zovhTR9CtkisrOFSBktt5J9zWtkBgEUAfyrzTw/8AEmRrGBtWspk3AZcKa7zStWsNXiEljOkg7gdR+FAF1iXRghwfWq9paLGWZyXdh1NWAMAjNIZAmNxwPWgDJ0LU447i4sXUx7JCASODmi2njt9Rv49wM0mNo79KzNcuodPmv0dC0kyho9vc+tV/ANnerfXE2vEG8cDyznjZ2/GgDd0a9I0+5E/yywMcg1c0+Z57VHYfe5rC8Uu2n61ZxomYtQfy3I7Ec106w+VGiIOAMUAGMUmDgjHFKEIJwetNIYMvHHegBUUlRk5pSTtx3pV646UwjbnB60AKQMc1DeTm2gMgBKr147VMy8delRs0M0LxNIvIwRmgCWCRZYVkTkMM5rg/iPocmqRTajp8nlz2kZO4fxY7VsJqzW9ibGy2PdByi5PT3rH8WJdQaE8VzqcdrE6/vCg5YntQBz2lfEmO78LrYaWBHqUUX7zzOAMdcetT+ANM1eaZdauZFW4m+XDDqPas7xX4L8OweEraa0uxb3+0MkueW71D4X+LtpbSw2F5EJTbr5YZO5HegD1XUNOv5kbzb4xRkdhzWNp/hq4uJSseoT+X0LE8mrGj+JbHX5BIJScdIumKq+KdVv7b5fDKb7vGSjfdoA8h+J/gq88J+KYr7T7iWSK7O5vmwytXS+HfE2mTaO1h4ktDkD/Wv1P41lxz+INR8aaXJ44jEds7FI1X7pPvXpeoeE9Nk1RbK+t1ezuF+RvQ/WgDidK8SaPp+o7NIvSMnARnr0Ky8UzxNF/aEGI5MbZAc1xWufA3T43a40eWQSA7tjMevtVnQIpNHJtNdikjK8JI43LQB6vG6yxiRDlW5FB/Sue0zVpZHaKBY5FXpg9RW5C7yqC6FPY0ATZwaGpPYUE9u9AC4PGeKAM/WkBOKjuJlt4TI3agCnqM86OYrcruxnmuXbVVubz7JcRzxv0MrD5fwNdJa2j3Dm4nYgN0HtV9YIFQoY1IPtQBS02wsokDRFZH9Sea0s9R2rB1y407RQtzOWiBONwBxV7T9Ttb2FJIJFZT3zQBeOAMnpWdqMSXd3Ai5Kqcn0q7cI0tu6QuNzDg15z4U8VXmna7daZ4mjEYEpWC46BhngUAemY2IFXoOKX+dKxUgEEFTyDWfPdF5fJteW6E+lAFma5CPsXDP6DtUqnIG4YqC2tlhG9uZDzk1OTwKAPKPCHjC98QaUySOUv4zsW3Qc+xJrrtP0i7mQSaxctI/wDCinAFcJ8Hv+Qle/7xr11+34UAZaaFYLLvMIdvU84rK8Z2Om2mhyo8YEko2IqdSTXTjrXI+Kv+Q/pv+9QBQskj8N+GxDo+jymRUyX6c+teUXfibTtV1J08QNIZAcOCv6CvozVv+QLcf9cj/Kvku+/4+rn/AK6H+ZoA+jvDni3w/Z6XDb6XEBGiZ2qteP8AifxZE/xQa60/R3dfJww2/wCs96reEP8AXH/crsvDf/Iz2v8A1zNAHUaHPpXjaxaCfQ/JdR86TJtx9KhuvhLpcNwl3plxJYPD85CtlT+FdLo//IcP+5W1r/8AyDLn/rmf5UAfJnxxe9l1OwaG+a6vjJ5UMcS8gDv9c13Xhj4X6/4jtbGfxXfzIiqCIic4rl7T/kf9O/67ivq0f6qP6CgDk/DvgPRNCIkgt0aYfxsM1p+KoIp9Ljh8lXVpV4x71qzfcaquo/6qL/eFAEy2tp5KxmCMqBjG2sy18O2VnqRvLVPJLcMqcA/hWxH92nN92gBfp0qnfTra2czTncuOAOtXf4TWTqf/AB9Q0AcV8PtTt9ZvdUi1KUf2gpKxRv8AeVO1diLOS70dSJvLuoshXHYivFbf/kuf4H+Ve6aR/wAec3++aAPJfFkfjbVL63/s6PfLYOXUkfLIe1VNN+PM+n6m+j+LNIezvYQAxU5B9690s+p+tfKPxa/5Kxqf/XH+lAHvWhfEPSNcVms723DAZKs2CPwq1pXjSwuT++vLdRuKj5utfIfhH/kYZPoa7yb/AJAVp/vf1oA+p4bq2uRm3nR8/wB01KE57815H8N/+Phf92vV/wDlitAEN3epAwjUeZIf4RUMNkj7pbtAnGcVn2//ACHx9K3NV/5B8v0oA5TRvClmddvNUCsBKcKNxwPetHxDodhdQRJcRh0Dg8n0rX0f/kHp9KzvFP8Ax6Rf74oA4nxbp0fiHV4tMtogsaps3gfdFavh34U+GdFtMz2yTXB5aR+STTfBH/IauvwrsNZ/1ZoA4vxV4eitNJlu9AyjQDO1PQdRXJ6J44u9VltrPSoPNIIErEfOB3r1WT/kXbz/AHG/lXgfwk/5Hlvq/wDOgDq/jDePb3uixbttvMVXcRgo+RzXTavquq6CmkDUIDe2cjqouIhkp9a5L9or/U6P/wBdhXol9/yJel/WP+lAHUW9/FOqvE/JHAPWi4igukKXEayA8HIrGX/j4X6VtJ938KAMW60GC1Iu9PBSWEFgq9CPSrmh6rHq1is8YwQSrKeoIrQX/Vv9DXI/D7/V6n/18v8AzoA649aTGB70o/rQ3SgBCcDHeoZbcTY38gHOKmP3xT27fSgCFXTcY1YZFOIwQc1n2H/H7P8AWr79RQBDfWkOoWr29yisjDuKw7O2i00/ZLqHMY+5IvcV0Q+8tUNa/wCPY/hQBT3RRybovtCgc+1clfanper399pBhe9eRNwZF5Rvr2Nd7D/x6f8AAa8v+GP/ACPWt/7x/maAOm+Heq6nJpMtlqdpIJLVzEGbqyjofyrrLae2VTgqj981DYf8hC7+tZ9z/rZKANwzxsuVkU/jSqxIyORXMRfe/Guisf8AUL9aAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic morphology of Fusobacterium nucleatum. Note delicate rods with tapered ends.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sherwood L. Gorbach, John G. Bartlett, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6163=[""].join("\n");
var outline_f6_1_6163=null;
var title_f6_1_6164="Seborrheic dermatitis (including dandruff and cradle cap)";
var content_f6_1_6164=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Denis Sasseville, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6164/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/1/6164/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     SEBORRHEIC DERMATITIS OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is an inflammatory condition that usually occurs in areas of the body that have many oil-producing glands, including the scalp, face, upper chest, and back. Dandruff is a mild form of seborrheic dermatitis. It is also common during infancy; this is called cradle cap. Cradle cap usually resolves by eight to 12 months of age.",
"   </p>",
"   <p>",
"    This topic discusses the symptoms and treatment of seborrheic dermatitis in infants and adults. Other types of dermatitis are discussed separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"     \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"     \"Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEBORRHEIC DERMATITIS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of seborrheic dermatitis is not completely clear. Symptoms may come and go, and may be worse during particular seasons (eg, during cold weather). Flares can also occur during periods of stress, hormonal changes, or illness. Certain neurologic conditions, such as Parkinson disease, may increase the risk of developing seborrheic dermatitis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"     \"Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEBORRHEIC DERMATITIS SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants, seborrheic dermatitis can cause a condition known as cradle cap. This causes redness and greasy scales, most commonly on the scalp, but also on the face, ears, neck, and in the diaper area (",
"    <a class=\"graphic graphic_picture graphicRef52972 \" href=\"UTD.htm?31/50/32546\">",
"     picture 1",
"    </a>",
"    ) and skin folds (",
"    <a class=\"graphic graphic_picture graphicRef60585 \" href=\"UTD.htm?13/21/13649\">",
"     picture 2",
"    </a>",
"    ). Unlike in adults, seborrheic dermatitis does not usually cause itching in infants.",
"   </p>",
"   <p>",
"    The condition usually resolves without treatment in weeks to months, although treatment may be used if needed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Infant treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis usually affects skin that contains many oil glands, including the scalp and face; dandruff of the scalp is a mild form of seborrheic dermatitis. It can also occur on the ears, eyebrows, the bridge and sides of the nose, in the crease between the nose and lip (",
"    <a class=\"graphic graphic_picture graphicRef74411 \" href=\"UTD.htm?27/43/28336\">",
"     picture 3",
"    </a>",
"    ), and central chest. It can affect the upper back, armpits, and groin. In men, seborrheic dermatitis is usually worse in hair bearing areas of the face.",
"   </p>",
"   <p>",
"    Common symptoms of seborrheic dermatitis in adults include redness, greasy, scaly patches, and itching of the affected skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SEBORRHEIC DERMATITIS DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific test for diagnosing seborrheic dermatitis. The diagnosis is usually based upon a person's history and physical examination. In rare cases, a skin biopsy (removing a small sample of skin) may be necessary to confirm the diagnosis or rule out other conditions that mimic seborrheic dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SEBORRHEIC DERMATITIS TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of seborrheic dermatitis can be effectively controlled with a combination of self-care measures and drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infant treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cradle cap usually resolves without treatment, it may require treatment in some cases. Suggestions for treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shampoo frequently with baby shampoo and gently remove scaly skin with a soft brush (eg, a soft toothbrush) or fine-tooth comb after shampooing.",
"     </li>",
"     <li>",
"      Apply a small amount of an emollient (white petroleum jelly, vegetable oil,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=see_link\">",
"       mineral oil",
"      </a>",
"      , baby oil) to the scalp (overnight, if necessary) to loosen the scaly patches, followed by gentle scalp massage with a soft brush (to lift the scale), then shampoo with a nonmedicated baby shampoo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If cradle cap persists despite these measures, a healthcare provider should be consulted. They may recommend mild topical corticosteroids or a prescription antifungal shampoo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adult treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis in adults is a chronic condition. Long term maintenance treatment is often necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539418960\">",
"    <span class=\"h3\">",
"     Scalp seborrheic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dandruff (mild seborrheic dermatitis of the scalp) can be treated with over-the-counter anti-dandruff shampoos. Several types of anti-dandruff shampoos are available, with the main difference between them being the active ingredient. All of these treatments are equally effective after four weeks of use.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=see_link\">",
"       Selenium sulfide",
"      </a>",
"      (Selsun",
"      <sup>",
"       &reg;",
"      </sup>",
"      and Exelderm",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Tar (Z-Tar",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Pentrax",
"      <sup>",
"       &reg;",
"      </sup>",
"      , DHS tar",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Ionil T plus",
"      <sup>",
"       &reg;",
"      </sup>",
"      , and T-Gel extra strength",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Zinc pyrithione (Head and Shoulders",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Zincon",
"      <sup>",
"       &reg;",
"      </sup>",
"      , and DHS zinc",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?37/52/38720?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      (Nizoral",
"      <sup>",
"       &reg;",
"      </sup>",
"      1%)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For best results, the shampoo should be left in place for 5 to 10 minutes before rinsing. The shampoo should be rinsed out of the hair completely.",
"   </p>",
"   <p>",
"    The shampoo may be used every day initially, and then every other day as symptoms improve. These shampoos can be used for as long as needed. If one type of shampoo does not improve symptoms after four to six weeks, a different shampoo may be tried. If the condition worsens, consult with a healthcare provider.",
"   </p>",
"   <p>",
"    For seborrheic dermatitis of the scalp that does not improve or worsens with the above measures, the healthcare provider may prescribe topical corticosteroids or antifungal drugs to treat itching and inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539418974\">",
"    <span class=\"h3\">",
"     Nonscalp seborrheic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis of the face, trunk, and skin folds generally is treated with topical corticosteroids or antifungal agents.",
"   </p>",
"   <p>",
"    Low potency topical corticosteroids (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?38/9/39056?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% cream, available over the counter) may be tried initially. The cream is applied once or twice a day until symptoms improve. If there is no improvement after two weeks, a healthcare provider should be consulted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498749413\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29457156\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?22/5/22610?source=see_link\">",
"     Patient information: Seborrheic dermatitis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=see_link\">",
"     Patient information: Diaper rash (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29457171\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"     Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"     Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"     Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=see_link\">",
"     Cradle cap and seborrheic dermatitis in infants",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link\">",
"     Seborrheic dermatitis in adolescents and adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=see_link\">",
"     Approach to the patient with a scalp eruption",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     Blepharitis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     Overview of dermatitis",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000963.htm\">",
"     www.nlm.nih.gov/medlineplus/ency/article/000963.htm",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Academy of Dermatology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aad.org/public/publications/pamphlets/common_seb_dermatitis.html\">",
"     www.aad.org/public/publications/pamphlets/common_seb_dermatitis.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6164/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6164/abstract/1\">",
"      Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6164/abstract/2\">",
"      Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6164/abstract/3\">",
"      Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7636 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6164=[""].join("\n");
var outline_f6_1_6164=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      SEBORRHEIC DERMATITIS OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEBORRHEIC DERMATITIS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEBORRHEIC DERMATITIS SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SEBORRHEIC DERMATITIS DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SEBORRHEIC DERMATITIS TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infant treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adult treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H539418960\">",
"      - Scalp seborrheic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H539418974\">",
"      - Nonscalp seborrheic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498749413\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29457156\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29457171\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/7636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/7636|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/50/32546\" title=\"picture 1\">",
"      Seborrheic dermatitis diaper area PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/21/13649\" title=\"picture 2\">",
"      Infantile seborrheic dermatitis multiple sites PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/43/28336\" title=\"picture 3\">",
"      Seborrheic dermatitis face 2 PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=related_link\">",
"      Approach to the patient with a scalp eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=related_link\">",
"      Cradle cap and seborrheic dermatitis in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/5/22610?source=related_link\">",
"      Patient information: Seborrheic dermatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_1_6165="Trihexyphenidyl: Drug information";
var content_f6_1_6165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trihexyphenidyl: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/30/39396?source=see_link\">",
"    see \"Trihexyphenidyl: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18244?source=see_link\">",
"    see \"Trihexyphenidyl: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Trihexyphenidyl;",
"     </li>",
"     <li>",
"      Trihexyphen;",
"     </li>",
"     <li>",
"      Trihexyphenidyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Anticholinergic;",
"     </li>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson&rsquo;s disease:",
"     </b>",
"     Oral: Initial: 1 mg/day, increase by 2 mg increments at intervals of 3-5 days; usual dose: 6-10 mg/day in 3-4 divided doses; doses of 12-15 mg/day may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Drug-induced EPS:",
"     </b>",
"     Oral: Initial: 1 mg/day; increase as necessary to usual range: 5-15 mg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:0em;margin-right:4em;\">",
"     Use in combination with levodopa: Usual range: 3-6 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parkinson&rsquo;s disease: Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Conservative initial doses and gradual titration is especially important in patients &gt;60 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as hydrochloride: 2 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered before or after meals; tolerated best if given in 3 daily doses and with food. High doses (&gt;10 mg/day) may be divided into 4 doses, at meal times and at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of Parkinson's disease; treatment of drug-induced extrapyramidal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trihexyphenidyl may be confused with trifluoperazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, delusions, dizziness, drowsiness, euphoria, hallucinations, headache, nervousness, paranoia, psychiatric disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dilatation of colon, ileus, nausea, parotitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, glaucoma, intraocular pressure increased, mydriasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anhidrosis/hyperthermia: May cause anhidrosis and hyperthermia, which may be severe; use with caution in hot weather or during exercise, especially when administered concomitantly with other anticholinergic drugs to chronically-ill patients, alcoholics, patients with CNS disease, or persons doing manual labor in a hot environment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weakness: When given in large doses or to susceptible patients, may cause weakness and inability to move particular muscle groups.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI obstruction: Use with caution in patients with obstructive disease of the GI tract.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mental illness: May exacerbate mental symptoms when used to treat extrapyramidal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in older adults; not recommended for prevention of extrapyramidal symptoms with antipsychotics; alternative agents preferred in the treatment of Parkinson disease. May be inappropriate in older adults depending on comorbidities(eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tardive dyskinesia: Does not relieve symptoms of tardive dyskinesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F231186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13823804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. One case report did not show evidence of adverse events after trihexyphenidyl administration during pregnancy (Robottom, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F231198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F231180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic agents may suppress lactation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9626964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken before or after meals; tolerated best if given with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Trihexyphenidyl HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/mL (473 mL): $30.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trihexyphenidyl HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $18.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $36.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F231168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IOP monitoring and gonioscopic evaluations should be performed periodically",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ACA (MY);",
"     </li>",
"     <li>",
"      Acamed (TH);",
"     </li>",
"     <li>",
"      Aparkan (HU);",
"     </li>",
"     <li>",
"      Apo-Trihex (MY);",
"     </li>",
"     <li>",
"      Arkine (ID);",
"     </li>",
"     <li>",
"      Artane (AE, AR, AT, AU, BE, BH, BR, CH, CN, CY, DE, EG, ES, FI, FR, GR, HR, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, NL, OM, PE, PT, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Beahexol (SG);",
"     </li>",
"     <li>",
"      Benzhexol (CL, TH, TW, ZA);",
"     </li>",
"     <li>",
"      Broflex (GB);",
"     </li>",
"     <li>",
"      Desagit 5 (PY);",
"     </li>",
"     <li>",
"      Hexymer-2 (ID);",
"     </li>",
"     <li>",
"      Hipokinon (MX);",
"     </li>",
"     <li>",
"      Kinsol (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pacitane (IN);",
"     </li>",
"     <li>",
"      Pargitan (SE);",
"     </li>",
"     <li>",
"      Parkan (HN, HU);",
"     </li>",
"     <li>",
"      Parkinane LP (FR);",
"     </li>",
"     <li>",
"      Parkopan (DE, EE, PL);",
"     </li>",
"     <li>",
"      Peragit (DK, NO);",
"     </li>",
"     <li>",
"      Pozhexol (TH);",
"     </li>",
"     <li>",
"      Pyramistin (JP);",
"     </li>",
"     <li>",
"      Sedrena (JP);",
"     </li>",
"     <li>",
"      Tridyl (TH);",
"     </li>",
"     <li>",
"      Trihexifenidilo (CO);",
"     </li>",
"     <li>",
"      Trihexine (KP);",
"     </li>",
"     <li>",
"      Triphenidyl (CZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts a direct inhibitory effect on the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly on the muscle itself and indirectly through parasympathetic nervous system (inhibitory effect)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hydroxylation of the alicyclic groups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and bile",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6165/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brocks DR, &ldquo;Anticholinergic Drugs Used in Parkinson&rsquo;s Disease: An Overlooked Class of Drugs From a Pharmacokinetic Perspective,&rdquo;",
"      <i>",
"       J Pharm Pharmaceut Sci",
"      </i>",
"      , 1999, 2(2):39-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6165/abstract-text/10952768/pubmed\" id=\"10952768\" target=\"_blank\">",
"        10952768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feinberg M, &ldquo;The Problems of Anticholinergic Adverse Effects in Older Patients,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1993, 3(4):335-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6165/abstract-text/8369593/pubmed\" id=\"8369593\" target=\"_blank\">",
"        8369593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      He H, McKay G, Wirshing B, et al, &ldquo;Development and Application of a Specific and Sensitive Radioimmunoassay for Trihexyphenidyl to a Pharmacokinetic Study in Humans,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1995, 84(5):561-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6165/abstract-text/7658345/pubmed\" id=\"7658345\" target=\"_blank\">",
"        7658345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robottom BJ and Reich SG, \"Exposure to High Dosage Trihexyphenidyl During Pregnancy for Treatment of Generalized Dystonia: Case Report and Literature Review,\"",
"      <i>",
"       Neurologist",
"      </i>",
"      , 2011, 17(6):340-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6165/abstract-text/22045287/pubmed\" id=\"22045287\" target=\"_blank\">",
"        22045287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10022 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6165=[""].join("\n");
var outline_f6_1_6165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231230\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231193\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231194\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231170\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231156\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803231\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231173\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231237\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231228\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231176\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231160\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300176\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231165\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231186\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823804\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823805\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231198\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231180\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626964\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231179\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231168\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231181\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231159\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231175\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/30/39396?source=related_link\">",
"      Trihexyphenidyl: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18244?source=related_link\">",
"      Trihexyphenidyl: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_1_6166="Pyoderma gangrenosum - early lesion";
var content_f6_1_6166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early lesion of pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmh4U0yyjMmt3NjbbV+WG2lErkkdyMiqN9B4fdPKsYrt3K5DBWJ+n0rIGseayxpHaWiEZ6F/xrZsbmADc3ieWA4wRDbYwPbmvPuuh7NmUtHjtVWVZ7W/t4zndIsAfaO/ODj8KrrfQpcfdG1lxEZHYgf7Xr0qaVfOu5EtJ9Tvj1WTlQfqO1WrC1voZ0LQIQUO3zZfu+/Q/lRcLFeG+Ek/kzLbyO3CBiNq/nnk8UxtLvLZvNjIjhdsvGpLH/AICfTjpWlNdTorR3kcM7Bflbd933HHHvViO2BgEr2yqhwC0Mny59TnvUuTGolGHPlIkJbudyn8RxnpzVwLNDbKPJiZn6sX3cVGIvs80k8CKkjZWROyn1qdrxRAom2gAjJXkZ/wA9qi5Y63a4jiWNmfy3yWDkD6BQAaqXUVtp8JV5ZdkmQR3bPua0X1IX+1bJPLjK4LSR5bPc47VnXVpc/MZIlZz92aZDyPqaExMg02SGZf3e8RZ29PlA75PSrdhc26zTGFgdgKiQNkADoFB/nVEQCNCtxJMqH5jhwc+5H+FVraOymcrAu11ztYAlm49v600K9jom+ULIpVIv4pW59eg9TUh1A3KYVJDISVWQghsdOnQCs0TWmwx3ECYjwflbkH1ZhwDz2q4vlbD9lHnjGd2cqv59ah+Rdxb2OOGMbzsZ+GLuN7H8O3FSraQmEyS3SwlOEjUfMD69f0rHlaa681BCJ2HOM5L+g9lzirFhBqYt5JtQs44VUnqcY6YB7YqrE8xZt7lYSDGqMobax28n6n1qeMRXQBaFyi5yZiQM84IA5Pt71Fb3LLsWGFWck/vS4KkHsB6fSr8pkNvHIzq0oXB8tsgj2AHAqb2KsY91bSxjyvLbyRw8SYQn0BP61JYad/ZsZ8i0WGBsM6pL83PYnr+VXbe4d1LGFyxGBjr6DOOaluIXjkladirPhSF4UY9c9KSbHyoosTbYBtzAidW8055+uf5VHLOupMWQFYVwGYN971z6VM0kaXC/aGE4Q/Ng7txx3q7D517aGK2i2Rg4JA6Z64FO4ilY6dZyYZYI44k5EoUMXFMupFnaOGFFiKjaEiXLP9cVK32SymFtcXQnnPyJEo/DHtmrkUBtR5yRFdxwMKFC/ShsaRGt7eCya2kt/JjK4B2Ko2+n16VDBL5Nq6AuWJBMg5Zj6ewqxJJEu9l82WUDdGhO/n8OPwqzBLO6OgECxgfwLyfbn+dFx2IEjtUiEjv5075zCOw/xouGgKt5aNGFGMAjAA4zk/0qfz9hZZPLgDEDcjA5Hoff9aZJbRyb5PsYcJyXeXIGen1pbhsRQ3sKlo0uo5FbqsgB59dw5qO5mNzKqKYZFHC7QSaszp5whaQIdow0cacYznr3qvcTqoZIZUjLcMgHzke9D7AiRYbOJmUzkyoSuAMFj/SnzyzLbNi7lhcYAULvIH1qpBYTJGZGVY0wSRIMZH0qyxuoo0byozasMCQkgZ+h6ilewys+fLVhcMsuRnanBOe5GKrNIklwkTFowTztQksfbNa9lcBQJhDJNg8EIVXHqCarXSpcTC52qTnBQDP5n196EBFDKpmzcSFwB8ol+7/LFSkwSxsPKYlOiqwKjP8As5qGWdhhY/MYFvmSNCAPbNO0/UrW2uJI1sWy33VcgfN7sOlOz3EpW0LkV8kceJpQtu/zbVixk44rLmvnW5AOySNwQMgH9P6VdiijmlZr10tWG9SEYHHHqO9TQNA0HlCCEqp/1svBPHX8jSTHuc+yajJPEvnqGjbKGEfKM9ielaFrZXRudsio0qnLiRuG/InNWormJYFW3driUsdsQTCH8TTlvLiRg01szJGxGyEcL+P+FNyuJRURUDXEbupYqCSUVeCR79eKDp8cdqHuFljGcgAAqTznJ6/hVstG11E1vBsDElRI4UY+o54pbhnDlB9n8rd0il3Ffz9aTK3MyW5mh2FXiaPJZVlXdn8Ktfb2eN3ayBB+/tYKCMenpUK3NrDfEx2D3qgDOFJYfjVd50uHfeqxKAAoI3DB6Dj+eKSuGw6SBJbaKaSJIEZwq4fcevYdBV/7CondLe4nlwSweRQ3A77fwqCC3csGjl3hMNudsKR6Adqnlu2YFIwzYbcGfjb7AjnH1o0AqhAfNl+z5JIU5j2jA71HMs0LKn2iOaMAFUdev459KvtdtLGUkmXy2OCqg8/1xS6deiO7aMWkffAU8Ajr/KgCuBbpGXQJCxOGEeMsO4AJqvqYitBKzuTB95GB3EEdeP0rQkaN53NwqSKp/eKVwQPUD0+lcrqdlHeX+62unhSEgmM/dkPHB55HFXGz0kRNtbGnoWs2jBlt2Qspz5RTAcHsB1Bz3rRknR42PltGu/eRJwCQOTkfyrnrHSZvt/mwI1uXcsFzjr257VtrafaCzeUmVHzO/AVh6DuaUtNBx2K7CWWMxiVjGF3KdhwM9frirtpatBDD9punmijGThcEZ96ZHd+XFtYKGjHAQfeyO/p3qQXN3PChdXVpDjJ4BU44z3xUXKOJsdZgt5F+z+GIXZDn97luPpWjL4h1K/KxW+ladbqeMRW4Ufiay7C7g+1BpZptRlOB5UALgnrztOP1ru9Hg8VXVqY9O0RNOsSOZboKnfrzgD9a6mu5zryOa1GW9ijhR1sTvXhYpGZvTn39qohL9XGPPmUYwNhAz6n+VdhLp9zIxklnW9nXIaOCMbR+ORxWHe3siuseIoM5BVmxt9AT6fSk/MBlvHJLETNFEDghmbJLN06nqBz0qQWVultM7SbF+7/rME57nHbrxRDtRkN3LbOOSsYbOP8AD61Hc3cEhkMbu5Q4EaLhDx3J/wA8VDRSZHOILaIvLOsERUbHyPfqCPSqekzRtPKqqkschxEdxzt9eOPWmPHJfwjMQcE4we2frT7bSYrd4fJ8xUiycq3yj1OB3pq1iXe50LWsYs1KeeHXgIQOOM8nOcVn3V45/wBGkTocgKWZm/z6Vo2yK+3zXKyEbeD8u3rz/nNTGaSEqLJZBJKhVmYDBXPG0Hv79KzW5ocbfNIH/eW4iSRsLJITnH0FRwS3Fn5kkzKLaQhQoALFgOgx09a6i4tGu7ZnaCEOcIEYncD7Htz3rG1K2tY7QxzorPx5ZA5yCOnfGK1jKxm0JBe2hkBuISY8cRKnI7ktnAPNaayG9gKxwlYVOEAIb3OQPeqi2tokcc0UbKQNqu5yDjsB3zWnazsbTcgjtuowclmPXJ7CkxodYrc2kDvEgRS2N49PTHQdKnmE13agXc8hjc5MS4wB2JFUo4YeIIZWmmcZkLSnYp9f/rVZfSLe3jkgnuQeDsxwPyFQyhI44BuhWZkXG3Gfnf6egq5YQ2lkNq2tw0YPKtlM/iarwxeTHGbTcDIAvyJhm9x7Vclt7idVe68yRQuWIcfgOe2aRRXnjVZUeVAsJO4RxSncR257/hVl7OCRiII3O8kiJSQVP1JyarWty5Sfy7ffIAAZSw4Gc4GelLtncl4/KUZA5Ykg+gpXGORJrWN/KjCx7+NzY5PU5796jTMccghIywOWRyo54PPerMdst7KjyTSSypkjI4A9AB1qPVIfKjSSB3jSTGFABLn2HakDMSaGKIh3jClDkMCQMdO/U1qW/mTjE4kA2g7N+1Pz69Ky7vTYbl1kvJbmUqP+Wj4UfQHkdaufZkKqLa1YxqMsCcKfXnqa0bViUnuy/kJNEkM0UD87dnVR396uPZpPbHMbvIOjs/XPTiqVlzamTPljJBWNdoPHQnrU8Mii5YKhCDJJG7j2zWbLRDJGbSNkESXRUHcQvAPt9KSSSCWJGMju4AAjJCgAdcj2qO8dpFMceGP8Kr8oP41SbS/tchaMTl0AJaLBGSPU1UdxO5o2Uj3UUiyXGyNufkOFb23CktbkWdw8FhIieZyhxkcYB5PJ+tSJprNZgpBAsSZXLyFmf14pBGUK7UtguAMrHvI9s0PyCPmSyXD+YRuW43MAXyMg+uOlTOzTttf7wPAkfdxj0xj8KjF5cW80cMcKsijLdCCfelmviySBYIw2CMwgnr25xUtlE0Vnb4Vrq8j2MTy4+6PQDpUb3CWkciRQn7O3JyceZg8HA9KpQ2s8zq88iIpyAG+Yj369a17a4tNNMLSxjI4M7c5+gP40XA52/juL1Vjjint4JCC8igqMY5PPWmWFlDaxmBjK8a8F5cgj3wK376+iaJNo8xnU7GLfKPUBfzqGwe0CFbq2aeQ/xH5l/Kqc7KxPJrcr2lvDEgdmUvITtmYfw5549enarU9rp0kICx3EkxOM9sdhxU0U1kA6Q2SrGwDZKZKmntGLcxkbY/m3eYpLNjHoOKlPsXaxQmjtQ0Qtw0YQ7mbIAx3+U9amm1SWeVDaWwmVFPRdnHTHpU8kccMMrIpYk8TS4A/XJB96pXF3JuygRgF2sqnGT6ZPX60JWYnsZtpqcCXrLLA0k5OSA+Qhz6dh2rSnjgkLtPbIhY5QIwGMnp9KzbaJVMuI3jtnYu7QjeATzhj1/CrkTWphktrlozI5yJW/hXtx2/OqlboTG9tSYw77fyrK4aOUf6vyxkD3J9qxdHuLqxm2rcSXEp4lYLgH3zVqKFHUokjr1G6Nm5FbEdiIFWYOGQDAXzA2OOnsaV9LA43ZAbdZUVmWYRu2WweD+FPu5IbdUaEQhfulpXPzfkOadayWiTmNIw25QMLnhs549vXNZF9YS3k22OcB8kgE8bh2BzS0G/Img1C2u5QXnaZlUhkXqq9jjtViMoJNqyNbPkhGcj5/b2OD2rE06yuYSsBuJJGb5WCgDjOeTWzDEltbsfszyCUkAOw+Y+ozzQ7X0CLdtSWW2Z4SlxIW8s4Xyxw2OxNQgWjF41tWVM8IyjCnPPPbj1p0ErtKqzTx2xj3Hb5fX0HXk9qat3IWdCocM/BjXAU+p9aQy7Fp5SRXknMcI+VogeUB75NZ0rRxzEWtxGXRmwjcgjOBg+tSxQ3Nx588UzMkZIIBGD6ZHYHnvWPJPcm/K+QoVDnLR7QykY6/nVJJq4m7M0xb/wCjpLM4MjnA8wEYwOnp3pJZ2SKPkq6EqJAQVPt7USzxpbvCy+bk4EsQztGOnNMt5bW2QRjbLG+SjSEgj1AJqRmfD4t1mxCyWscEIxhNsKqo9gBT31PX9ZAk1PWGWIDIUvtUDP8AdFYkltbWsHN/DcYb5QpPze+D0qz5puAFit0kyACzjA/+vXW7s5rmhjT4y27Ubu5bqViHHTnP6VF5gWfdp88ktm3BeWPYFHpuwefpVuzjjkYQ3rb416RqQiD8B1P1q5rMt3DbOlrZLbjblBKwZsewweaVrBzXOburW/UW5dQGf/V4TJbnr79z6VfsrOaPm6mKDb8qZ3E+/HAqExT+Q1zF9teYkfPLhVHsPenw306L9nlUqrD55T87cHoo7VLRUTUjSLytkj+SMYLsMFh2wtSQadaoyjy3kD/MGJ2/Ljq3sPWmWwih8piGZx/G0ZGc+venw+dcRvJ5jC3Q427toZvTHpxWbLG3cEUT/wDHzgqwwIuAfxFJAzNBv84yTA4yQXAX0z2qdljjlEjRxSK3OxiBz7CqUrw/aWVpgEIOYg5VPx9am/YfqSXMxE6iKNmlc4yzHavP6ms29gZ4ZmZ4BjJM0hI4x/npW/aXEHkuYgAyAru2nJ/D61jzwy3ETy+XlkHytLzk1SepMkYVnqUcgia4EhjCggLFgkj0Jqa8vUaNzCqNO7DA81nIB9h0xViXzngjRoY1nCrl5PmHI7AUkFm1skkcqmKJuXJ+8/I4HpWl7EWuasD+XEiRoywsM+Y544HoP8auT2s8ccUrxKsbDAbdgnvnHPX3qnbXkcsaGOGQIpIAkxggDj3rUtri2nieOTEcfXIbBJ9D3rKTNUNtrh1IVNiq4AJHLAfXt0pXErRSJcSeXGCSpeTc3POMDt06VYXyLlFghUBFU8g4HGeSfz60kMFvs8uPbJISDuZuFxxwM89qRQ22fZHJJdDzCMAA4AH5cVUmlmKlU3qrt92M4yPUmr0Wn20YcyPK02cDI44p4lVmf5C5GACRhcHsO9IEQTSeUqrGkoVhnOAuePXt+FU7S2u5r0uIiWH3SOmPYnAGK0I53XcokglUDavAO36ZomvZFG/zAoRdwMgC/l6//WoAg8m5SdpLpGSRfmU8scex/wAKV7u6micwQGQ+rJ830Aqxpt/O7yuqyXOxTk5wvHp3psl5cBBIWMbn7hMZP5CnYCG1+1KzP5e4t8uzaE7ds96c9zcylIrmLbu/vN156dOaZBflFkMySrL18wr1981V1DVltYN84QkkbSyGQu3bjtimtXYNlcmubBre23TSRAg4CB9px7cc0uk7Z52EeduBtVcneR/LiodJt7q/8ua6EyeYM5cAKgPfA/lVu7tI7V4iJ5JXwcrCmzj6ilsxJ3JfljlkJeR48nepYKOR065NNUN5Zh3SuuMlFOFDdgT/AEp8SRPbLJDYZk3DG+QM2e/FMNsnmPPOqRc8ICQQfw9u9BRYis4pmPnyBolXLrGwAHbPv706RIojH5bxpbxAEJIRk+pA64+tUxAkEEs8UEjZcCMxswX8ScZ9adJbPKiTrdBmHVY1LF/UZpMBUuIpruOKSIzMzYQklAvBOfp0qTy7i0ZohD8xycxDeQfXJ4GBVC4kWGVCUgVlXmQkk+2ferVoFezdmlmEucJtYBcntg0IBkVuiyPGbeSQxEZxzhT2yOAOau3U93La/ZysAhU52nJaMZ4A9asWdrcI4mW4iaMjBj285HHzY96pybPtDPIUnGSGjOTz2yQRmlqMjtcM7Lbh550BB2kOP5ds002M0Fwk90sRgcbcNJuZO244PFW0vEtpgFs0IIAAifjnturNhstRubiXzrGO3ti52maQ5JHU5H+eKuMU9SG7Fk2cUgMQvnuF3HYqsV+vB5pv2YxuBcOzk/fVWO7HGBipRE0CBUe2tULbt0Y7j3J5/AU2KGW6ug7TSO7Hkk5J9/apbLGKkEcpWS2EFqxJI38kfWqpuLa3ZjHbqBn5G27cj3OOlXJFaO4ljRSZ1O0bipz+f86WW0uWMjXyyFg3PcN7Z6frSuFh9tLJdo/2tl2SDpGeQOxHt9KYbaxtZVgZ2mI+YeYx29PTpRvtlk8qWAidgAUckAD2x3qrJFO8mzmOOMhiWUknGegP8qVwsOvrRvIkjtwgQtnzN6nr04FIlm72yiRv3ijOFYnj14FLFBGsUd00j+b9wAAr+Pp+FS2s0roJIGuBk4QqoHUc5J5xRuMnW4WKIrcwjft2NsUfNxjgevfNVVLJIGkG9DxH5hGU/CpLyxngQPfKkcxxteNxjnHJ9vpUOoYaSIR3OWDcIy5x3ySB1/OmJlS9u0juz5St5yk7RHF79fapjdzXUcYYETJkY6jHT8TxWbOBLK7MziRh8u0nkdcH/wCtWhZTXMcKW8sT+aDnds5YZ/PP+NNpEpvqWbZ5hLIqQ5QEhyxwCvp0qGfEM+YjsZwNoZcr26Z7/SrMJS4be3nGNiAyom0ZpfMSF2tniIDg7fNj3cdcd6SKsQQ7kWQTw7WUFv3keR25zURaF8yy26CHnLxjG0+oGPwqy0Ms2JGuY2QNhELYz3wR6VFdpAPLB2QksV4baQepzSTGzjLWCCPzI7gxIQMhuvP1rZsLuz8qMJDcXxHBCDaPzFU7XT9KsZxLqMkksbfMT03ewzWnY62LiUDQdLktbRTtNwoJw2Djk+tdzSRw3ZoNb6peRxi20aOOIjP71h09MnmsjUERmaGVIkm4VUt2kkJPbAOeatobx4Fm1K8ESucFI5juyPUCtbSPPQg2FxMkgyykKdw9SMcmsnqzVaI5zyr6GQW8kN042ZEc5RNpPQikju3hLLOscCFgfLC5znsuRWtrVkl2qzNd3VxIOGkchQfoo6fzqhLYQ3DGYTMFUD+IlmPanII66li51e3jjVt00kI/hVCPzP6dqijuZpomW3QRxOdx3nJGfbpmpEt5RBHdSpJMM5+YDDemQKztZinlO6RgEONsaPgH3P61mlfQpu2prafOIw6yxiSTJUtsywB7+2PSprSXcrL9ldnBIM8vOQDxwOlc/p01w05jGYYAcAIM5J4GSeK1YFmjLK5Mqg/MFOxsf1+nFJqzsNO6uaIMjOGedAUxuAAVPxNVYZfNkbZvnZAVG6LOD7L/AFxVux8uFC9kY3Kn95n+HPqDUFyj28yyQTPbCc/vG67x14JpWGYl9FKLpGkjllRgMIWyQfQgdB7VWgE7XJZw8MC5CblJbPHQfnWrcWt7PCXtmZI1zlpGGW9CAKxo5CXRrm5cqpLMqgDBz+ZNWk2ZuyOisIrQlN5adg2djHJJ9MVaW5ndxGbRbeMnlX6k+mfSuVs75Evo545JyowSzJkZ6dB2roZr2Bs75zOWwQPuHP0qZItMsXSskcfzo6ZOFUkgD39cVHOkdvHE3nPJk5CxoExkd/8ACobrUDuSPYsZfKtgFyo9R6c1a08QrOfMcySE/JJKAcfRe1TYq5akWFoVSFZHmI+eQOcIPTniqUiJZReWsDT3HVlQk7hnrz0qSWK6j1CbZKrwYAV1XCj16/0q3uZbEvbThABhiyAbm9BRYGynD5trEWd44Y1GUQLyeehNV7XfHOstyxww3BSNznrjGazdcutR1JLe0t3ETv1mEecAZwB7nirui217ERKsckpxte4mwBnnOPxzVNK1ybtuxsCCaR1a5dktyBhlI3EdOe1WYnsY0ZbYEH7rOWI5/n0qtFa3M8u/yBgrtBd8r7nnHSnXelOIyJv3hHOQcJjtyKm5oV55Gd3ikCMoHCrl2z749KrS6ZJOzSsrhEXG5gF3Z68Zz2Faji4S1iitkBkHQKAu0D+dNt5xDeM7qZ5XIDMxwgPcLSv1CyKun2iO6LapORtIYO56+uemKUwW8LyFVZ5t3O9vkX8T1+lXb24ht0LxuS/B2p0/PuKrTut0YHuJDKGyTvXCj6DvSHZIVp/JkwizvCfvlRhR9CRnFPgaQXAk0+3EkZOHZ1Kpn0z1I+lSSOtla+ZBGXRl2mebhUJ4JHeqkk0sSJFLLLhRhZGTaTx3+tWtrku9y21rdx3jnO+J2yokQKv/AAEHt0/CrN3usYo4bu1DK3QRthevVcVTt57m9tfJUKwR8KU+Ukdv/wBdQztcoNoURyjKgHGQCOpPb6VNxmRfwmbUEeBPs1qB87SKHMjew7Vci8xL6MPFGi7iQ8q/eB9B7UsNv87LuEkrEEGJjx9W6VqwWszNsu5IoAMYVVB4+p6Uc19BcttSo4ihldpZJJoieETCYHvio7q4nXy7aK0jUHlcgyEAngcVYuFtI7txGHKbiCVxnPt2x71VF9HDKiogjjZQCrOWIPvSvrqMfAjKwUs0s4OSGUBMDt7fnRNeIxEeQiqpXETctk85OP61LI1tE8Zkaec5yyCIqoGenuOasrhVLSjfHwxSNdqqPTiluMrWJKXEkgt0yi5IkcYxjnA71YLIyK8aldy/MO/5CkuCuFkdoljPBCA5x6Y9aWJYVdjZNIVUYk3Pge2B3pIZZi3C1jkQr5ynG6VgMj2Hf+VBhmviPtc6wRDbgREIpx6+vfms+5uHLtgpnIz5g5OO/wD9asm11O5nu3LSXjeWxDvtBAbqPYDtVxV0TJnRblhJ+wPIW++wfCgehyelVX1I3cTTkOZVfdk/OuRjHTtUstxbkLcvGJWYkATMD0/2epFZ02q+TA0FoZAMAtu+RVx2Hv0pW7DvY0oLoTWss10IzJkkgnAXpjA6VnDWvs84gtsMxJYL93t0GahubryoTcM6idyQsQHJPYZ/+tVa3sYWLajelJHlG0qZCW4789Oo4FO3clu+xuWGoRQo6z+ZMcblCJkuSPu8j39qgNlPNvS8j+yENuXzeAT2AIqW3KTaYvlxbZF4Xa20n0zUcU9zdu63UUztGRliPl2j29aVyyD7bFLtjkuPJlgUqdkYwfx7n3qWO4uZAstsyZjG7O7c+fX2qxcNDHO6G22DAI3Rjk9eg6Z4qvLPZzrsQG1mZRzGpPlknuKBFeW9mtLVmkctGh3hcZHHPb1qdr03N3BdI6+YfnRBjah6gc+1ZV1aNdBI2uRB5Q4Bbh8cZPrz2q99jlWLckZkiyDkkE8e46ChpJCTbZYuXk81LxF8mNsqoxyeORn8652yu5HuW22kyQuT87D5R2xzk10d5p13HD5yKUjX94fm3bQemQaoLY+XI8ryFN4yj5yDz1HPf0pqwNNlfTJPCunpGYLC78Qap5nBuPkt1+g7/U0viC51W9igEk+iadZqTL9itbseYQD364/CqVjpPh+NHGq67cJGE+5BGA0jAdB14oW58M2w2adaz3IZh/rn2fgT16812L0ORstW+I7ZJyYnkwSxJAxyPrk96RNSuWkQ2bOzg/ejBz0/pUsb28ZbcYtpOCIsNj8f0q6iXN1IqWqukYXG5Iwi49yaljSIGe6nmUzLJKmNyhFyT06k/KBUUSzLAl1dzARk4BJCn6AY/Wr97aSyYsbe4ae4A3+RC+Sw/kAPpWIVnknKXo/eoRjLhpMeg7D8Kzexa3LrXkcr7YnYhVyNxwAB6DuaYUFwjIImWUru3uc4Pv6Uq3UMMi4xFIHCiQIWIJ/vds81Ndi1XKl5ZCQN6KQRn1PbFZ63uaWKdnC0IbZMElJwZG5AP0FXQtuGTGBIVJk8yTk/T0FTNKIo0kEQjkQAEA5A9OPXv3qC3SKa3llliEsidyuSc9yfTPalfQCNYY0t99greZkfNklT9T3GalmjvLmyc3olWMHYVJBVSf7uMkj3qW3j3Wgl2vvD42RHAXHTg9akgVLaXfJP5zHo57Z6DH4UJ9waM2CwzvUeZGqnIZgR+G33z7VzmoWHlXsNwWKgM4IDgKcDI9xz710Op2k9zMpa48uSQ/dH+rH5/hWeujyS3DySXrNJECUjWJT83cY+netISt1M2r7oYsTCyKlPLkbl3Pz7z3OPSprW/t4EMCxlZiMPIw3O5B7enamXOmgzq93MzHGCrttUZ55A7VdhiKQxoI4GXfxIjbdvHbjryKGxpBcXM8cCtLayxqxALyPtJ9gOo/I1Thh1OzuDd5jVHX5fMH3R2GD1PT862Le2vWnxcL5hI+UScnGeM9+tXIJ2jjSO/jheUSbVI52en4fhUqdtinG5RhluJ1jdkeUykBpC+zafoBxVu2tJQCyuESPLOo54zjOef0q3dCR50aWcyQABWwBhcdMdicUXruYo2Ms0YLfKXYrvUccetQ2XYS3gt/7RZrsucRsyxRHG0nGMt3pTexrIyC1kEZBwC4Ab/Oaja0MkLNB5u5sHfKx+fk9AOlOsmtptsc0a+byrSvkgfRRRcLDmmuEKR+Snk4ONzcL7cd6fDdDg3DtPMOAN2Ag68dh9agVozOyQS+aM9XU84/2aZDaOzmeacIFOAuMED6dqNSi8lxPfzCK2VNqNuLcHcPXceBVVYkmmcPJ5nltw8j8f8B7Usd5aIYWEGFVsMHB5Hr796s3lxJcOGSMtGvzbEgGCB0J9Pxo5RJls2ckVyt208SRMNu4ICR15A6CoiipcYja5u7cHAd8Koz7+lMF0TOxk2gMuf3nzlCOw7Z/CoLl1LEjzWRxgEtgA98/5FTcon1SKNXEQtrSZsDAUl8fTtVcWNpO8sl9+8uEX5ERggGPr0x71PDPbra5e3S5aIhVBBRMdyfWmQR2IVnuYUaUsCYlJKgg8Db3oAhf/AEiPaZF3FhhVAyRnu3QUwxxrviQF58HcA2Qvt0x2qK4h8ku6yJapKSCgOWA9x0FXbVrZv+PYSvM42l3YIoOOMY5NO4h8SkvCrk2ycHYBjI9eetNuvsnkuZU3Nj7ztnA9aebMQSlJ7rzThdu9QefrzioZYbPzJQ1zwygo27kY64A4P40hlubUoZtPhh+TKrwep/Af0qpEZLsi0ykMbMS0koUORj1qCS2EalhKqrIu5XYH8sVkxreC5lSaSZ43cHOwnaQOw9apW+0Q730OoEelSxMjtKz9UZXLEegwP8mqTG5LbIvMijVeGkJye33feq6+dblJYrgD5/kQIR+JHGOpqybmbzv9IT7QCOACUbGOvc470m+xYW9o5UO90rkndleT9P8AIp8Nt5PmXMRtwoUjExwSfUAVHp5uZYZE4jwM7kG35c8ZJ5NW0gvIVaJ57U7/AOFV69fbg/hRYLlF3eNWuJAjFiAWCkED8Tg/UVXuFlup4JPKYeWMfNJhRjvtHbnvWvZ2wkuQkse4jOwFssB9expLnTG8hJHu445ADtyfm2jtj1otYW5mSWzbZ5IzDEoGCFYnP0Ydv0rOa2gltEM1yyFyWCA7uRn+H+pro7W3ijbc0++PeFG+MFX6cY6Vm+IIQhEFtEgQ9Ziu0g/yIxVxRE9DCg068ml3NeALIQoyoyOOD+PrWrZWEcVwkYPnbRtk2Jj8cjAJ+tXreK2nt1BR5Zcr5nzk4x1x7HtU0TLbyPhXETAbieMAcZGaUpJ7jjGw8QSJEAsKRA8qO+0evvT4WlFz5UpBjYYC429sZ9DUZ1bzSsTgKw5LD5i3GOAPX1NJDvuJ5I47gwhVLAzrwy9x0x+FZ6FkjpF50AIkExz85XG7nGcn6VLdz2flnCq6zna6qcuAPXI6j1FYq20n2idbe7LeWSsnlrxg+np+dahK6aTElqHhK8yIwOcj1FMSdytJHbxOw+yBosg+Y6ZZB6470+1EKsGjjEgz8oCAAevpVie4JighmhV2bIADDkD+g96pJbLHdFJJVWGXJJ3HH1BpDJLkSQgyJcZ7tGwLY7An39qpWifZpnS43SJI24Njaqn+XWrsMhTi3nZZWYDcWG3pjB69f0ptw8628iSqY2B27l5LDr06EUAcYjRsif6OZzuI2rhcAj1/OmSJDA7xDS/Lycqq5Yk1cjtfI02NAyRtwcBi2SD61cjEAuUnM7xqR8zDO78K9Hlszz09A0u3eKGN7q3NpxwGXnOetX7m/t7nKT2usT25PDFxEp+nTj86c+rW11MINNtp5Etxl5pWLlz647Cm6iIVSOXVdWVBtyIIVDMeeAQOgpSVkUncoXerWAhVdP06Ky2AqWa42se2fl5P4msqxs7mQlkR2LsdjLFtQfUn29K6C0urNoHlsLJIFAw0kyhWbPXp2rN1aOcIptLsSRknfHbn5B6YzzxWTNEPFqirF5rAR5wQjcfUKP5mr9lMEiaGNfs1sckNwzMfp6Gsy2RUWMSsYySDyCBkDq3erlzNFYqp3mQk4CIuQQec89BWRomTB2EC78iPhiRwx/2ame7jV/KdkVmBxHH1z7fh3qsZpDYwmRkkQ4ZHB38d1+tNS1EN2qxktJK3zY6p9DU7bjuOs52hdsQcdgz7Q3rntV2FhLbNNsaWcvkKn3Vx2Hp60ya4tYLsRxhd5/gzkggdT6+tRtqFvIrjzds6/wAQxt3eg9e3FAxPtyNbiQt50o6DHyoe3Hc06CCSy2vsLCVuZWxlj3IH6Vmx2YtNQe7e2naN/wDWx574+8MdK6RmEum2syCOCM8blGScfxZPenclLuYd3FN5jvHBGxHVn6qMdDx1xUGkQJHK8oYMUYH5jkDt1rXEEM0VxC+xUQfMEc5fPcnPWsCDSpFuGiJWOBjgMcM/HoeoFPdBszopGjl2qjAzZ3Kc9vp61BZxRieWWdmwgLKG5G71xVW0dtLXKo0iOwDoDy6/X0/Grc98LpHZYkhkwPnPBHHQH8OTUFE5eW9kC+YoEbAiSTGcDkHA71Ya5iBZbv8AfLkbZDjeB7ZPA/Cs+ytJ5bWNzMc52h2B9f4R/U1emhSGGPzUD3Dnars3P1I9KLDIbG7IiO0Md6sFweNu4/p9KZPDOwUxPEsbDOUXjtgbsetRx7pAoKtcglgGJwigZxz/AIVJLdyIjJcEBF6qDjp2/l0pDLn2CSJYniz5zDcQzAdOO3NUNQkjSJQ86yXEi7/LXk7vdj0H50h1NbyabzJTbs6gbV5xz69vrR/Z1ucGSQFfRDk/maadtQavoc/4buL9ftBvJJLhpMqqQdRycfMeMV1FuNQeIW53JGXyVY8DuQQOtPVbC1lCRAhx9zAMnB9hxnNP/tCGOcCZJo2UcnLM34KOlXKfNqyYRUVYdHdR2xa0gEeZG+aRsqo69AOaEeKVFiup0dgvLHhYz1xjufepYdRS+hWCG1kVN3y4Xlj36f41VksponAaOOFGyd7gMevb0PHrWb8i0WVW3WMjc1zNkEN1A9cgcYqtd3rOMqfKAI2QqNzS89Tz61HcO0MZkuAWy5x+84A7YAFMcw294JozJGzABsK2QOwyaErhewCKeWKV7q3VHPfKqMY71ZsXWKONpliVD8u9iXXpyRjvWJqklys7vbo904fDZkO0LjPHatT7RE1ozySeW7IMNOwOMjkKo/nVuDtczU9bGiWupZtlmMxZypKbSRjPH5Ustp9pPmS3ifKMqBHjA7lj/SsuK4aeeKMs9zgYDqdqj6g1tTxSQqWW2gkA+ZoFY8dOT0wKg0KgsJzGTajzJehdR0P1qubgSSRQXKBSqlW8odTnnJ9avW91NMuILdUV23EI5wcevrio2iZ7lzOoG85QIuFH0BFSMjjkmuI2tIkUKvO3HBPr70zmO2CvC00pycKmAB0wasxSLiSIRu4XO2R1OQ3tiqckc253WbypQ20q5LE8emePWqQMrXOsyWt8i3QtiDGGjgbOCvQ4q/Dq8kj+Uxt4PKThiCDjOVx39BWOiyJds8ckKBl2sZFLEj0GQcc1sQ6XaM3m/wBoFmLZdRGFyc8jNW7PYzSlfUY2qzRbFhJyW48tPun2Prx1pknnG8YsYCxGSWfcQfUnuasmTSbO5m3RExkHDb8quR7nqKrWkaTzxS2seZCTsXZwR2/rUNFrVj1jmu5I4JA7BxiP5uM57Ywc5qeTR0jyt7MrsuSFcEjPYHJyKspIJsw2wY3IJOV+8DVa4DAgNbr5igsXZznPrx09qm9irE0e6CJhDbEQg/wHAAPfPXFU4njjufkhkuEO44dsLuwOc9qkNg8tiHkeQ4+Y7V5981Nut7GPAXdEw+Uuu/A78+uaN9xbEEcrqjCGCOGRjjIbJ/DFBgidNxuGTDHPmZJJPoPaqU9xE0+6WBnjYhOUwM8jJrUtnt0gk+yxSM+CCSu4BexI/qKdrAU7G2f7S0jW0iw4AIU43H39K0p5oY7Zo7i3adUUiP5cbs/3j149KSKGZ4BBEPLliYSk9Wbn6/jUt3Agmjknu/M/d5ZgcjPZQKNQsZIntrOEzbmSVSNqscBsf/rqtq1+8tiGSNZWyBHLyCMf5GTTtW+zNKY0i8uORsnc3OPSkaOKIBLPz1RCEXZnH5elJMGiWGd72BY8Im1i3ypnk9ST35/nV6KdE3IyeZHs2OUUkn1yPUe1ZsNnNI8xjmjd0QNwTjnjk002ixxrK8yxu54PmEEjpmhX7AYVjbnY0VvBIEyQGmOOO/Xp0q9DBaJbyi4lTan+1x+FVpzekO8saBiM7hxx0OBU8oeEQXSQTGF4wFaYBQ7Dg7R+VenoebZ2uX9M1SGKMWwURwzH95sGC3GDk+mKiZbBZpFi8mQbs7d3yH/H8TWfYXkS3G++2xNx0GQOec/h/Ko7/UNPi1SRLAjUJBkLKqEr+I7UpaIqOpqs0V5G7pbJfXOdqMECRp3xknHHtWJqdrHYSunlwG9BGRaszhfXIxV7SrLUb6fzGtl+RPk86YqPwIwfwxWr/Z8iW+y+ItyAf3Nr90qe/HJ7dTWLNkmczZHL77iOZEc/dVBn2GTx+laDwMS8ckHmwKCQFZdw+uO3PSrKWkPklEDxxscIWOT16E0t+JSkaFcRg5DH5UOB19/61i9DRLoUrOO6hljt4ijwj7gILBB12rWrPFK8bSxOhVBtd2PT2H41kTRmJlmXcX2hlxxt7fy9KlivZoWEhgfd/AGOcnnt/Wpvcq2gq2scrLMziKJeCwON3ufzxV/y4pIFIVLcK+MqCAD7D+prM1P7TdWoktrQxSYLF2YY6ckjsaTTppLy0RXcCWNgGdiSM/7P+NNoSdzaVnELW8GX2rwGAODxkk9hVV45GWP7Rl4iwCRRjgEdSB6VYnES8WmxJgQHz835nuaqR3FyZpGXezg4DLwp/wAPwpbDWpLf6fHZXDyFj03PsztBxisa6dprfEZYhU3bmJbpk9B9K2zBc3MeXiR4CMFFY4B7k561k3SrAz26r84PG05THfdimtxMct4lzYSb7m5eV0G8thQPTgD0pbeaI+U0ALFCdrSkjcR3A7n2xRbW6sHkMo8yMZLOeNvT5Rxnii0kBvJEg+duGDEDK9jj0HvTbQRR0S3F29pI7g4xkYIz7VB5mnS26POHeZDhomztY885B57VP9idiblYcWkYA3SS7txI7YqPVI0W2jntwqb8R5AAA9TjsKhosbuWUQrHKEjOcBgeB6Y6etSSNbWtx5Zh/wBIGMyzjII9gec+1ZsV9BBMYVjln28YU5XPck9TWnaz21wI1kt13sCcKfmHHHTmqtcV7EqtCUMsCIsrHa2IyX2+vp+FU7SI3MskYEpUEnEnT8fQfj3qxZs7SXK6hMws4yGCRnlz7t19OKma8UI6gxWkPGDMcHHbAHJosA1IH85oZ12rgACM8N/WprW0lhSSO3ICLx0Gc/jzVIapE0RCGd7jhgeFB7Zz1pPP1OQbp8whseYFPLfieTS0W47jlZtPZTgQAgs2ZAxPHbsD7U+21aNp3SNZJ3Y/L8nQe+enNZN7OUt9qwJufJO5zuPbOPSqmnC+mkVZGaOADDCBCAR23NwKaSJcmjoGgkmd3T7/AHPJVT3wTwffFPvNPkhP+kX6AvyBEAFJPOCO34UxDm0DTM8iDKDMvX8BjFQw3BxPbCCIIhwcjccDoMj9aVrFNle6sAELLM8pYlti8fj9PrV3SpbV7SMRxwhjkgsu1lPsT2qkkU0lzIi3cjRygDC/JnPbHp2zmrlrF9kJ/wBCE6dWBH5fNQFiysmxQsQMzryXCYz9D3H1phhXfI9zcTqJPm2AcBueo5zUlx5qyrcOBbRBBtWOPlh9emapvcl7vz9PWWby/mVZRvzntxik1rYdzSaV7ZIzbRSyMwVixQDB9R7VTOp3ZuD9pjKlvmDlwcmq1jd3N+8iXMW1VIV1eTaFOM8Acn86cLMW8Ra4mDq+dgSTAXnuMd+lO1iU7lq4nhEYd2YOzbjhxgjufUmnhLWOMubaUyOv3sk54+9164qNJhBGkUdsvmqdxYx9Ceg9av2uWuma4tmn+YkeZlUbjqAKksrXNukVq7R7pQuFVxHjafeoo7heZc5TAEjCPgfpjNXzJPC8RZIjFkBi0nBPXkDnA9qqxCJLppHVGt2JTzNhYKfUDgUguUbqNJHAQW0/cfuxISuDkEEcdeTiluNLl82J/tDJEV4RONq+wHIxV25WBbd1+1K6qN0ZQEEn/dpIEhXaIy/3PmJODuz9earmvoyVGzuTWgn+yiOGNImX+MHa3+NPknSFgu0TEg4cksAf/wBdRrPDbPLsiNzEBxv/AIXxjj/69Bv7e9kZVSOzXaCflySc98cfhUlDrUyuu24naO1ZmDbAAQSPQ/zrMuMrAbSS+UMH6k9iOMDqT/hUzW8dxblJUYlekp3Ekew6fhU9lLZrG8sduMwYBG3qT3z+GcGhX3B6mHaWcsQaEeawGDHI7Fcd/wAa3YYvJ2tdzXDptwqlwoPHGT6Z9qctzDfbE+zt1O12cKB64piaarRssUm1yMghh0/xobbeokktjPnnlW5c28sQYFcHcTz/AL1SPHJGnmzs5Ct8gD8ZHXkY9ferS2aBJoWj2quB5nTK+p9+f0rD1SUabcwpEN+VLKpQkHB+vHrTUebRA3Zam5H5EtuvG2YKzbpBgFvT8qo3jrLskdiINvsWU9wB3wake8N1BCFdZnnG4YyCGPamIptlmhe3CBiFbMeQpHU+vpS12GR3CTi1ieHc+9cFggPbkDHTHFZZUpaTG5tIppdgeNpmyBxz83atO5u5GEUdwzeWoCKyD7w+nWjdH8ixyZU87WA6fU596cHyu4pK6M6GDUzK63USI5BOJDyOc1YktZriOJ7i+jSNOCT8xx04H5VFLbXMN3tuJgZ2HQY4IHeqkMLsbiIOM7hkjkZ/yK9BpI89M1tO0CxuLqWS/vZWt0AZUjUuZTyMACpb3w3FnzTElnEhH3jhz6ZXIABH1qhFqX9nNbrb3BWSQEMw6jsefrU6S2klqyuZJ7oEMGlDuWHbHYflUSaNEhG1PSpLkKZJ9ynIm3Fiq/3cHAqleXMt7JHHax7sA4nbJJHYY+6KqalOrz7NrqWPJaLhfQAYyfxNXNOnWSARPd3ELrzEpT7x7YHQCspJM0je2pf06wnSNpLi4S3dRh3bLOfoD0zVeV0YO6BmhQgr52cn3Aq9bXbLayS3WZr9Wwd0mQB36cn+lZV7LJIdscplYcnOEUc4A461DsWmzQe4A8p5oxJKSQSw4UY4wOmKVpHQeZHEwUKBJKw+96kVzum38/8Aajx3aSyQKpZBjgDsMCuiuLh45RECo3qrLEv8OegxmpasNO4stnDPIhkfaCPM2yEgE9iccNVaazQ3DNCcoh+YE4+Xvgd/WrUMCyzlo2c7VXDzDG36D86ddArtEkWxmBVsDBlH98ntQOxOj2sVp5K5KAEiIYPzE/xGhby0nXy7mVbbI27IEJJ9MY5rPjhg81onIMK8HBO0n/e6kVbliUQxCKGOGM4Py/eYHuT2obGhs+qxxQmG1icDozngtn2/nmqE7ebOjSRBFXG0RNtBP+0f6VotcQtcJFDL5u9RiOBRgsOPmPQGsya1UEhpAoBAwX+VW9z0zSswbRHqFuqOzXkygucBIVy7Z6Aeg96ZDJLHCsdlZsVkJJld8/N6HHWn3UMIIErxiNeMbCu4Y646846mnzSi4gEFq8kcK/O+0Y59M4qr2INDTxJbLukn/wBYuUBw4z6Adue/WnrbmCL7RfKbhg23Y2WAIPQLwKgtpbYWBKnE6kCONVzgf3i1LOJpRG7yzL5n35PvKo+n+etTuX5FLWjKLTzrVJQIjlyAFCDPK+/1NP8AD/mJbo4lCSrldkRO8+hz9DU91pbz28v2iVhFsbahGScA9h+FN0K2aXTbcCWWHKL9wcgepPQVV3axPLqbMn2maFXligQI3ljADHnrx3PqazriN7eZI7eACR+WkdMbRn73Pp6Vp6Syac5VEe7AO4sc7wD169vpip9TMkkazlUUnJIY5YHpz78dKhMtrQybOW3jeeaRpGl3YDHALDJHTH8qlYpva4aVgOVWNvmeT2HoKigtCk6zKGLlhncPnP8AT1rSkjs4ohJ5EaXQUjcz5bk/kKad2CVlYyre5KXDM0CsjHHAyc/WtaHzZnVIlEEbE43nCg+uB25qC7nLuI/MDS5yCijI/HtUF9LOgJTMRK7dxcng9OlLYLEsFsryol3KZxv/ANVFt5HqTU08MUgkhtLOC3BG3bncSc8kdvzrFE7LGux13jj5BnHr/wDrqYajLuJW2dtvysHUDnFNXBtIuiH7KokupZN6gDYDxz9O9Whenyo447bcuMiRhgE98/8A16yIJpZQkuxF+bdu2l1X0z268VVgubm7kdZSJJoQSwIKRkdjgdRTUeYTkkbdzbCRCt5dsVKbkQHC+vTr9KqtKbBhLKZEgbjbGnLDGP8AP41Xha4uUeGOOJZOCRGgLcep7DFRwy3DStBcSNIdowvQZ9MelFmDdxsyzSLbXNjb24hVyGLShpGycj5ecYH9ant4ozA7zWwaRSdoEuQfck0scEMc8326eKAKSGHByevJB57Y61ctruwU4tw0uRkrImQDznnpWl047EJWe5W86JpfN8tbeQjaqoxOcepJ4/CtNPMuYfLimae5ALOFUkoRnqxPtVcIlwpRCZWYBiu0he/Bz1P0pdJnW2k2eatsqcbkU8+2O5NYM2CygeViHng2gYYv8xGenHfFNuIoxatbvcyyASEnYcL7EVI8gWVgm8SkfuxKAm4H29Tmm3WkuIGuHdUCjARPmK9znFADJLBREpS4RQPl+XLHOOnt061cPlpbtHeSM3RkXPyg9Oo7VgXMItGivD5k0cbbDGZGByRwePxpNPvHd8yRR5zgbiSfyFNxa1Emr2Nm0itirI2WAO7IwPQZyefwq1ffYVmMfkthyCrDPUdsmqM14zu/lzIZyozwflAHSsqMXLx3sxWWQpIq/O2MlsYwB0pKLaBtI6GVAdghla3tyCxaQlwT7dOfpVQTS3EXLLKQeMkrz6frSySy30aQ+WkM6dV2cnjHbp0pq2/2doXuRJIN/wA3zY5/DmlYZSurqRrVmuJR54ONqHBz2PSrC3USQ7Ysy7V3NheNx4+9/nmrsUlsGbzSqgq3yquCMDvnjNc+Fglv5ILg3G6EjYUkDZ9OnFO2grmxfzyXEAS5IR3XJ8kAnPYGqVwjeSkV2rGQfNulHH4EH0rVtIbmW1EzJGHiYKP4XH/66gkiuQzOpDM/DKRkrzSWmo3qU0lHllrTJY43I3Kpz29akuo7siYPNEfM6nORu9M9R/8AWpxmFsrW0gbzC3mK4TGKS8uJjZjy28mY/wDLTH8WOD+J7U9+onoNjSW7ijPklgzFUKA4JHbPc+1WGjbeYbbfGgjBYXKgPu6EYA9c4zV2FobnTNOh/taK0mtITHPDLuCF8kmRcA5JzzVbWtSa/wBVJtUdzBEitcOpUy4GC+OvPvVSgo7Exm5OzRw2m+HnN+Eu9UuLkgghzwCD05z6iutsNEsbaQ+Wm0jcSzSE5IxwB09a5iz0eJJI2N5KRjGenH512ekWGmxTRy3F3NNEBgxbtuCeM59jzXbZHGrmTq9lZ6VGXLW63JO5fmydvPAAB570WOtai9qUsLB4B08+RsZ69WIz+QrqNS02O3jS90+28xOUbcvHtzyfwArAfUIIJ974jwRu2x9PZQen41nOxrG6IX0e7W0SR5hcTz/MEChQp77mPJpiafaW9mkiul5cKuHgXc/kj1zwBk1rak8l5Z7bedbeyOFBcjzGHqcdKzIbZbBWXTp5XiYgFl4Dt1xjkmo0TKK/2R/LjkhiVITzIuQ2P5ACl8qBZBAI4t6cgKuQe44/+sKa1jdxSiWRmiWVsosre/p0FTzh0uVHnqGk6SdQD6eprNlIhuMW++eK3KB8fewWJ69ugpYnCPHKUjcyAqZFBwh+vc+/5VHFHJgbiwj3fMNuS30H9an+yyRWx8+f5SMCMckD3x6+1DdykivdapLa3BxkoQMRxnGMdCxPQfrVjT3gu42nvZQy9PKUnGfqeazbm2/ewgRERr0ToWJ4Bq3buYlCFU6ZVFOcfieBQmJpkqzqt3DlA28bDnO3IHp3OKvTrbwMYrtnYBsc5CqPQj19q53Ulur2aO7E6KIWGxlAKmtSxHmxyHUG2K4JDr8xJ7D1H5UNLoEWzUXECqFgdbJRgLwD9c9h+Fc7q147XQSyt5XtGONiL1b1x3rUjiVnEVshnJJyzZAI7DGaj1HTJJYUDs8MYwNqDBJ/CiM7CkrmXKEaISySolyh+4rbmY++eB9KjhulleNVDLGGI3sc5z2UDrWhMYZZ2syIlWLIGFCoPUj+8e1ZyxQWl0nnCUbuV8sjeV56elOzsF9SVpzBOrNAzQIfnTH8I45A5rWurwyqs9rG0cEa/KrgEMfpWA4MLzl0UJJjcCdxGOR06+5Nb2mTyNaxSCBZmJ4aSP5fbAqX5DQivPfxbo0lIIO8yjaByPujPP41P4diulsQTO/lBmiZ1Hoe2fUEVNPdT2sk32d4xIT8zDtzyBjp2rMhnhgleKe4ndpQGVBKQq9QflA/3e9D1Gtzo9RtTArMsiptGf3j7ncHpjH0xVGW4OYwJEafd8zyk7s/4VJDb29so+1OCXGVTdhT6Z9fxNJH9kaIyFGkkzlMLwPYVNmXdFa7aeeQRrJun5Cm3XHGOSTnitA2k1qpjkeJN4Bzt3OR9TUUcZuVaWIvG4w4jUZUD/aJ/AVDcTobOT7S0ak8YAySPT2/lQgK9z5IbaIrq9mGQijg+vPoPeohK1xD/pV0sMJG3YST06KDjJNNvd1xpxEEctxdkBUKydT6YA/nUImki8iGTy4roDa+AGx9FArTlVrmXM0y/aXQm054wH/djaTnjn8Kq6RDahJlKzT3ch3MFySPfHTGKuxM8UoUQ3UoY7XyuNy+3p9KczSBVNlamMsxDsc/MM9fYc0LQq3MV9zvcSCIhYCCrq4CjOMZ/Cm/YpDCZLiWbyi3Kp8ikj6Dk1dkhFgNz3MTK68qAXI/CoJZHimX528nOI3bCgDrnGeKWqG7MngjjhRltI7nasY8/wCY7cdR7097eMwLILsW8hJJUYwOPXrmqiSCa8YLPLMGxiTopwOvPX60YNmBOwWVMkDL5Gf8ntQmFiF57e5UNFbJ5iD5pSSMGrtvdj7MyyyAIV5bqG54z68+tUwLCBZGNwGWQAnDbQW9T3OPSnRmKSweMzyEKQoiQnbtHc0AtCcGJUEginlJcYO4bc47mo4ZZWWa4jt08kgqS43An244FZuoQsbDdDn7wUnJP4j0Fb1vpMkaCeQtKoiQ+XM+FBwfvKP0pqKaJcncZZ27bRO1wZXKnCLCXC/rgZNPla4SCISToY2yQisAc+pUfzqO3HlRm1IQpId6vjGPUenb9aHlDKyRtCV/jjAOc/XvWbRoggtZZZttsRJKAMYXCj1PPX8KsJax29pJhGluAzEsSqkE57dxV4Wt7cWQdlS3VFG5B8pUVXSNQo8sTE4z8zfe9cY5o5nawW6lAzXN0dknl70XbvkX35yfWiCNXhSO5kljMbblAfKBcc8dSff+VRQvHbSPEh85mB3gHn8+9WI7ho7KZU8pXlP3pcuVAz93/wCvU3HoSX72+lx2sllJEJGJDcklh6mqcN+ZS06Oodcr++Yjd9CB2qeezjVVikZ5A5BLK4wD6HtUI0ryZHkaDaO4HPGf5U7gPsBFfRodn7w9XJJx/wABFPKCE+ZbzbZOoOMsR3HPHWozI4n3WsrRLjBKqF2cdBVmK3uFijJjWXe5A3/MQOpAHX3oQXIYbq+3NIxjAdf9bsyFHsOmalthIr73m/1gOfmw3GOw6VBPc3DOsbSFihyoZvlPA6jtgYqKANIzKkJJJzuQbj/LNFhFqUrEXIiEyuSED8n2Pv60s7QRRcRecxwxU5AGB78d6hDp9oVYY5HjJC7pTlVJ7ZFXrNyNSUStFcBWOUlAKnHGP5UuozZt5tVj0TS10Q6fbRtEwkSSVFbzCTzzyRjGM1zOupez6vLFqckDyLGpd4mUlxjjBHFbd3qkEYBfSNKLcYXaxP8AOsm8vZS0nkWkNpbqqh/JQ7UX6Hk1pKSasmZQi07tGVaaBbRxRylmjiDbWLHof6101nbaRHYO02WlCfuyeF3f4VhQ3dpArNq955mSCkMZ5J4429a321Ge5toGttPa3gwUVrhRzkYyF612KxhYrX08z6UrRo3kv1mMmxEwOScZOMVhNeW9pcxEfY53IxlX3Ac9cDk/jjvXbXOnLFaxG+v5gky8Kh2AnHAIFc/faHY21zPPLBBbxRLhCg+aUgd89O/TrWc9S0n1K7yyXsb5eCMYz5cCgyOPw6dOg/OqWnyPps7vGvkRsp3eaM4X6Y/XNX7m+v8A7BEYohBCBtj3LtOMdh3rEuhISsV9le5ygJb2JrKTaLRcnuTNF5nnQxwj+8MuwJ6k+lQwxP5TtGEdc5SV8lgPr2HGR0qr9pa2fEkHms4CpG5yzHtgHnA/KpJZkiDLOCEYg7QcEH3HpUtPcNjQSItDN5bJLcg8lj8oH+ewpbmcQ7WQ73AO5to5PcAVSe2vL5reSGV4owp2t1JHsv09akEHkRSXCFjIxAKhuZB+NFh8xad57m1iiClQ+MpwSPcntVQW6wwtEIS4VgpkLcKfX3Fc/da/cDVGg8n5A2FVGI4z6966CO5u7hA4iCRleTuzn2x2+tEo2CL5i0FONoG4hQFCxj5fp2HbnrUFhMReFo8xkDDsBxj1J/wp9sbrycN5YgX5ih+v8WOv41bkWA+SGCiF8l3wRn6Co0LEv5U/s92sMxpnl2O059cdxWeL25t0LsksjOoxIzbQPUBasrMnmtGFLW2RuLgAhSegz1NPNtMEE1rbtHaqTtE8gyoP8qaYmuxz+oRTXlxERG/kRrjafkDtnkcck/jUd9FDalFjjUO69cFgPYdjz61rz7XdxJJvJ+7h8ID6E9x9KgmJtYhJcOsfHyygAgYHQc8darmb2IasVfLy0MeR9nI/eyv3/D0+gp82pvZwL50/kW4k+URr8xzjgfh61WW+tprhY1hluC42rICVAP8ASq95pcv9oRTSSLOUOGgXj5f9nPUVSWuontoalpfW0SNHaLIEZmYNIc7QOrD1PvVW9lR7hJ1L2kefnkkOXIbjimWEU0s4js4HkxKwxt+5nHBJ4Hf1rQ1HTnuAY70AtEpIhK5C+/H40SSuEb2Ltq1q+YLdZLmYAbW3AhSBzhmpZJJZJIzfyb3i+UoznHbjI5NZGmiS1VxKC6yKMRLGGK/j2rdkht/scRs7AIFG+SeSRSxbjtnj8KckraCiyQ2s5nKC58sEB3UEhemRn1qvmSBJIDPDhxuLEEM+ew7k1FHPLH53llzuABCZOeBwSaimjmtV81jBE7ZdU37nJ7cjp9Kzsa7bklrbqXDs1wxf+NlwoH4VJb6glrFItss88h4kCR5G0nk5HSm3F1PLbQtO07QvkgBNoI6flmql1O7OrSMkAI4Zs5x2+UfTpWiINZdfdLcP5J+bjcxC4PT146Ui6xFcQufJlMn99G+U5/nXLxvaCeaS6AklUgox+QdOMD+dXJDGqoYnmuWCgFIRhF9evU1fITz2ZpXFxNsVYFQK+1iR1/Ola2e9YOkbKynBLHn/APXWTHeNEWd9Pk2lyFHRV9C3bPvWvYapdFJkLW1rGFy0jtuDjpgYFJwGppj7qA2Y+ZFfYDu8t8Z9MY7+1RRWhgtS115XK7suSxGfQDnNVobuc3EQhAmG9gGI6k+56dOtSgvbs/m3EcQc43JlyfVdx7HJ6VNkh630I7TyZHURuHg6EiPcwPP3c9K0Vt7dUaFWuBKc7HC7MY9aWwlaxUQxqturDO6YjAA7jP8ASpyIPs7m3mSSQ5XakXbjkZ6Gs2aIgt1MkDxxB5EDEoZCdoPsBxk1MqRrbBRI6SgktluHPbnPp60lvatNkJFKYh9/c20Dnjgd6ttaxgk+QVRFyW27mJ9M4qWxpFINEjgTmRlHIJZunSp/LLShrNn3nlFhAG4d+R1qy89sroxtzd87SpXkn0NO1DzmkaZdNiijiABYDOD05xSHsPFtd3UaFD8xbeUJyx65OPwqnN9qM6w7pXRuZGPygHHTiobh7wQTG3nkEBXJwAhP+yO4BNUYrl7i1kVZCphcCT5mDOSPuhTxxzTUW9hNpGqlqiWrA2rLJuzu6BAf1NVL2OeJrZwqxvOSsbFAQwxg/SpraNg88NxJdsGQA4OCBnNLHEgU+dKfnxsUtuI49Bx60LTcGr7GePIGFjmd3X7q7lb5s/lWpdSCe2GZM+d3eTPQdO/GaqKLK2lgZLSKZf4lfhGJ68fl37UsaxuIygEcYJcIqE/5H8qT8gKn2q3tbkJMP3pTICjAVz0J7H0xVl7mWWWOV5CkT4SREkw49efpUcn2x/KVwDDGQyh1zz2Jx6f1qWytw1+BdyR/Z2P3UXJ9yAfpVya0sTFPqOvLiK2uFlhKnaPlC4bGen1Pf8KwLjUzHPHBcu0CEZRwMZbvnHb+ddF5du8ebdTHsGC74G0c/rWPdWf2iCYERTwD5A+CdvfjvRFxv7wTTtoWbCeZZWt55FWN23iNOOQOp9Birt1JFDhIyjSDDPtGRk+/6ZrItbcj/WHMmOcDoMdSc9farRS6MPnSI00EC5APpnGal6uyKWi1JYlee5jS1tJJC7FE2KWyenHHP9K1L/5wLeW2uraWJVEgdlOfqMAjnp14qzpOsZ0aG5j82O5htHgECxMyws7/ADylx/skcdag8QX4uLm2bzJnNvEsKs0ex5Co+ZiOoz788VUocq3M4TcnaxyXh6x86Ui2jjlkRd7vuJC46knqf0rrtPdzaJm9DsMgrjCrj9MVl2mmOWijNwYkkBBS2THTsT/9atLS7C3t98TR4Yn5TK/THbH0rqRj1Hz3NxJdpHYKl1Ng4mlyEhHX6fgKriK1nkJup5bq9ZiQAcRq3rjGBx9TWlcpHJAFW/8APlA2raRcgL7kZP8AKs7UI5obcyyWphjXDBYpAojHuOtQ0UmQQ6Xdm8mQ3qjeThnGcewDVDewR2FqtuypNMBwWIBz3JJP/wBapDqBlt0e2+eVQSpb5VRe/wAx6n2FZF75Vy6STStNNHyGTO3PsKhlGDdq91d7bTf9o3fLOSVAAGOPX+VXbAywySlmYugw6LzubPUt6VJLK17KUjXyWAwBjLNjt7D1rTht5zGkoghAAwAMAbf6kVMmOMR0VxdWjMysqRPtYs2D19KtyIEBmhXLn7/zZH4+9UlRogPObG77oPQDp+H4UQ6hHa3PktE7AnKKg4JJ6UrlNEOoaM11BPPb+WHhbKzBdvzdQB7VasIjJZGK2ZE3IrM8jdTycE9//rVYW5McsktwSEAx5LH5Ax4HGeeaz1sri2hUz7jsA2rnPP8AdGB9aTkCWpPGzSCSNpGkCthii4TjuPWpoolMsk8dxcPOANsZQN+fYDmkinkmEkLBIY+uQPmI/oadcGW2Z4YZEWHADMuef6k+tKxVxs1kY2SfULg7cnCk5CkdRnv17VLJsAx5rzIy7v3h9Pbp+NV9RUyxweZA3lkrnzMqufamPMsEGBEFzwGPzZHYAdcUILkd7MqB94iEw4EaqGA9/QEVRvYBIXupm37SuMvu3Z68Hj8BVhvtMMJLxxRLIhcFiBjtjb9fXmsMwloijSSzkqSzO+1V7bePcdq1jFLVmU7vY0Bf20sCmzdYzGSzP/EpGR+Rqt/aSXF6GVHDJEV3Z3M/XPzHpVXT7DMzfZre3jLjf84O0nuBnn8a2LWwttym4dXOCVYDADf1PNOUk9iYp9S1oly5sYoyPs46DblsY74H9auwPM2oFLaR3Migyb3wrexxz1qpFPFDG26aF4wCAWOcfTHGajtDFNKp86Qrt5I6lvX9KyNLXNGfSkAM0xdgGBmYZVev3sD0FRC5geykS1tiFi6yAAB+eQSeabc3bebsggRlaNQ7l+QenX3qq9rFYJI06LJaKGOxCWWPPTJ6n09qpaiehpX15GYklkjeQrgBFGVAx1zgCoo9R33R+xQRiTiMKi7go64Ln9cVk2kUk00d0CDG5B8pnOAMcAVuQ2kQmVblkiilJO1M4yfpRbUEynPeSFwZ7iKKFdwYK2Pc+4GaxL24ijTzrOSaYE4baOcnp8x7Vr32mWxSWGORXZ2+4q5LAdCSP5VzwllmvHttjwxwtlgzZ5+natYkSujU03Topts86mSTHV2zge2a73R/DxntGmgCPIF3AHoB9a5HSYIjg/M6qcnPpXpvg7UNJ0m5V55HS3kByh9R0yMc/hWqMXexw+sWl0pZZmVU/ujjFc7EtvFKEmiTy0OA4PQfjXdeMdSju7qUREiAnKh9o+XnHA6V5tOlwb8zQowhABLAEqvPU+tJ6IcNzoLyeGSFTbGUlXCttXORjrnPfnj2psUc146qTCpY/djADcDjk8UxU8+NohKIxnKKOWb1PoP/AK9X7a1hBEkpEkYG44fOD3z0wfaudnSvMatgyOkjwRtNGAoJbzMAexqzp7Tt8qGWCJidzog6Y471Np8oPnfY0CcfPuPyr7H3qRpWSJEe5XDjPlQLuKDsT25+tQ2WkO1CW7tJWEUJZchS7KB+O2qUNtqF0AIi1xsJaVgxxjPpx/OohfnYwkhfy1VmJeQg8dD055z0qdb+aaM+X+5SQKwSBSQ2f7zZ49afLdBfUdb2jyJ9nWXYTndHkhmJPp2454rQtXmiulhvLiSK1wGGRkAY4xnrWYfPt0Vv7NmlJ5YySLtb6kdKsmOS+EREkSyK33RlmXn16VFtBj7uJpFcmZ5PMAHMeScdBzUHkToktusIi80/N5kwAPYZ/I9KsqlwjblaXMWfnKYXbx196kW289xNGI9wGGDk4H9enpTTCxjQyOm9pIFOw7cltvb26461dthNqr4ZoecDeo27T0wMU+4e4lkSB4oUXosu7KjHoaiitJd7R27HDtgIrbQR26njr3qRk1/I0QAu0+0GFgFHVcDoMd+nP1p8V5blplCeS5+WVEBAHt6dMVWltJSrTXSMqoQdjSBTyfTHNMl1N4ZjJbWcYDYRVyMMeMkg+9AEySO5ETSZUqVU46jr0+uMUy1lxf8AmTiV3iIJDEYYDHH0rOXVLyG8RXyreXgug3cd8CpCFuCt0ks7v33gBffbnmn5iLCXEcV5cCSLCsTjcpLKD/hU8axyWBgtopWdm3E4Kn2A9z1qWSa0ht1SWNS/UhDgBcd/es24vDZpGA8io0gIRcqx9CPr0pWAmS5jlsxbyJFGVJ3upwT9T+FVWnl3N9nbFm+AynKgfrk896vOsQePyrdmMoKfMvGfr6j1pkzQSxAXxEUPJVFHDEcHHfn8qBnS6U/neGzbafc2ilrNozFLKIz5u/O456gjvz0rL8Uzh7iNPOFwyRIsjKciSQAAt07+p9K1rSIx6XpxsdKtr5WjOZGtg7b9xwjEdMDHWjxJZ20+l3jeTbWbwNCu6FQNshHzISOCBn6itpXcTni1GR5/baxOVjVWit1DZVpGx+O3qfyqykYvbv8A0u7e83/dHMa/XaOSPrXM2uniykYXt0PNzgxw5Yse/A+Y/mKn/tl4pTb2cbwKD1iA8xh6ZHT8Sa1JOvN1/YYewtoMyOPMEEeF+Xn5nYche9OS4F2VV9104BLqq5ijJ/ujv9TWDo0D6gQtrHPcygkushHlH2Y9WP1P4V1y2UmnwLBfalFI6puW2sl2jbz8oA5yD3NFykkZd20Vs/2a4eP7OM7ggLNj0z2zWHPeoXKWsIis3JLqvD49S3+FbV7pkQw0irBE2GWIPnOe5bufaqTwxyW5ENsr2oYEOCcEnsT3rKW5aVyGGCFsSqvlQIoPBAUEHgk+n50JdfaLgxxuYYVbKlV4Hqef61dsbaSJ2le2RoAdvzn5FPYgVV12cS2gFiiFm+RvKPAI+opWuF7E1zKJZFhtVV5iMPxk59Sfel8pIIt9yBEQcSTt/Fg87QOmPSsfR5THOwYNGfLwfmGMdCSea2tHsUvCslxE3khi8IZcbj2Y/wBB6c1Nh3uPtEkmlNzOh8uM5hhZeT6O3ocdB2qO4umd2ExMxQ4CqTwOnart0EhYSIQ827LpnPHc1T8jcweR1G07iU5I9qRSC4tfmjmQhkVCGEb8Lnpkjv7VDp8VykRJiVHDZV2PDDJOQP1q+3kRoXnnjiJwVV+cn+n0qle6jmPepyobhjn8MDr2pgWcSyREzoZBuLCWU42D0C/WspdQuLid4Y7YhMt++I+XPtjrVuzvjOWe6jLnIIQ8An6H+VOtzLHcoodUDfMMLyo6jB6D8Kd1YjW5Xe0zLI98iSMvdhznHUD+tV4bSFbuCTCiEruU8kknt0rbmu2jHmTxxlVYnLkF3B9R3xWZLfzTRI6FEjQ/KWAJ/AdKm6KaF1Kdra3jMMJdsjD42jgdPWs66dtQaOaScJgeYABsH0Ax/jUjbpUVzKpOcNklyB79h3qoLVhcGSS4eKEk7QeD+OMenaqWpL0JLWFWu/L1G5ZVUEhT2BPQDqTV1Fggu2hWK5WMjJ3nt2OM1TC5kd1VVBwwdsgBu59SKt291Ct06q6xuseWkQktKCe3t9adrivYlN3aWTRR+UwmJOCBnYPQigy/a33tk7gd6kct6/Smz3PmwGOCBMvzukxuJ9fWoLOW5hj8gOqxg58uNSWP/wBak9A3LFhNFb2pLQoApwu8fc57DuKc0l1dXLuplazxhvlCjI9KsW9nJHbNJAoDhMMCMnB9z0+gqOHzY4V3XQgUrsDSMRnB6fWmgKAMiB5Q+2QZ3Hd1H0yPyqvq9rOVS8WJgWwHIXG7J4z68VbaIJdeZYvFcEckBc5x3wB+taLz3uoWMsc0ccCA/wDLRicjqSP/ANdaRdhNGbpt88Mo3ICQeUfIP0rf+1287jdG6Sc8q28fl2rnb2ygmkVYpHmZ3CkBduMD9SaXyDb5RLiRFxgx7uTV8xjyMv6lcwrKsLKzytgAOeT+A6fjWZHIP3qvcSGPIOAuAfQcZzj2pLqJZJFdLaUAAgtgZbJ4wBz+dWrcMY1jcyQzhsBURSVA7nHSk5X0LjG2oQTy7hIDIrbsN8gOAfrV+1K211vNvJIgOd5UOf8AAGorCyaEobm4kjXfv3PtLDjjp3/Gtm0vU8wpG7TYU4+XOc9fpWLVjZK5btZJ7+3ljVY1DgFmwMnHqelVwIFgCFsuVJCooA49Tnmqi6XdSr5sNwowSGiGSxH8sH2rUt7QmFV8wIp7MoyuBz71LV9i0yl9hiuIlEZlZihU4UHnOaJ5Lm2C53bQwIj2gsx/wFFoEsncW93IHBIACjBz/KnT+XbTN9snE6biWkJBz9KSkwsiZILjYiymV3UfKhkGB+A9aryySQRq4iC4BBjwTk469etWZ7y3uEdlaSSNRtAjUDn3bsPp6VUs5ZkwXOx9+SGYcD6DrSAeNSee2EckflsigHzP88nvUZ8m1DPNeBhtLbN/XnHA9fr6VbdYJJC8kxVhhmCMPy9jTXawCki6iaUMQoYhiRjnA9femo3BshgvFv7VPLhkZAcBlHDd8Zao/teomZyjgJvAy5BI+g781WRmW5eOPz5beRdy7l2c5/Wkvrj7TOVeW4gIUEOqgFAPqeKOVNibaRbu5JbtN1/OpiDEhcjrnuKzLdYZ3MSAIdpPzkgnvwenani3c2rC3ZnlP3nb5sc9cnuRSQ6KTBmKSVQuFUkgEn2x1xijl1C7Y+B5I52uCpSGHCnJA3cHpz0qxcXks7yJFEkcJAIJOSAOMZIFSxWdi0biBg1yFBdZ2yUbnJJ9aZbGM2bW7wGaYuNhDZC89SevrVMUb9QuL5fs6qiojOMMik4yDxnv71k313btfvE10k1wRwACSSew/U1salBLHIzTLGJHw6CMdunT1rJg0+S6vvtEiQKUxuw3PXGT3zz2qYpapjd+hLaQvNEIIvNeMNtZUJ2Z7ke/0q+qWqsplQFETaCxPOCRjnoPpViytyAzCZbaEMVBC4X8O5NQ+WLe6i82QrC/zF1GWGehwelLS41ex1ulNYCKHzYJ2eWxa6MkczJHgNgqAPbvWDr0KWt6RYwFbKWJJYdzllywzuOerdarafHZ6ItnJPqms3KvvuoTblBFEWYhlGep45HSq2qXDajqJlR7iWN3ADXRBcevKjgD0rSdrWRlTT5rnm+mtLeIZ4tkFsn3ppMncSemTy5/IVetPDmqmxW6SYw20rERhxkuQCSdvAx9c1pafahbmGNIzLK6jDSDiPB6hR0rsI7aaO1uUUxs8cnDsMk54wMcDjNdSijnu9zlF0DULWK1f7Y0zyfvGCuVCjPTHT+ldRY6/Y2EM0UWmXfmfKC7bW+b0JHBGe9c5uuYhG1y8lwVfb5KnOAPT/69btvqNxM0NotipQ/Mka5fjoN3YntUPRlx7kdzqS37GSeWLy/ujyxxnvz0/lTpbwqiC3VSsZKmVztRW/2cdaWTSIpWiIhkgdss9soLAnPUjoKp3twIZvLgWORlBVDwQnHpnGfes3oWmypcXbyQXEM++SKQ/Mcn17AVas5Ifs8Zn5ZV2pCnyjP94kd6ZYPJMpS4Ck5wuwd8dfTio7UwWcM11IyxsvJRuWYditZXLSC0tY47l4iwkUAmUqpA39hn3xmry3bxMEDSOeqqufoM5qOyEr2YjfzBEz73Kn7zHkn3/wDrVNnbvWVBnGN2ckZ6Hj/PNLm7FpWBHNuolUEyPwykbgD9O9V7WPZcOZjLI/REX1P941fs7W5W3laUJgnJ6bwvsT/SsuLUPK1l4RujifOxmbL9Ocn35p20uK4T2weRRMhaAtyBxtfHHPpV/wAqMgkO37sA7dmAR7euKbvZ3/eozgLkuoOAfTH9akWOJHW4nG6IEAFxyfy6CpGRXDxRRq6Qwh2PVjuI/wDr00QXY3ShVTgEkjb9SOpPFW7t7tZlARURsPjrs7YwfrSJcCNHSZkVuQGDEhvXoOfwp3ArCHzplkeVZpguDlMKwPrmqU8akOnyNFuOQg4BP55/SrqsAQsyMQhDKqjBI7DHr9adIqGQsN0cZXeQMls46elCfUTMkRxWnmNI0bIq4QzYGeP7o5/E1kG/Ek/mEKx34LMQFA9h1P1rQuLRZp3a4Y7JEByrZJHuB/Ko/sVtaSl5HSVvu7COe/Sr6EMXcn7kTTmdWydh6sSewH8qgt4JnvDOxWKOFNhRyFyPXHqPSmWMJS5M9vDcZPO3IUA+/cgVpx2st06xRoFVsOSvOT7YH0ouG4mjxPOxWzPn4O1ih2KvH941MgFkh3ELIvURjk+ozUUkVxa3WyWI7ZM5QMAue/41eUIYy8UcapGNpZpMbfb3/CpHsSRT30sU0NuCkTHLMFBOfYUyW1bAjltmZ2O7zZTg5xUUNyIIXVpYieduzJOM/WrlvMOZJLIzl8AZON3sB2HvT1AgWS1tZYzDLI3mKfMSNTw3A2/hmm3lrdiRVlEwtiMiMNgLnqTn+tXJ7tBMDEkUecgkv0b8PXpU0V1O6IVuYoo2JXAGR75z1607gUjaSW12pktXEIOWUsSefU+n0FQl4ovP8uJGQ87VBzn69a2JbOGNhO9yskQBwjyEL7cA1TupbO3IKRqSeQYmI9O3f0ouwsZTujxZuI5yQAquc85x0qrcWt5tMUrEQnJLjG4Z6rwf0rWvXcui200kv8RIBI6dPr71ZhtB9nGyyIaTiPe+Gbvk54pqVhON9Crp9mLieNIdxjYElmRS4HcitK2MH2l45reWZznY5fGxemcDv+lMBhkG27kaGX+IcrwPp1qS0l0+NsOs7MOR975eOBik3cqKsNguY7a72rcTRKeoQEleepPTpUr/AGG7knaS5miSPBzISCxxycYpqIJF82BEyS3LdTx0xzgVKYIopFNzMXeRQcMOOex9anYpEsRjkhDW4e5AYqVSLaM/XHNRxy+a72k0CRtn+NVbGB0BOaljntra5VFWRIGPKseG9wP89Kry6iklwUgs0ZtwDOcAHn9M+tJK427DVie1R1CoyL/CCMketPWW1niC3MccbbASHY5yORjPY+1EUZnuH5hxGQcI4YEfU9altbKGeZmtNocHLFiOnXnPH4UrMLmbNplhcygwB94/5ZhRjHHAHc1Ws7V4r+WZ5oSgBjEKw7SvPrWrKlq88j+Y/BxuXhm9QAO/UZqpb2hllJtXdbcE/KOG4z6dT7mqTaJauW2t7m5Rlnl2oU6AZKj0GfX1FRW629terujOUIL7wHDH+7jpSMYxcOYkkITornJH/wBaieVp4na3jMcrEKQo4Offpx+dK9yki0tyHaaOQrbxsSXU8DjPb9Klt5Le5t54y5CAbigbAOPTjp9TWVd208zxRBNzMhIZ8ZJ46/r1qTT2mQ+XDFCpVdrADdnsP/10k2DGpCJ7KOOK2bzQ53SMML78Z6/41bsbBYS3nXRLEBUEXdz25/yKxb6WW11hreNSzkg/I2Ru9R69K0dNcl4g1zFHCgKFhhijHk46c1TQi95Jijk+1SxzvEuFWR84BPb1OT0qC0sPMSSO4m8otk/KmT14A+vc02F23yTxszJG+RIT82fxqWExLI0rXLsHIBYEbz64zUFFxoVt4xIG8so2UJbkc8gdRyOaoX9wl3I0TWyEBt7zgY3D0Xp1qleq7zMsM000UZBO8nJJ7gdu3NWrCX+zwXnt4rlmXlJCccdQcUAdXC8tvpOmppl/YWlsImMiSsgZpM/e5B6/nxXO67PqD6rve4t52AAE0JG0nHsMce1SRa7pwRZJ9CskTG4ZZzn3xninJLay3f2wRwW8C7UEEfOOvzLn365rSTutzKCad2jM3WsWnobeMbo+WI6/U1Q1HxhZ2810nmExNGpKxDLEjvnoOajGhPdRtHJLyD82TkDvwPuj8az5bbRNOu7eS5uI55gSNit5r45HAHGfpXWmzlloZ2j6lJKZQ0UskDHkAksAfc4H5D8a7601KWOxQDTo4II8gO78jj9OlciLuVdQvX0+1n8i4iCssi+WQO+e/SrXh+5ht7h471jNMG24K4AI6bc9fqKmS6ouDWzOq1Od7y1JunEVnKmF8ogOzcd/8PzrlImtA00YvAqKcBPvb/bp81aU9vLM7teMCGH7uCBgTj39PxNUHntrOVkC2/nnAWFAX2+uW/Wspa7mqt0HMZ7e2AlQRwswI2qGfAPf2ptvErOJxGJFV8+ZJnbGcfl71LFZ3NzcmeVg0i/MwBCiP/DGOnWmfa0llaK12TOch8D5Uz39zWbKWppFY4hGY5i5xwijj6+9AlxDuCBpSeWIysY9fpUVmLeL7xXayHlOG/D0FPkAmIjQu0S4IIOeaixdxrD7XMIVleSUsAHToB61PeWUYnghSKOORPmLY3A47EdKkTZC6SRxLG0fLHqXPfGetWZ2FxbETQuGlfcsanJ/EnvRYCjrUh+zQnzBIzDAw3EeCODVSWOad42mdPIjHAizhGz1NXrhY2iKSmNFHHkA55z1zUNu6bvIKliWwSBnb7AdB9abAmlcSwF2ZvODbG8zgfl3P1qlAXbzGCD5DuP7sk/7o7VLPFDBdO6oSADw7cE/Smpcb3lcZjz/AAKxOeOanqMtPLPFOBAjHPG4RjLKenHb8aqXLSx3KSkea2O/IPr7d6ktbq5fzFkhaN/4Fb5F+gPX1rNu1u57sPkM6tn937f3R3psRbuEmuEDRQLEoPQfKTj1Pf8ACsaZ4VuVeOQyLGNxwOFb0OP61pQ+dczyx3EggOcqXYnJPOQB1Pt0qCa3hjRrAqXcn/WMMBgTxwKrqS9imbkbEkEMYVSdhkfqD3A/pV9dXeY+b5pUD5FaOPbx2zVGG3SG9dWLYDY2qASf0NLq07TQz20Fm+CQSzyYCemfWmI1IZNxKjM7u2dzZJzjpz2pBaq95GrQwKy5bPPHPUdjWfbTzRQFUWM/KuZGPCHv/wDrrUFzPdPGUkG9AAI4l2sfbJ6CkgG2x8uIxlgiSg5Urhn+hNWYA6W77pUXeuVVZQRtHQcc1Wt4jNlvLBMakvI+XP4egpE05Gj860UyRuBvUNtx/jQgLV8BdW6QsLeDd0YEtjGORgdetQRoi4jlkg3F+ecg/wC0ff8ACpZ5PIH2cAxAqMEBVA54xVaTy4xHNI0bYH3Wk3E8/oabAsq0DzsqRqzDncgAXaT9OlKNzszfaIVRTtVBt3e7Z7AelRt5Lu7xwSSwlOM/dz34NPkt7VUE9vE7XDpjYMYAIxxjj86XqN6j5LaTzQP7RLPjIjBVPlB5PH1p0SSbG/0OSV88M8nmbvwqpp2o2ay3EbmATIMHKAbcckHv+NbcOorcMpEzM4PKwx9MDjnFXbuSn2GQXDRtEt1ELfcoO9LfJ4/kenNUHKu8z5kkiDZ5kIHPHQdT9adrF7J57h/tcsrEsGfC4PTk9hwKzY9QefZgsgfdwsxbI6Zx70h3N6O02mF7OG4dUU+YxBUE5P3c8n8aIrYSSg/aNjBgFYsB15wM8n8Kpx3EsTiI3cqBjyGfYGP1HSoxHD9rXejhFbAKMXAJ6+/vSdh3J7/TxDK6TyJFC3KyE5PH196pL5cLSKrxPcSDnCne4Hbj6VqXD2TIASV28s/lknPv1qpb3FwTKQI1DcI4BB9BnPbmi7Q9yL7TDlo7iORbeMcJ0GT2yTSWzorjIBhbDD5fug9MHqT7VK1qZd0kscUjxjcvI2sQcce3pT55LiBkjvIEt2MZCOWBVR7KOrYxSsF2WSIURjbwyOhI2sflHPrnr9agsNQmt5Qt5bqyEEKkcmAvHtVYpFKxdZMNgbnOO/oDVtby1jQRyNE8iMdoZ8qQQeeOvaqUWHMthhkV7gSmG3J3fKuTnPr9MetRXWpSRTTSqYhDEe2Ao74yep/lTbkCSNBbiRSQAS2FU4/TqetZtxpS3sDR3NzGi79wjSItvI444wealJX1B3toa9tdm5Uy3U2xGBVcYye+Pan3cs0UbwQySbGIUFDhdo7E1R/s+a0tdhRldT8smdxP4U6IT4UzFw2OcHBPfn/9VJvUpK4+5O+fEsr2qjOXC7nPsPT/AOvUtpbW4jEcVqYVLZSdnI+uOf1x1qwscLh3lUyOGCAFuAD/APXqW3sGlaV1AjkHyru+4B0Bzii7CxSk8q1i82dTwcBQN3OcA8dKuur3SI8aRCKHCTbSAxzzkEnr2qMh4n2qtu8gwpx8y8c8joQPWnW1iXWRXiTMh3eaMqoyePoKLqwtUOZwiosLiRclc9h+Pf60tlBAjqXtvNTcRIAxG4H8yOTTLaB5i5SCNNzCMYHUdz7D/CnSXO7MYlL5GG44z6e9TexVrmtJo8d5pqzWXhwyBn4Z70oSo43ZPYGue1mwns5/LazNmxQfujMJBGf97rk56dq3IdQjkayjntLpEkhfTmZVymM5Vlz1bJGVqrrUVxd6nB9+KOFVhzcIEklKLyxHUfSt5OLjoc8FLnON02wl1WRf7RuZ5Yz1UtsT8fyqRLnT9NGbSG3mlVvmVR8o6YyepqhHfXF/cLGjOIc4YKnWtqxsILedvOVXwQQx+6pB7iuhWRg02RxM99CtzcSyFN5BjiXag78n6Zqe8i0zTrlZE2yOFO4gZ3g44GerD2qjrOrabCbjYUdeuxhwT2x26dzUdvrE7NbJpluJ5ogWLlfujrgA9APU4qZFQWhu3L3KWjPGHQlcpC6Zbnueyj8MmszT7e6uMyW1tDC2753bJcjvjt+VWi91exR3Os6jbRwu2VgUlyP+Ajg/TmoL+X7VceZJMGCcbXO52wODgcD6Vm33NEiUX6XG61twPsqNkjYDn3NVJyUudtjk24ODMrAA+pzjjmm63PNutYrSICJ1DeQg3MAO7emTU25Wj2XiMgTIYAFkP1+n5VDRadizJtjngVEiZJAC5ZSQOf4j3/lVnUDHBapJNLvuXGBu+6gA4B9OO3pWTDMolWMDzbdl8tdzcfn1P0qZrcLtjmZd7cqXOMj+gqCnqLb6t9ut3lMyRgNsIUclu2PatVZVZfMUu+fv5PJ+lZ/2KO0ANxGr3AYt5m3AEbcZC9+cGm2+y13m3jbyjgYDHPXgE9/pSkEXoW7gqV82FiCBgxBRxRFJM0ALKVQZAB5OP8aiOICBdjyVYEhUGfy5606eYmZPLcQxrhWAO5ifoelIq5I1oPLdZNzXDNlR3I9TTYp2tsIkSqynGcYGfcng/rT0Di7ZpCxIzhpW+QD3FZV/uWMSXMu0FjEjLk7j7Kc00kxN2NKQSGdLjLmMgjlsYOeh4yetVnme43Fo5EVflXy+FH41Bbw3DWru7Py5Usc4I6H684qSWJkj2vMrIoyoU7nyff0pivcWF2c4i2RgL+9Ows2B3JNUbm5gM28xGaVn+ViTjHt7/lSXYeJI55A6pnY5kkx1PHHem3Rtijy+Ubhhn5mPy8Y6D/Cmib2IppJGzKjGEMMAKQAMdqGEUZCvLhRzknfnj7uB71JNHG1pu8xfMIY7Bzgdcc81TdI1txJDcSO5wSm7YB6HmmlqJsqO9u9rIplLukgOAMrgduPz6fjWnbyzOIVt+YmGGcZXaR1IOfccVQ8gKjzuwhY/xsc569R6HpkVqWTwvBFHHbMrA8iRiRnHXHfpTlpsJakTrII/3+oiROSqgkheeh4qVEOEhglMceVbZ82D609ZrW3kdJYzl2bIjXbx2IHXrVl3jtmhMCSgsMRiOPHPfJP86mxWhYRUWUKzPLFj+KDqfY8/rV0XFpA8CMjvCWACLEMtxWY8N1cNG0sjwB053sAAM/r6VWKRpclB5ZeEfK3mnj04pFNm/JpZZ1msrWRVLnYHcYwTwCvqOaR7meKxlUW0UIVwGy/8Wec9MetZ7X9wyKgvZFJbcI0BOCOnOKsTpIRF51vd/OCGBbczDHp170N9RC2lq0col2Su8xyxKBUb6+tTIJvKZYF+fu0bYZPxqtptw+nvMggieF2ysgDcD0yemas+es0ckaWcC7sAsWKnOe/FMaKckIM6+Y3mSY5M0xwT6Y9farYidxIoNsNpyqK2Mg+nrio71J7VFES2Bd8Z2KSRj685pd013EFDhHgyFKIAc/Q9RSsDZYittsUjzPburMGG4FumeCKcPsyozSXUJdj8qFyFXt0z1rMhnhd9sxePy8cSHOD6gLUt4IInEiPG078hREA34Z6d6qyFqaTraGJBFNI24ZcRrkhv61UZi7ulu9w0hPAZlJLY7j8qXTBJcIyvppaQgHbI2Ao9Sc9farOGTdHb20EQUffDYz64zyeT2pMq+hnxo0iuUhlBQ4Pmndz7D0FStBaXFsyLxIqkByp+U47fjVu3lu7dJM3UcOzAPz5YjvjtUc62+Qr3LTJtLbY13Z9sj19aQ0YUtrZ3cbRyKQ6/ebJYufQACrdlYSmFpbVVXACs5QBR6/U1Ztoiil1hEEWOXKnGOuPcmlCW0LJsuPMIY+ZCrkY/pj3p8z2JUbDBIDIkXno205JxwrY7nHYdqui6WG9gZxLJGMByowCM8AfkKimkihCMsYRxk4RsADp+OaqG8+1TLH5qFh8vk45P/wBboal3K2N4zNcQyyQ2wWQtvLE/Mox6fhVFo4cZk8ySSPk8jb9PrSNLJLZtFLcwo79Qg3MSONuR0/KpZLmE27RGWWN24KAYB46HuTmp1KEme3lBDRRwyMfuAAAH8TUlmkdyHeWF5GK/ed8jIHIwOoqnJANm+eMkjIRSNwB4zVmxuWhjSWPy2bb8wj52j3NIBRatFGpKKY422jbgZHpkcU6QDZ+9bcFGQd2AOcc+vNRLf3LyQNAMxREtsSPOD35P+FF1aPLGJoAZVYZQlgDyc9Pw5oC5FO0jL+62qknbPX1I9frVm9lgtYktrWL/AEgHEi7t5Yf0rBhhhe9kl/0lnIDO8jZC46hR6dK3LIyWbLImYxkujjmQHGMk/wBKp2Qk2bAex1axsGlvRZNZoU2NG7JnJO5CBy2OtZXiXXIDqSy26zz7kSEAgh2VRgO2e5P6V0mnTLZ6Xp6T61d2rSRfu4FjB2jJ+brWd4h02MXL6lcX/wBteFI/ME0WzKMPlcYPT61q72MU/e/r/I8xe8s7QpHbNNPLnkIo59hxiknmvb+QrlLQdgxMsvthRwKbDDNKruRHDEuAcMVU/Vup+gpgvUT91Yy7nPy7LZSgb6kc/mRVXfUSS6F2LQdOjnUajJOZuskkvL7RzwgOQPriuks7DUPsXl6Zp8NlYN84nucMWUdCFzyfqaz9JgK2Ut81tawlMHzZiG2sPTJwOnU5NX7vUL29tortoftCbiqSv+7t0bHVQeXI+mKpNrVha5mXt3DaMgi2XNxneJrkKQq46BRgY9hxUGmwXVy6zJHHDFk7p3YB2HcIDwB9B+dT21jb3F611qcr3M+3ILDdhgeioOMdOpAFJNol3LJJKcEM20JnG8nphR1H5D60pO+okrEksmn2ImeJXmuJDtcrKdqnsC3c1kLP9ouI7aWZmWNjuBJww9OP51oXEbW0DwTmItGuERSSqeu7tu/SqCWMdvcs1sZkiXls8NL6nn7o5698cUtWh9TXj2x7IwmXLZUYztOeAcdKdIsSLKLy5CYOWMQ+96dfwqvZFWaR7U75gAEIztRD3J9KsXFu88+bx408k8onzBDn1PWoasXcq37tdTB7eMqBGcKx3n171tLHuhT7RJGrn7ojH3cj17Gh0aK16+WZFwE25dhjOc9hVR45WifYr7ZOqj070gBri2ATyVO/hfNZdxHqPYVA1uHu2MUjFWPzYfJB9asSyQ3EEsQ8pRtK7lXjHsB1P4cVk2kBtD5UaLjJB4yy5PQnoKLA2bsM8Lk43S3IXAxnAx2zxVK5hNzFILqbLYO0ZzjHU/1yaoPIInxCqqWYYwAenv8A4VfvISkEkm5pQFIwi4UE+ppIGNjnBkSW5V54VACFBngjjB6VFvnn83YRDCM4OSWGPQVMLQnTIJFZt0YHyjPH1Pft/hUdq5WEO/myEHGFBwT6Zo6gVdRBufKhASReQHbgqP8AeJqq0clphYJSDs2khNwye2T0q3bwNu8yNk2FsxiQ5GM8DHX+VTPCxDxLMC5ByQNoz+OeaolmcLSSSRTMJN3DkyDoOg6cdqS8i3WspKMUVgdwQRgDPPXvUU0hMKtIkhaMFdxyOAfUnNRyXcKyPiJkLYVcEYI9Tnp35qtxMsacsccYndWZYyNmSG4zgc1sRH7XuBtmjULwzgYAwSeTiueil2mQSEsAQBtLEj06YqOSUtLH/ozOiDHzyHG735z0qRpm5HO9k8ix5Ifp8yqF4556/hUeohmgi85oiwOHYPkqe2SOlV4LpIQ5kES7jgkqzED646U+E2bQhma4Kk5wFcdT29e9Kw7kkDhZN73rP5Sk5ij35Htuz0q1ZPGzOGgvZZHfCnzVAJ7cdqhaRDKWt1vTGzbTgkY5569R2xTba4invGjgt5twfDbjyOfQUAia8kuPtp2RXQIjDZSQbWx6nHJxmrV08pkBkldQnADSMxOR645qORJ0lw6zSRgggw5OB6c+9WIJmS2nWC4vSE+cxlBtYnse9Ax0UoZ2T7YI4MhXJ2nB9eeRUmqReVPFNaXM88bDc+erDHPOOtUjctNazzPEVAwoGwnJHPXsRSCaU6eJXnlnLDKxu+GAPp7U7aBctebDN5UsMVxIobkPLtLZ6L2p0sayYkEUcTAklADgn0H+e1ZsssdokjPIqvgFg0xbJ9AOlQwPE04XzZCDxxv2nH1p2Fc0bK4+zXQWdY2AO5i/yj6dK2LaX7ZK80EQznb94MQfesO3toGkl+ePc4wTNkbfbOaWC/msTs2QypghfKfAJHYZ6k0rXYXNi8jukEflx5wu47mALDPT2HuagktjK23FtFIwxtV95HqPp71nXDpPKs621xbl8JJCJQSfUVcsbN7YyubaJUxhyWwSOaGug07ksEEkU7rH5EoJCggcD9MVLdW97mfy4w4U/N5S4HsAv9asJcRxri2nKL98sQp2kDoPQ1marc3Bdirq5dAPkfGMH261Nin5CTor+W8gmcNgEOGXd9DV2CwDqsTeTDE43hSucDtyf5moZrmbyP3w8pkOFjB47dB69+aZMGeJZLp3eRMElztx7KmBmhjTJ1gUykhIojwETJbf6nPYcVTvrZUuRI4iiuxhGjjj+4uePx96lvZWmSEww+TlR5ks3DD2HPeh5YXmaWVWOVKOW4Bx9KV7Ba5o6d5dnbhFijn6sckFz2+g5qzdSO8xnlERk2gKCwQJjkKB3HNZVpcx27xiIxwLnk+UXz/wEVMIY2txIqNc3IJyrOOMnknA4+lJ6jDfmWRbmZmGMtGikjJ/z+lU73C3dtaNA0UUp2mUnC46/N3rRtdU2FoIrSLznVldSPlUD/CqV5EyW0Dz3AlfOFt2yA/YZ74604pdQd3sTtEVtiLPbIoYqr/dyPX3pUhhgtElfPmMSApONx6Cq4lllAEixCPtnKjHovt2p00CKUZo3kc7sqCS4GOw7fU0uoy7J5srCEIu7GWm3YBJ/h9KrpFI7NkB1c4MnGFPsO4xVaxklSNjcwzkniNH7AepPcnrik1S+lkkENw6QO68Ii5YClYSemp2tpFBbaXbR6o9nLKAfsxuFd2VM452/wAOc9awtdudTjmmsrwQyGd1lZ4UwpjUDYqn+7/k0umalY3VjbW2rQPHJCPLEsM4RigOcN16ZPSmazdXCakAkUcMLwRiNQckQ4+QZ65x1q5O8dDKK97U8jgSVhiUy3MnZVGUX8W6VZhkETBEKRs5O3kuPp2X8s1UvNSivAY7YfZ4u6qNxOOny9PzqsNQv4kxbWsca9TPJ8z/AF54H0Ga6OVvcyUrHXWsccey61jUXitIwSvmpuy3YKnTPufyq5FeafdXG2y8+PGVF1fEyu+f4Y4/64wK5LTYfPRpp1kvpyQPMkdhHH9B+PtXc6b5S28El3PEgY+UzEEEkfT5umOBVctiVO7HWtrJaWTSwokbyAY3yiSUjP3tv3V/HJ9qpwpII7mG7u7hr2ZlZ5CxL7ey/wCcVaurvR9OtJEt53Z1BKCEAlmJ6EnhfrnNYkV/eBlSytvK3MW2t8x57sT1NQ0luaLU6CK3W1QJcrFbbF8xmlO47uvze/sOKwmvVurFx8yKJwqpIWD3Jz/Fj+v4Cr8el3dxpvnX8uQ7ebvlYgD1G3ue1TXf2doQJhtRflWRk5X6KP6VOyKKsV4bcJDIVRpDmSOPoBnocc4+taPkPKDdJkQIPkYLtwPZe3bk1RtYbZpmMZlWJ0Jzn7+Ockdquwb5Q8Msx2cFVVtoP1rO5WxAt5NLbPIF2zI4JlPb2J6AUy0aAIJL2aQ4ziJTkkDufUZzj61c1wLPGghUrCMDCcIGx0H94+9U7Am2V4jGkZ6lpOcA9c+tAMdcyhWPmAWjuwCpwSVPpUUEUcsOxmCRHqWUlm47DucinLPA8qrGWur4nO4LkgdCCT0HX3pl6m24c3TSLJjCxRjrx69QPenYm5MIjM6lpfJ7JkYIA54x0zSm4Zy1tJI8il8LEBxk9Tmore4aS0dIkCSu3AAPGB2Hfp941Dcrc3MWJFZGVfmdecn36daOWw7liJpoGKERLt5VQ2/HbJHSqEkyQvgyMxPIBJkAJ9umaWOTfB5ckqylcZXhVz6HHWpYo5Whk228kcedy7TgLgY6nn9KdkIk8+ZYi0kZC4OEZec/QYHvUf2ncpmY4iyEIwCzNj0H+PaotSjNsqLNIroGBUtl8/h+NPFnJLbMXT5sYAkG1VHUYz0/Wiwm7mdcl/mYRvn7vK9ADnG0dc0guHSKB4vLVyMOVQhsE9ACOv1qZIGZJGWVTIV2Mqys23Hf64qoX8i1LERtgYbhm47HiqSJZXvizTThpXGXPzCRsAeuKkjlszcLCs0I3YACjq2OxamRRxzTzuyvGFUZbZznPoSas3U00UIa3DPuyGYuo3c9dvY0/VCWhYFwx815neORiqozuFyD0IA69KllltkZG81PMbORJIScjqR9faoRGJVjjKnqAsbEAnp74z+NTsxtbgxsJmXC7pMgg+x+ntUlXFiu3gfAuFKMNzFFGCO4weOPWlt5RLLMytMdz5Z1cE/72B7U2XUA0jKYuGPDs20Y54GRjP4URXMIlQCW3CKeQ7Bd2O446dal6FF2R2VSFkdIiThmlxvPoOKluyEihd0lZmGC3ncsOOMcDrUXMjRL5MGT8zBGAHsOn8qtpgMyCJvlI8tXVSAevXvmkMhuHjt1hjmjuTbqdzbJflXPBOPwqeKS08uOVHhGwlo1mXJPoMHr9KZ5buJJJreFGEpXou4/h6U6SKI3kOxo4zGQSwcBvwqtBalTXGjuFQeVZb3YsqBOoyKdYs8cru0UC/w/60D26f41IkFvO5fzZPtCk7GXBwfTFS20zXDwwLZp5o++CgUseeCcflSTAWG6k8po5GkaMHA2HIbPc1mSEX4OJolhXIVSPmDc9s9K2JA1u80c2mW8zMoUB8Ax8ZwMdqz9HsLOaYxq7IQo/dxH75/HGKBlqxtoolSWO4lM/wB1m25OPbdwfwp0iotx5lxcXWcciRSSc9CQKbbzs+VmNxJNFn5QAAi9hn1qQPJnMvmr5g4VpOox3wMYobGtB3nefcYhQvEvBwjJx2GM80PC0Ue8JJHCM5ckcnOAOTQWlTciSxBmI2qwP5gf1qQz28UQlNw8rq5G98YU9OB6nn3pWKuV5rm7D5ikaMHAYsAxJ79KljuHiIeSRXCnO1lHJNN86QZe1jjYv1JjK4755PX8Kcvk3FgfOUidm3tIV2gD0AwOevtSYRJbi4adgQEt4xgZI5HuaeFDyAoZJFVNv7sFQfb1NUeGSMx3ahFYBt6DAH1zmrL3F3OdlvtMSHDSKpUEDpik46BzGvaz2a2csl6CLmMbYUZTuY461nrLOcqXby8/Kq9WOeue1RW1s1whiXPnKxLs+Cf/AK2PrV6OzW0gBa5kbcSWBOenTjrSKKotpEmVkiMRk6nnJGeW9qkZ7SGdoo5GlyeGXhic9WJo1G5uDOiMbgKyDD7fmx6ADpmqZ2xT+dIGjjxhVVd5bHc+vNF30C5b8km53MzkucEou4Bfb05qws1rayXCpsBVCpyCWc8d8ZqnCZbpSUY/v1BAMewgepHYe3WoHV7adIF3Mc48qPIJPGQT+VKwGjFJJPdbgYkfjmUk7RjriqDLajVBcai0kylyzCHh2BB6D6461NcW0pTz5UjiRjxEh5I+p5qbSbCe/kjtoRbxBm2qc4Zj9T6U0wa0JrWTwzZPvVNVeTODH5cRJ9sD61V8Q65b3WpRG289YxCkSxsAWBAxzjgfXNaEtlowEttDqjpcD70q2zsoHfknkZ71RvNLTTnCXEq3TBBKkm7CFG+6wFW3pqjNb6M81HlQiNIY44SpI3EZZvck0K0RLTTr5uwnknCj/gR4/Km3ht3us2AmVl6y3PzuT7DtSw2EsjD7PC73IOfOm+cn6L0FbKdnYx5G9WPF/qTwTNpyxWlsePMC5Un1DN3/AN0Gq0YzdGeVbvWL+Q43SNhPxHt+H0rb/wCEfSEx3Gs3xllcgrEWDEg+gHSr0Z0uzCPK6DaceUvXp0PpVXfUmyvoUbWGKMbpXggVlCusJyT/AMDPU9sLWnb2d3ksZY7W2i+YF+Xx/sqec/Xmi1vVlkRdJtYvtUeVWdxwmfQngcetNtIT5kjRo17fKSfOiw4Qn/aPyr+Gah2Zpqh8yS3UgWJNqht+ZmJLc9cZ/lxVuSKOKWR7yQyy7NzRocgk9BgcLUQka0BEs8EM0h+fyVLv9N5/pULvHc7oNNgbeTuz3JHdiOD/ACqbFXuMdJrZkbqj/d7qo7kAVrWlzF5DKJGdz8oUJ8oYjg571nlXs90jzI7gENHuJAPPGe5qJDJKvmmE7N21SnTpkgc9qlqwy8ILhZ41uWa4kC7RH/D9G7D6Ci6+YO8gUsQBtQYRSR0z1qH7ZK9ksccaxwR5MgLYX6sf6CqOp30RgjQZkjcgK5DZ57gfWhIGytBdm1llCQ7UOBvYYxn0AP6nNWZYVuoJE3tHCcFpGHzHHbnk/Wq626x3dvKzILgAmQkAE49un9eK0UQpEFO6cqeVJ4bqQSfT2q27bEbleOR4pI4bdTKgyfn4Bz/ebqfXHNTztKQplViM5IXhDg9cdOPU09rJJVeOaKRZWI2opxz2Pp+nas25vAf9GnUiWMlSD82Ce47D8cVOo7ovusSbJVAlmDZKbdwIJ9BxUl1MZrdpJQBIDgb/AE7YA4qgZJpoFU+bGg5XYf3jY7knjp6VBNJMjRbZEER43Pgb8cdfw7VaimQ52NHTbiDYU+0OxLbSpUgA9uB3+pFVrzUBIHUzLGclSSoz6e5rLupCJpIp5dhb5lBb5WOOwHH5mmeYvmqyh5chSUZgoY++OB+dUoXJ5yS5SL93Ik8k27IkLDaN34+1Mkb7MjRtOi5fccksSQPX0qp5Elz5gSQRI/KuZArA8E8k5PHHFRzxSeW2+QzkfMuCAw9jnvVcrJ5rGgbiFLIqkyqzPuzFtHTkjpk1Vfy1GQW8tgSSMvznntUF3Kj2cQikceUzKVjIAPHuPY0LJLb2wk8uWNyxJCnBAxjB+tHKLnNiFY3WIy2+6PgBsFdxx/8ArqG2mjdtkNvKxz8uGGSeapGdleEtGkm45BIYZJ9xSyzZhWMZMYyykPu25Pb6fWs3E0UjcSdvNAtmZFBA2SLweOenHFG5o3DHyYzLwkwHyscnqeRn8qzLPdESXYRbRvRzGxLAn1HbHrUkEpEpVLWKQtyS3IB7HHGe1JpIrmLst9IsjB4oHVQFVotuC3c896mmuI8RCRliYgbWaM59j0rPZp40XzbUqOwDggn6YzV6W6OMRzRxKRywB478HtU2RVydZ8CRXcSvj/WISdufQj+VC3S48hzOAnTzAW+b8uKiE03lTBLlHJQEEHJ/P/Go/LuAvmZkjjT5Squu4j8eufWiwXL7ziB9xmhfoqkoysD7HIzSrPullDSXML537wu5T78c4qvE7yRB47Ryh4Bd/mzjjGeferIbUI0EkTrFGMKsqH7uB/F1zTsCZLbahdTQHy5BKxbDO+7LHPc9qtzQT3O1ZNryNy+EBHHvisN5XlkkMlyzANuXyUwT1zkfnTRd7nBLNcMTtCb+mf8Adx+tDQJmtJLp0U7Q3KOrAbQsKdfbI/nTVZv3arKY4ySB9oYkxg1jYeO9ilihZJYD92Q8N6k561pwXc6R7I5oCf8Anmxxv5657fSk1oNPUuMlv56tgvHGMlslCT3JI60ryxnabW3RQTyyKCTj09ulLJNc3FmquYx5fQjgE/n2qmnkQzBluC7so3bOmc8cnFSXoalvateFZXuGgJbYIY2yzdulONzbR2+2QSEldgDFjnt17ZqpFErT+UspZuCiR4+c+m7tjNaCW727uZrcmNcBmQD5c9+e/uaVikZYSS2Qfut4/hRV3Z+v+JpUju97lbkwJjd5Yf7q+mc/41pC8MtuscUok5P7voR/tZ/xqrLJNNOhmUER8oOBu7A7iKBEGnXEyGJQQkXLM6cZzwRuPNaNnIWSR4g8zKMEvjg9fwFVZRPIIvPlSNFUjCdM56E9z/hT1iRIN7SyspOQhO1XPY8YyancpKxNPNutts96pYkEoh+VQOnA61SuCDMssaSSIFHXAGMe1Tx+Y0arb2WyX7vnupyc+gP8qsWdjLEsssyo6KT+9Jwo9doPX6015AVY0myWmuDyM8uAQo7D0HtSwPDHDJKInRc4BX7xJ6kkdKkknjW+UxL9pkOcbxuB44Jweee1VnseHgnuTGspMjRowHX1x39qI26ku/QmTU4mk2whgWfbgNuZBwR+PWrsM0kN4l3ZxMrxkeTkbmJHqPzzVCK2WKNY4oglsDguEOcDB9KsWl0sN2txZJNuVl2zKMbW6AL/APXoG9tTbN3avCxm8OuS+GYRmUIT346/h0rI1d5ry5kkuYWjjAVEVoyqgAYCKua39Qn8XanOj21rfWaFfnIkIBOPvY9/SsW7klllQ6ldTz3YxmKZseV7NzkfzqpbEQ3/AODc5KFIEZZETcijbv8ALCjj0H9ade6gkQ2rKkTLn/VsC5FZ0r2EiEKsjkkn5iWP4AcfrVZSkaEwRSKx/vEJ/Lt+NXe2pG5Hc37qh8mArn/lpKcEj1yetQoLf5pNRuVt4mGUT+Jz798e5/KrjWn2gs1zeLbsOdsQ5/76PNWbFNEt/wDj0tGvp+Dvk+4p9/WtFdktIWzS33JJZ27XsagDdc5it09P94fWrEmoS3kptIJWulzyLVfLgHsCetN1AvcJEdTuobK0XlYzzvP+6OveqT3vnRothamO3PEckzD8diDt7n9abSJVyaSWW3na3lO4nCtGnQe2T1Hr0rUAlltFFvCttEHAyp/eSHtk+3oOK595WMphusRyZJMr8uRjoAOg9sVJZ3ksN4s7SvbW4G3ew3MAfQdBms2WjRaGGK4ZWmCR/wAY2k56dcDLE/1qS1vYnWRAx2E/u4lOWYf7R7L681Qu5pLyRIBhYDkoHG2SRv7x/wDr8Y7VSitZYYwqTxiNnHmCEFQB2JPU9+KpiUmbeoobmVTH5c0SnDorFgG9Seh+lNuIi8xEMzSugBaSRdoGQcgDt/h6VUsL+K1E8ceyNei5Q7mHcqD0z+daVtIt1smcKi4yqbuBjj5vb2qRlaXmWAQxOWY4O87SfUD0HHUVYhuHcpmGOFxzsVcooHGQPUepqEXircCQBiobDSlOvfgZ6UTvERlnPmOWcIDk7eu5iOn0oE2Sy3pYH7KGln3lRIy5H4HvVPNna22RGs9y2CFQELkdc+p6c1EyO9uZLclYcALcDglu+B36n/69VPNkkZobdgrKChmx8p+p7kdz+Aq4oiUiPUb8wEG7kXdK+dm/LAegHp9eKbHqCPaHYzO8Uh3u3zHHop6flT3iaOD7DclWmmBBkGAwyBt9wMVBo+j3thFIsyo0WcZPGGAHU9+vQVpyX2MnLuM1JZr/AOzSeW7wgbWZuCy9uegrNiWeyuY0uJlhKsAqupz/AOPdeO4rqrlFttKRpkM0vVBKMck9VQdqyh580K3IIBGOQVXjOMe34mqjG25Ep9jAvUks7tmnUyKZGVJYwfu9QfY8/pSafJcXouUtvtU52hkIZRuwe/PPetO6lv4L2Q31ssPlfP5fmK/3eOVTkcZqnHrAuL6R4ESa4kQqAI0Ub8DAXjjp6VfKiOdmfBOZLg+dL5G5WIFwpUfhgVdsI5GgaRZkdt2QoYMSOpOOwHvT4xcGVY9R054pJY2jRdpaMr6qQTtwTnpSy2pa0IRfMhRgrbpFJz0B7MR2pOKKUrlmJrlvKbKgEELluVB6twfT0p8aTLFyY5FGCr5AOMc5OefTmsWCOVZikgeNGG9STlVHQMO4/GtZw4hV5DEQw5YjDcH8j+IrOSsaRNCBprcb0UiTjEe0qeR0P/68U5rnz4A32aKSZm+bDfMp9iOQKqFvKeMWkkoZmyY3O0EHrg9jUSTh5SJIwzA9HyrZPTDr1/GoLuaKOzHypY54JM7h5zjYo+pPv1pTJcxo0Mlx5MUnJznaw9c+lVHikBlhuI97FQ4LHcR9PWprVESDclzIyMhU4PIIxlWWkWaKwXcTJGn2dkkAZizcfp2qxOk8ckBaG3miydzQscD0zj09qw4SGyAZQ0QwTCm1vX1xV2KUJIokkYRyLnY+MOTxk47CosWjRsmiQlYJ7qOcnkbPlx14JqVpkeWT95scv8+8kD9Bxk1SQwrmBppDgkArjB9ce1TobeFQIZfNlPAHl5O3H6Uhl6Lz5FMKpHKeuN4Gc9znr1/SoZQID5UqQDy+8I2/rSJIrRONjlIxlS3G0EdOKen71yWjdQoyEC5XHbBHfigBHmn1RpvMeJIogq7F5P1HpVoNYQEO3mI3B+Ujex/H+VYoacSyLHvigDkuRjqcDr+f0rbtIre3uLgXbhSoygf5znHTHU0PyFEprKZ7sNJIyQvksGKqcewqzp2o225oJl8uMthWA5c9uO49qlMX219yxxwRAYJZF/H/ACKitLW0tXbrvA5KofXj6VN7F2uaU8hbbDYBon/il+6pOeuPTioppZjKPtVxJN8oBQnknj7o9Peobq0lG2WV3jiPAQsOBjjI9aLUYjDxK7zjBeeT5VVewH+FJu41oy8IYgCxuPIjkIyiAMQvoc96md5JV/d2+wdpZD37cdhjms9Z1RppXk824JBUbPlB9R/9erluL2ZlAmS1jnyzT3BGcjP16570W7FXJoo0jZRI5lk2ZeRx8kfPOB3qPz7OO7VLecXKAffySR7BT36VBHBHDAjX1xISc5jiIG44/l70WSBCz5McbAnhfnJxxkntS2GaL3kRuYms4386NV3Mz8A9s571X1Zpr3/WStIoH+rQEL17mnxJFbqA7PG2MooHAPqzeuPSoZ7mVISloknkEnc38LZ7DPSjcNihFcXI3xQLsjU5fcAPx9RWhnnfFh/l273GFUn06frVK209YY2BXyLeRieXBc8cAe1actsinz5YWI4GMDrjjApSS6BG/UmsNPSNF+2TsyA7mJbaMYzwDjJ9Kl0K5t9Oubedo57h1kDqF7LyOnTI4NVbe1kY+YYSzD5sHovHcn0qbRLyGPVbQ6lOgtjMAIxkjnoW/wBnOKUd0OVrMmOmxzSzt/wkLeWXDABJfMU+pHOT9Dis3XJFl1FJY/PaHy44jJMcSz7Vx5hXrk47107ahJcXs+na8IogGIivVKnyjjI5HBT27VleL2SHV447dlkKWsKGVDu5C9iOua0lbldjGPxK55gDdXEoaDYkODh2XA47Cp3028kUbiwycdAM015xDIkTGWR4/wDlmEwGPchew9jVZru6uYiLeIRpnBYn/IrSy6kXtsXJdFCSkzTK6qMsdwwo9zVY31rDJ5do5uDjH7hDge+elZ123kxMtwJrojnaASAce+B/OoNPk+2tGhQwKfupGdzkeoA/oKvl7Im9t2alvHbrcpcX8ygM3+rJ82Rvw6ZrprFp5RutbUWsbKQs03zSyegAPC/54rEkD2UEsVpaQ6fn/WXVy371lx0A7fTrV208TjTFlSzfIIVPtVxHuYD/AGEHAGfz70WtqDZNf6WLPyyTIvmkkFhmSU99oHIX3NV1hSIwxwwpLcM2I9wzu/oMU9dRffJI8rK03yyybsyMOu3Pp6hakEqpJLOZGjhUjKhf3jKOgH90fjn1qGrstPQivNNuQZTPKryA/vJYznaem0HsfpWddNawTx2tqks8o++gBAB6DHp/Or6agJoi8ym206NTiJW+Z/Xnt9aqajHNc2Zn+wNBaP8AMjAlWCn0x6/rVRJlsFg0LzOq3SpIh3SzFPlQ/wB0ev09qvxKMR+QkgjZ8gs2ZJfXA7Dvn3rIgsDugjL7lUbijDCp68VqX8jxzSP5om835WIwryYH3Rjov0oYkOnEkaERqBGe5OVUZ5wf4v61WmWNpJDKrJbLuLdixGPxwaZdXFy6wJPGJJgAY44s/IOxI9aZqKi3t2k1GMz3h27SeGyeQMZ+YfypqNyJSIobuWKBGuJFa3P3IGOcj0AHQn9ahubmG3jaOEmSbJIgboh4wWPcj06cVBdfbrdrhtm6Ur5W+M/u4RjkYxktiq+n6XI2yeceWjNiJHADE9fnOeK1UDJzNS0ExWIPhJCAJJZpADn+Ij0z0BpLrXoXvxazvtKIEiRUGFPY/U9yeaTyLu++WGGBkgbBTzVy/qf90Y496hXR2gv1ktwJ4XTbvYfvJM8knPQDmtFEyc7m1pNqssvnakkoZydo6/KPcfzPFdMdN0hzG8ds8gMZ2JJ951A9B1rG0y68rNvEMMJfLV3bGcn7ufTIr0fStAk1t7kMBFM0a/MT0GOeeoH0piWp507wz2Es2maR9kMRSN08jDSITgjJ69O+KoxT3e+1gSzhFuszMzfZewJztbGBgd816vrfh600rSHF3Jbw2RAMgAI565yTk9K888RTxaVPm8vRHpk9sJYrabcNwPT5cdOOv0qiXoZt3YwWVzNe20iN9oQttQGIojHqoBw3XOK43U7aCO9mEDibblVCOUGO2M9fp+tb9lImoW0175rGKFAv79SGjXGAo9qyL6zgaJXupDLhS+YsbRjG7d6HGBn3qXEcZFWC28gebfZljjIeKUZVo+/H/wASfSoftLLckYM0EqbtpGNw9R2P86li1SK20+2jkbfaSMUcsxLRnbwcegPPHanWeo/YyLeZUjw+d0YB2uf4h6hh2qGjWMi3b/aDZM0Ll7KJjII5lKhTwCCvX8qdczxQyQtbxBJCDuy3Gc9R2/CqlxcS2cawyOJolbzlMRyQjdM+n41NBqE9qwAeKW2lyXTAxz3x7H9azlpsaRJ4Zy0ajkgDqCRz7ehqW2uN0qLIyyBTksUGQPTPf6dKYsgKxLE8MzxE7UZcZB6nn8PehGNxF/pqrCwcjehBIGOmBxiosacw95EuFIaXy7xm24P3GyOoPb6VPESqAqpRCw3HgoT0GAeapKkccpiCh2jO3ceQ3Xp7VZi1C4hgYhhskj8tCyghUPBXGMjrSKuW2mW3R43RWbdzheCPb2qeKeQPHFJGVtgcqicFj6lvasiORox9oXJKthgxy2PXH41eF4Cqf2dlYxwQw4U9c+31qeUaZpwXcYnX7TK5hDndk7SPQVPeX8LKBbxtgjG7PLfXnn2rIh+eUPMzvGFJVsbssfbsMmrW8W5txwPMbYzHJbjv+OaVug0TQW0giKIuzJ3nnn3+tS2dvunLK5mkZcB3JJx3x6Zq5cQgKBZI0TRnpI247T6+lLFb+Yq28dxlSC7eWBkY96hmiRdZVRMSLGx25/d8g+/PTvVVr0QQrvskCP8Awn5cjsfXPOfyqSKyXYz23nJG2SsjcFwO1LPPYWoEIxcSvxI8R3sc9RzQt9QK0E8+otJDPK4hjwXEabtuema1EsYlsxcySl5E24VmwPTseoFZFk+oLIyLObeFAFPHzMCeFPr/AErRjtJTKu9pJ2UnKh8Dp0H4+lDY0XkvUE5a0t0IZSflXCxjjI/H1HNVGkmkdxP5ixkgiOPjcO3FWrfyI4xNcS7Y+T5SYBUduvPaqUzyXsINosjRBsRyNlSxNK/cfoWoymniTz0hdcfKzAnPHQGiVCESS1Ekh/jmPCqcds/kDTLFTbRMl0bdp9v+skbI49B36UkUhlZnnM86ZztC4GfWk2mUi2trJcQ7mlbnPOTljx0Pf+VNcIziO2Lu0bcM+Rj29AfarF0ZNjK2yOPCnaGyxXsOKqrLEHDpG3HRQ3zE/XoPwqSidZIre28xQJ5kPyjHCH1IqJ5oRvkZQsjkbnYZ2j/ZFRztI3+tdIFyP3anJH+J/Gpp1s3h22ziF4wcyE7mb2HpmlcCCS6efCoJJVD43zSFUX14pbeB3nWCFi7fwCMZBJPQegqrMZbq1hEcLpbxkH5WG3GcYY+vWtzwwjxarApUWsJDEMEBP3SA2evBINOy0Ju7DW0G0Ephlv4YpSfmiO5+QOcvjaO/POKytXSLTLhba5glEwHMNrgd+AWz1OQc12UkLwarbXEk1y3kIsS2aW7M0uFwVUgbSrcnJOOeawPEUSG8iBRGeOCOHqCCwHIB746Z9qtpLUiMnJ2OI0/SrW6szIyFXJGSrc54yefWse51S8eR7ZZ2ijj+QbAASKKK3lscyDQ9LtruaWS68ybYA2Gc4P1p/wDb11p0ky2MdvBtYoGWMZAHTk0UVUAmZlrPJrF9/phBby2fcowRjnA9Bn05rpNM0m0VhM0Zkk8tJMuxIGc/KB0xRRV9DMoWJ86UyuAHa4eJSvHlKOcKO31qZYV8rzcsWkk2EFiQB/jRRWUtjdDpZTdFZJwrKnAjxhMA8cVYu7me7YedM/ygYwcY/wD1UUUDK8SlwuXfbuwVBwDwetVFIls3mZEDF9vA4AGKKKEZsbpU8tzcTRyyMVAbofRc4p0kYlgmLFt5nMZcE7toHAoorWOxlLcwtSDW32W0hkkWJyXf5uXZjgk/hU8EskeoTRh2ZMBNrHPH+RRRWq2MmV9K/wBJ16KByVjf5Ds4IBGSAa07AvFfXc8Ujo9ogEQB4GeOlFFUjFmjbSvq3iWwgvDmIyjKqNuSQMk+9fRPhpzDZXYQA+RnYTyeAMCiiiRtT3PO/Gl1Lf69YWtyd0DyqpXnABU5wK8p8aXk95eatPcuXdJDCgJ4VF+UKPbAoopdSZk+j6dEvhbzVeUNcRuHwR25GDjPt9Kv6JZwxWcrFN/2G58uJX5BVhyG9RRRT6EmZr+mWkml3DmIAbyQqnCr97p+QrFmto2s1hOdkFwiJzzhhyD/AEoopSNIlrUbaO1s7a9t8x3ALjcD1APcd6lulQahbsI0z5fmnAxliMnNFFYS2NYlXUnKXTRL9zaCB6ZA4/WrMW2dXMiKTCFVccZHvjrRRWbNEWWRRD5yja+0dKo28rfa0zghhgjtzjNFFCGyWQFvK3M3KjP5kY/StzTIkMKJtGHwWPfrRRSnuXEks5mME8bBWjBAC4wPrx3qtMS7ROTyrEfXpRRWfUsupO8cs0an7vzhj1z9a0tKAjgnkABdVVwT6nOfwoop9hodNK9xAu92AMe7apwM1Pom1p57fYoUyKu4DDAexoopR3GyW8m8q/STZGx+6Qw4Ix6CnT6hNKFhAjjREJBRcH86KKT6ldi3DY28SSL5Ycypks/JHGePSp4Y0+zA7RnK+3WiioKQ2CKNb6cCNcQldoPOct3qfxHcvbWaNCFRmdlYjuMUUU47DewaXbrOyvcPJKd4++xINR37i0tbhoUQHcMArwvPb0ooqWMSGFWt7WR8sXZhgnhQBngUzV22LawRqkaSBixVcE8kf0ooqraEsrTXcqCBMhlSPeAwyMjpx+NWy7zrDLI53NIV4wAAR2xRRUS3HHY0NPkmfRtSRrm48u3ACIJCF5bHIrndS1O4ubxY3EarBGFTYuPSiijoO2p//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pustule on an erythematous base represents an early lesion of pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6166=[""].join("\n");
var outline_f6_1_6166=null;
var title_f6_1_6167="Hydrocodone and chlorpheniramine: Drug information";
var content_f6_1_6167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone and chlorpheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/56/39812?source=see_link\">",
"    see \"Hydrocodone and chlorpheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TussiCaps&reg;;",
"     </li>",
"     <li>",
"      Tussionex&reg; Pennkinetic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antitussive/antihistamine: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TussiCaps&reg; 10 mg/8 mg: One capsule every 12 hours (maximum: 2 capsules/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tussionex&reg;: 5 mL every 12 hours; do not exceed 10 mL/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Antitussive/antihistamine: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 year:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TussiCaps&reg;: 5 mg/4 mg: One capsule every 12 hours (maximum: 2 capsules/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tussionex&reg;: 2.5 mL every 12 hours; do not exceed 5 mL/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TussiCaps&reg; 5/4: Hydrocodone polistirex [equivalent to hydrocodone bitartrate 5 mg] and chlorpheniramine polistirex [equivalent to chlorpheniramine maleate 4 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TussiCaps&reg; 10/8: Hydrocodone polistirex [equivalent to hydrocodone bitartrate 10 mg] and chlorpheniramine polistirex [equivalent to chlorpheniramine maleate 8 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, extended release, oral: Hydrocodone polistirex [equivalent to hydrocodone bitartrate 10 mg] and chlorpheniramine polistirex [equivalent to chlorpheniramine maleate 8 mg] per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tussionex&reg; Pennkinetic&reg;: Hydrocodone polistirex [equivalent to hydrocodone bitartrate 10 mg] and chlorpheniramine polistirex [equivalent to chlorpheniramine maleate 8 mg] per 5 mL (115 mL, 480 mL [DSC]) [contains propylene glycol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Extended release suspension",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16253298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Vituz (hydrocodone bitartrate 5 mg and chlorpheniramine maleate 4 mg) oral solution: FDA approved February 2013; anticipated availability currently unknown.  Refer to prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F179980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2871423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Administer without regard to meals. Do not dilute with fluid or mix with other medications. Do not give more frequently than every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Shake well before using. Use calibrated oral syringe to measure doses. Do not give more frequently than every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of cough and upper respiratory symptoms associated with cold and allergy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6839203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tussionex&reg; represents a different product in the U.S. than it does in Canada. In the U.S., Tussionex&reg; (Pennkinetic&reg;) contains hydrocodone and chlorpheniramine, while in Canada the product bearing this name contains hydrocodone and phenyltoloxamine.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also refer to Chlorpheniramine monograph. Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest tightness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, drowsiness, dysphoria, euphoria, fear, lethargy, mental impairment, mood changes, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ureteral spasm, urinary retention, vesicle sphincter spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dryness of pharynx, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to hydrocodone, chlorpheniramine, or any component of the formulation; children &lt;6 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, morphine, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause dose-related respiratory depression, risk increased in children, elderly, patients with pulmonary disease, and when used postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstructive bowel disease: Use with caution in patients with obstructive bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pulmonary disease or decrease ventilatory function; dose-related respiratory depression occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children &ge;6 years of age; may be more sensitive to adverse effects. Contraindicated in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Frequency of dosing: Appropriate use: Should not be given any more frequently than every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Measuring device: Appropriate use: Accurate measuring devices should be used to measure suspension doses. Calibrated oral syringes are most accurate. Household teaspoons and tablespoons are not recommended for measurement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F179974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F179963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2871396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hydrocodone is teratogenic in animal reproduction studies. In humans, birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery. Also refer to the chlorpheniramine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2872297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hydrocodone is excreted in breast milk; information for chlorpheniramine is not available. In one study, the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean: 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturers recommend discontinuing the medication or to discontinue nursing during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9550694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (TussiCaps Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-4 mg (100): $780.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-8 mg (20): $156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid, controlled release",
"     </b>",
"     (Hydrocod Polst-CPM Polst ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-8 mg/5 mL (473 mL): $307.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid, controlled release",
"     </b>",
"     (Tussionex Pennkinetic ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-8 mg/5 mL (115 mL): $142.45",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrocodone binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorpheniramine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlorpheniramine:",
"     </b>",
"     See Chlorpheniramine monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 3.3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?,&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/1/6167/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8757 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6167=[""].join("\n");
var outline_f6_1_6167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179978\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179968\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179973\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179969\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179953\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253298\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179980\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2871423\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179954\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839203\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179976\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179957\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179943\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179974\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179947\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179963\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179948\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2871396\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179970\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2872297\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9550694\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524633\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179942\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179956\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/56/39812?source=related_link\">",
"      Hydrocodone and chlorpheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_1_6168="Med bronchogen cyst CXR IV";
var content_f6_1_6168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77346%7EPULM%2F72317%7EPULM%2F72838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77346%7EPULM%2F72317%7EPULM%2F72838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An axial T2-weighted spin echo MR scan shows high signal in the right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays a non-enhancing right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Spark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6168=[""].join("\n");
var outline_f6_1_6168=null;
var title_f6_1_6169="Clinical manifestations and diagnosis of bicuspid aortic valve";
var content_f6_1_6169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of bicuspid aortic valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Martin G Keane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Martin G St. John Sutton, MBBS, FRCP, FACC, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6169/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/1/6169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular outflow tract (LVOT) obstructive lesions account for approximately 6 percent of cases of congenital heart disease in children; in one series, the incidence was estimated to be 6 in 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Obstruction can occur at valvular, subvalvular, and supravalvular levels (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"UTD.htm?42/11/43196\">",
"     table 1",
"    </a>",
"    ). Valvular aortic stenosis is by far the most common, while subvalvar and supravalvar disease each accounts for 8 to 14 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes and clinical course of unoperated valvular aortic stenosis due to a bicuspid aortic valve in adults will be emphasized here. The treatment of bicuspid aortic valve stenosis in adults and issues related to pregnancy in women with a bicuspid aortic valve are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF LEFT VENTRICULAR OUTFLOW OBSTRUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Valvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital valvular aortic stenosis is most often due to a bicuspid or bicommissural aortic valve. The estimated incidence of bicuspid aortic valve is 1 to 2 percent of the population. Affected patients usually have other cardiovascular abnormalities, including abnormal histology of the media of the ascending aorta and coarctation of the aorta. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Associated cardiovascular anomalies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less common forms of congenital AS include unicommissural or unicuspid aortic valves, in which two of the three commissures are fused, and aortic annular hypoplasia, which may be an isolated abnormality or may be associated with leaflet abnormalities. These rarer forms of congenital aortic stenosis are often associated with severe obstruction to left ventricular outflow and heart failure in infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Subvalvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subvalvar aortic stenosis is also called subaortic stenosis. It can be caused by a fixed obstruction, or may have a dynamic component that is primarily due to the genetic disease hypertrophic obstructive cardiomyopathy (previously called idiopathic hypertrophic subaortic stenosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fixed subvalvar stenosis encompasses a variety of lesions including a thin membrane (the most common lesion), thick fibromuscular ridge, diffuse tunnel-like obstruction, abnormal mitral valve attachments, and occasionally, accessory endocardial cushion tissue. Affected patients typically present in childhood, unless the child is brought to medical attention earlier because of other cardiac lesions, the most common of which are patent ductus arteriosus, ventricular septal defect, and coarctation of the aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Supravalvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvular aortic stenosis, which is typically characterized by \"hourglass\" narrowing of the ascending aorta above the valve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"UTD.htm?15/62/16355\">",
"     image 1",
"    </a>",
"    ), occurs in Williams syndrome, in an autosomal dominant familial form without features of Williams syndrome, in patients with homozygous and less frequently heterozygous familial hypercholesterolemia, and as a sporadic disease. The prognosis of untreated supravalvular aortic stenosis is poor and survival to adulthood without intervention is unusual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link\">",
"     \"Supravalvar aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BICUSPID AORTIC VALVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that a bicuspid aortic valve is present in approximately 2 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"     1",
"    </a>",
"    ], but a lower value (0.8 percent) was noted in almost 21,000 men (mean age 18) in Italy who underwent screening echocardiography for the military [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/5\">",
"     5",
"    </a>",
"    ]. In these young men with a bicuspid aortic valve, aortic regurgitation was the most common hemodynamic lesion and was moderate to severe in 12 percent. Mild aortic stenosis was present in 5 percent, and ascending aortic size was increased compared to normal controls. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Associated cardiovascular anomalies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bicuspid aortic valve is the most common cause of isolated valvular aortic stenosis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/2,6\">",
"     2,6",
"    </a>",
"    ] with a male-to-female ratio of 3:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. It is also the most common cause of aortic valve replacement for aortic stenosis up to age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Course in unoperated patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two distinct anatomical configurations of a bicuspid aortic valve. The two commissures are oriented in an anteroposterior direction in approximately 53 percent of cases, resulting in left and right cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"     1",
"    </a>",
"    ]. The right coronary artery originates from the right cusp and the left coronary from the left cusp. A false raphe, which can make the valve appear tricuspid on echocardiography, is present in the majority of these patients, and is exclusively located in the right cusp. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Echocardiographic diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the remaining 47 percent of patients, the commissures are located on the right and left sides of the annulus, resulting in anterior and posterior cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"     1",
"    </a>",
"    ]. The anterior cusp contains the ostia of both coronary arteries, as well as the false raphe.",
"   </p>",
"   <p>",
"    Fusion of the right and left coronary cusps tends to coincide with coarctation of the aorta. Fusion of the right and non-coronary cusps tends to be associated with cuspal pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Course in unoperated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bicuspid valve may be functionally normal, ie, no significant pressure gradient and no more than trace regurgitation. However, thickening and focal calcification of the functionally normal bicuspid valve can be detected pathologically and on echocardiography as early as the second decade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Almost all patients with a bicuspid aortic valve eventually develop symptoms due to aortic stenosis or regurgitation, although many are now diagnosed when asymptomatic due to the widespread use of echocardiography. Occasionally, a minimally calcified bicuspid aortic valve is discovered in patients &ge;70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive fibrocalcific stenosis requiring surgery eventually occurs in over 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The nodular calcium deposits originate at the base of the cusps and extend outward toward the free edge, causing obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/10\">",
"     10",
"    </a>",
"    ]. In a small number of patients, stenosis results from excessive fibrosis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/10\">",
"     10",
"    </a>",
"    ]. The pathogenesis of valve calcification is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peak incidence of symptoms (angina, syncope, or heart failure) occurs between the ages of 40 and 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/10\">",
"     10",
"    </a>",
"    ]. Once symptoms develop, survival without valve replacement is less than five years. The incidence of sudden death in symptomatic patients, attributed to myocardial ischemia and arrhythmias, is 15 to 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A bicuspid valve is a common cause of aortic stenosis that requires surgery in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. This was illustrated in a report of 932 adults with isolated nonrheumatic aortic stenosis who underwent operative excision of the stenotic valve; none underwent mitral valve replacement, none had mitral stenosis, and none had undergone previous aortic valvulotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/6\">",
"     6",
"    </a>",
"    ]. A congenitally malformed valve was present in 54 percent: 49 percent had a bicuspid valve and 4 percent had a unicuspid valve (mostly in patients &le;50 years of age).",
"   </p>",
"   <p>",
"    The causes according to age at the time of aortic valve replacement were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 7 percent of patients who underwent surgery at &le;50 years of age, approximately two-thirds had a bicuspid valve and one-third had a unicuspid valve.",
"     </li>",
"     <li>",
"      Among the 40 percent of patients who underwent surgery between the ages of 50 and 70, approximately two-thirds had a bicuspid valve and one-third a tricuspid valve; a unicuspid valve was rare.",
"     </li>",
"     <li>",
"      Among the remaining patients over age 70, approximately 60 percent had a tricuspid valve and 40 percent had a bicuspid valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk factors for stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all bicuspid valves eventually become stenotic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the factors that affect the rate of valve narrowing are incompletely defined. The clinical risk factors for the development of calcific stenosis are the same as those for the development of atherosclerosis; of particular importance are elevated total cholesterol, systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/12\">",
"     12",
"    </a>",
"    ], and inherent cuspal inequality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also some anatomic data indicating which valves are more likely to become stenotic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sclerotic changes may occur earlier in valves with",
"      <span class=\"nowrap\">",
"       anterior/posterior",
"      </span>",
"      leaflets as compared to those with a",
"      <span class=\"nowrap\">",
"       right/left",
"      </span>",
"      orientation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bicuspid valves with asymmetrical leaflet sizes (ie, greater cuspal inequality) are more prone to rapid calcification. It has been proposed that valve calcification is induced by excessive hemodynamic stress, resulting from straightening and stretching of the leaflets when they are open and close [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/13\">",
"       13",
"      </a>",
"      ]. These permutations are more pronounced in a valve with asymmetrical cusps.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence for familial clustering and therefore heritability of bicuspid aortic valve. This was illustrated in a report of 30 consecutive patients with bicuspid aortic valve confirmed on echocardiography; among 210 first-degree relatives, 190 agreed to undergo echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/14\">",
"     14",
"    </a>",
"    ]. A bicuspid aortic valve was present in 9.1 percent of first-degree relatives, and 37 percent of the families had at least one additional member with a bicuspid aortic valve. The pattern in these families was consistent with autosomal dominant inheritance.",
"   </p>",
"   <p>",
"    Similar findings were noted in a review of 50 probands with bicuspid aortic valve and 259 first-degree relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/15\">",
"     15",
"    </a>",
"    ]. A bicuspid aortic valve was present in 9.3 percent of first-degree relatives, and 32 percent of the families had at least one additional member with a bicuspid aortic valve. Using extended family analysis, the heritability estimate of bicuspid aortic valve was 89 percent, suggesting that almost all cases were genetic.",
"   </p>",
"   <p>",
"    Recommendations for screening of relatives of patients with bicuspid aortic valve are discussed below (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Screening'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated cardiovascular anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bicuspid aortic valve often is seen in patients with other congenital aortic and cardiac anomalies. In addition, a subset of patients with an isolated bicuspid aortic valve develop dilation of the ascending aorta which occasionally progresses to aortic aneurysm and less frequently to aortic dissection. In a series cited above, 22 of 74 patients with bicuspid aortic valve (30 percent) had other congenital anomalies or aortic root dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/15\">",
"     15",
"    </a>",
"    ]. The most common associated anomaly was coarctation of the aorta. An autopsy series found coexisting coarctation of the aorta in 6 percent of patients with bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, as many as 30 to 40 percent of patients with coarctation have a bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .) Less common concomitant congenital anomalies include ventricular or atrial septal defect, hypoplastic left heart syndrome, patent ductus arteriosus, bicuspid pulmonic valve, and Ebstein's anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilatation of the aortic root and ascending thoracic aorta is associated with the presence of a bicuspid aortic valve and the degree of aortic dilation is independent of valve dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/5,18-20\">",
"     5,18-20",
"    </a>",
"    ]. In a study of young men with normally functioning bicuspid aortic valves, dilation at the aortic root or ascending aortic level compared to controls was noted in 52 percent; this finding was independent of the functional state of the bicuspid valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/18\">",
"     18",
"    </a>",
"    ]. In another series, ascending aortic dimensions were significantly larger in patients with bicuspid valves compared to those with tricuspid valves with comparable degrees of aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/20\">",
"     20",
"    </a>",
"    ]. Aortic root dilatation in Turner syndrome occurs with or without a coexisting bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aortic root dilatation progressing to aortic aneurysm is associated with increased risk of aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .) The risk of aortic progression and complications are illustrated by the following observations from an Olmsted County study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascending aortic aneurysm (defined as diameter &ge;45 mm, mean aortic diameter 48 mm) was detected at baseline evaluation in 32 (8 percent, mean age 55 years) of 416 patients with bicuspid aortic valve. In these 32 patients, the 15 year risk of aortic surgery was 46 percent and of aortic dissection was 7 percent.",
"     </li>",
"     <li>",
"      During follow-up of 384 patients with bicuspid aortic valve without baseline ascending aortic aneurysm, 49 developed aneurysms with mean age at diagnosis of 47 years; thus, the incidence was 85 per 10,000 patient-years with an age-adjusted relative risk of 86 (95% CI, 65-114). Following aneurysm diagnosis in these 49 patients, the 5-year risk of aortic surgery was 47 percent.",
"     </li>",
"     <li>",
"      Of the total cohort of 416 patients (mean age 35) with bicuspid aortic valve, 49 patients underwent thoracic aorta surgery during 16 year follow-up: 36 for elective aneurysm repair, 11 patients underwent surgery for aortic coarctation or recoarctation and 2 for ascending aorta dissection. During this period, 133 patients underwent aortic valve replacement for severe aortic valve dysfunction. Bicuspid aortic valves are also an independent predictor of ascending aortic aneurysm formation after surgical correction of aortic coarctation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aortic dissection occurred in 2 of 416 patients with bicuspid aortic valve followed for a mean of 16 years, for an incidence of 3.1 cases per 10,000 patient-years with an age-adjusted relative-risk of 8.4 (95% CI, 2.1-33.5) compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/24\">",
"     24",
"    </a>",
"    ]. Higher incidence rates were observed in patients 50 years or older at baseline and in those with baseline aortic aneurysm (17.4 and 44.9 cases per 10,000 patient-years, respectively).",
"   </p>",
"   <p>",
"    Among patients with bicuspid aortic valve, those with coarctation of the aorta are at greater risk for developing ascending aorta complications than those with an isolated valve lesion. In one series of 622 patients with bicuspid aortic valve (mean age 32 years), the prevalence of ascending aorta complications (defined as aneurysm with diameter &ge;55 mm, aortic dissection, or rupture) was 8 percent in patients with associated coarctation versus 4 percent in patients with isolated bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/26\">",
"     26",
"    </a>",
"    ]. Among 341 patients with bicuspid aortic valve with no baseline ascending aorta complications who were followed for a median of 7 years, the incidence of developing complications was significantly higher in the group with coarctation of the aorta (130 versus 20 per 10,000 patient years; hazard ratio 7.5, 95% CI 2.0 to 28). &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The increased risk of aortic disease in patients with bicuspid aortic valves, including those that function normally [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], is mediated by coexisting defects in the aortic media, including fragmentation of elastin, loss of smooth muscle cells, and an increase in collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/19,24,27-30\">",
"     19,24,27-30",
"    </a>",
"    ]. These abnormalities may be mediated at least in part by increased release of matrix metalloproteinase-2 from microfibrils due to deficient expression of fibrillin-1, the protein that is abnormal in Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/29\">",
"     29",
"    </a>",
"    ]. The fibrillin-1 abnormality is also found in the bicuspid valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with a bicuspid aortic stenosis correlate with severity and tend to occur with a critical reduction in valve size (orifice area less than 0.8 cm2) (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 2",
"    </a>",
"    ). However, there is a wide variability in the degree of outflow obstruction that causes symptoms, depending in part upon patient size and the level of physical activity",
"   </p>",
"   <p>",
"    The major symptoms, which typically occur with exertion, are dizziness or syncope, chest pain that may be typical of angina, and heart failure (eg, dyspnea). The onset of these symptoms is associated with a poor prognosis; as a result, intervention is recommended for symptomatic aortic stenosis. Other manifestations include aortic dissection as noted above, aortic regurgitation, sudden death, and infective endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant aortic regurgitation is relatively common and is often independent of aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/20,31,32\">",
"     20,31,32",
"    </a>",
"    ]. These relationships were illustrated in a review of 118 patients with bicuspid aortic valves, 84 of whom (71 percent) had aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 70 patients with no aortic stenosis, moderate to severe aortic regurgitation was present in 28 (40 percent). On the other hand, among the 28 patients with moderate to severe aortic stenosis, moderate to severe aortic regurgitation was present in only five (18 percent). The presence and severity of aortic regurgitation were strongly correlated with ascending aortic size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden death can occur in children with aortic stenosis due to a bicuspid aortic valve, especially during and immediately after exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/33\">",
"     33",
"    </a>",
"    ]. Sudden death in children (mean age 10 years at study entry) was evaluated in the Second Natural History Study of Congenital Heart Defects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/34\">",
"     34",
"    </a>",
"    ]. At more than 15-year follow-up, more than one-half of deaths were sudden and unexpected; the incidence was higher in children with more than a 50 mmHg pressure gradient across the aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated incidence of sudden death in affected young adults is between 0.3 and 0.4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Nearly all sudden deaths in adults with congenital aortic stenosis are preceded by a history of symptoms; in comparison, the majority of children are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/33\">",
"     33",
"    </a>",
"    ]. Subtle repolarization abnormalities on ECG, including exercise-induced prolongation of the QT interval, may be associated with increased risk in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/36\">",
"     36",
"    </a>",
"    ]. In older adults with a bicuspid valve, the risk of sudden death is related to the presence of severe aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bicuspid aortic valve is susceptible to infective endocarditis. The estimated incidence is approximately 0.16 percent per year in unoperated children and adolescents, and 0.41 percent per year following valvulotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/37\">",
"     37",
"    </a>",
"    ]. The risk increases with age and endocarditis can induce aortic regurgitation, which may be sudden and severe, in functionally normal bicuspid valves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"     1",
"    </a>",
"    ]. However, endocarditis prophylaxis has not been shown to be effective in prevention and routine endocarditis prophylaxis for patients with a bicuspid valve is not currently recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H10#H10\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'No longer indicated'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical and laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with a midsystolic systolic murmur introduced by a prominent ejection sound typically heard best at the apex [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/38\">",
"     38",
"    </a>",
"    ]. As the severity of stenosis increases, the auscultatory signs change. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ejection sound and the intensity of the aortic component of the second sound decrease.",
"     </li>",
"     <li>",
"      Paradoxical splitting of the second sound occurs in severe stenosis.",
"     </li>",
"     <li>",
"      The midsystolic murmur becomes harsh and long but remains symmetric with increasing obstruction, and is accompanied by a slowed carotid upstroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrocardiogram is often normal until the later stages of stenosis or regurgitation, although left ventricular hypertrophy, with or without repolarization abnormality, has been described in approximately 30 percent of children with significant aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/34\">",
"     34",
"    </a>",
"    ]. Cardiomegaly on chest x-ray is uncommon unless there is advanced left ventricular failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Echocardiographic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included recommendations for the use of echocardiography in patients with symptomatic and asymptomatic murmurs (",
"    <a class=\"graphic graphic_table graphicRef50108 graphicRef58419 \" href=\"UTD.htm?39/46/40684\">",
"     table 3A-B",
"    </a>",
"    ) and for the diagnostic evaluation of adolescents and young adults with congenital aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef72431 \" href=\"UTD.htm?18/39/19068\">",
"     table 4",
"    </a>",
"    ) and for older adults in whom aortic stenosis is due to either bicuspid or degenerative tricuspid disease (",
"    <a class=\"graphic graphic_table graphicRef80790 \" href=\"UTD.htm?14/18/14635\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Course in unoperated patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of congenital aortic stenosis in children discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a bicuspid aortic valve can be made noninvasively by transthoracic (",
"    <a class=\"graphic graphic_movie graphicRef66664 \" href=\"UTD.htm?21/52/22351\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59607 \" href=\"UTD.htm?27/17/27921\">",
"     movie 2",
"    </a>",
"    ), or transesophageal echocardiography (",
"    <a class=\"graphic graphic_movie graphicRef80529 \" href=\"UTD.htm?20/47/21235\">",
"     movie 3",
"    </a>",
"    ). The two cusps and commissures can be identified in the parasternal short axis view (",
"    <a class=\"graphic graphic_movie graphicRef59607 \" href=\"UTD.htm?27/17/27921\">",
"     movie 2",
"    </a>",
"    ). The presence of a raphe may cause the valve to appear tricuspid in diastole, but the classic systolic opening pattern allows these two conditions to be distinguished. The tricuspid valve opens in a triangular fashion, with straightening of the leaflets; in contrast, the bicuspid valve opens in an elliptical shape, with curvilinear leaflets.",
"   </p>",
"   <p>",
"    Other echocardiographic findings in the long axis can include asymmetric coaptation, as well as bowing or prolapse of the leaflets. In addition to its diagnostic utility, the echocardiogram can also assess the presence and degree of aortic stenosis, insufficiency, or vegetations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Evaluation for aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicuspid aortic valves are often associated with dilatation of the aortic root (sinuses of Valsalva and sinotubular junction)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending thoracic aorta, which can lead to aneurysm formation or dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Associated cardiovascular anomalies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the proximal 3 to 4 cm of the aortic root is easily visualized with echocardiography, the midportion of the ascending aorta may not be; as a result, evaluation with magnetic resonance imaging (MRI) or computed tomography (CT) is often needed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines made the following recommendations (",
"    <a class=\"graphic graphic_table graphicRef82459 \" href=\"UTD.htm?23/34/24107\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial transthoracic echocardiogram should be performed in all patients with known bicuspid aortic valves to determine the diameter of the aortic root and ascending aorta.",
"     </li>",
"     <li>",
"      Cardiac MRI or CT should be performed when the morphology of the aortic root and ascending aorta cannot be accurately assessed by echocardiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was also concluded that the weight of evidence or opinion was in favor of the efficacy of cardiac MRI or CT when aortic root dilatation is detected by echocardiography, to further assess the severity of aortic root dilatation as well as possible involvement of the ascending aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recommendations for monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of progressive aortic valve and ascending aortic disease, serial monitoring is warranted in asymptomatic patients with congenital aortic stenosis in whom the rate of progression is highly variable.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines included recommendations for monitoring in adolescents and young adults (",
"    <a class=\"graphic graphic_table graphicRef72431 \" href=\"UTD.htm?18/39/19068\">",
"     table 4",
"    </a>",
"    ), in older patients with aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef80790 \" href=\"UTD.htm?14/18/14635\">",
"     table 5",
"    </a>",
"    ), and in patients with a bicuspid aortic valve and dilatation of the aortic root or ascending aorta (",
"    <a class=\"graphic graphic_table graphicRef82459 \" href=\"UTD.htm?23/34/24107\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"     39",
"    </a>",
"    ]. The frequency of monitoring is based upon the severity of aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 2",
"    </a>",
"    ), the severity of aortic regurgitation, which is defined elsewhere, and the severity of ascending aortic dilatation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Severity of AR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend the following approach, which is consistent with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every year for severe aortic stenosis or severe aortic regurgitation.",
"     </li>",
"     <li>",
"      Every one to two years for moderate aortic stenosis or moderate aortic regurgitation.",
"     </li>",
"     <li>",
"      Every three to five years for mild aortic stenosis or mild aortic regurgitation.",
"     </li>",
"     <li>",
"      Every year if the aortic root and ascending aorta maximum dimension is &gt;40 mm (normal &le;35 mm). If the aortic root (sinuses of Valsalva, sinotubular junction, and ascending aorta) are not well visualized on echocardiography, cardiac CT or MRI imaging should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of children with valvular aortic stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for screening of relatives of patients with bicuspid aortic valve were not included in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    valve guidelines with 2008 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines recommend echocardiographic screening for the presence of bicuspid aortic valve for first-degree relative of patients with bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6169/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412885\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital left ventricular outflow lesions can occur at valvular, subvalvular and supravalvular levels. The most common lesion is bicuspid aortic valve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of left ventricular outflow obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A congenitally bicuspid aortic valve is present in about 1 to 2 percent of the population. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Valvular aortic stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bicuspid valve function may be normal at birth but evolves with age. In young adults, aortic regurgitation is more common that aortic stenosis. Progressive fibrocalcific stenosis requiring surgery eventually occurs in over 75 percent of patients with bicuspid aortic valve. The peak incidence of symptoms of aortic stenosis occurs between the ages of 40 and 60. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bicuspid aortic valve'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Course in unoperated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bicuspid aortic valve is a genetic condition with autosomal dominant inheritance in some families. Echocardiographic screening of first degree relatives of patients with bicuspid aortic valve and a positive family history and in those with a dilated aorta is recommended. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Familial disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bicuspid aortic valve is associated with dilation of the ascending aorta in some patients which occasionally progresses to aortic aneurysm and less frequently to aortic dissection. Bicuspid aortic valve is also associated with coarctation of the aorta. Lesions less commonly associated with bicuspid aortic valve include ventricular or atrial septal defect, hypoplastic left heart syndrome, patent ductus arteriosus, bicuspid pulmonic valve, and Ebstein&rsquo;s anomaly. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Associated cardiovascular anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of aortic stenosis include dizziness or syncope, chest pain that may be typical angina, and dyspnea due to heart failure. The onset of these symptoms is associated with a poor prognosis; as a result, intervention is recommended for symptomatic aortic stenosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Aortic stenosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"       \"Treatment of bicuspid aortic valve stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sudden death can occur in children with aortic stenosis due to a bicuspid aortic valve, especially during and immediately after exertion. In older adults with a bicuspid valve, the risk of sudden death is related to the presence of severe aortic stenosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sudden death'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"       \"Natural history of aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The bicuspid aortic valve is susceptible to infective endocarditis but routine endocarditis prophylaxis is not recommended. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infective endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      By echocardiography, although a bicuspid aortic valve with a raphe may appear similar to a tricuspid valve during diastole, the systolic opening shape of a bicuspid valve is elliptical rather than the triangular pattern of a tricuspid valve. Echocardiography is also helpful is evaluating the diameter of the aortic root and ascending aorta. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Echocardiographic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/1\">",
"      Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/2\">",
"      Subramanian R, Olson LJ, Edwards WD. Surgical pathology of pure aortic stenosis: a study of 374 cases. Mayo Clin Proc 1984; 59:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/3\">",
"      Kitchiner D, Jackson M, Malaiya N, et al. Incidence and prognosis of obstruction of the left ventricular outflow tract in Liverpool (1960-91): a study of 313 patients. Br Heart J 1994; 71:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/4\">",
"      Liu CW, Hwang B, Lee BC, et al. Aortic stenosis in children: 19-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 59:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/5\">",
"      Nistri S, Basso C, Marzari C, et al. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. Am J Cardiol 2005; 96:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/6\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/7\">",
"      Campbell M. Calcific aortic stenosis and congenital bicuspid aortic valves. Br Heart J 1968; 30:606.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. The Clinical Recognition of Congenital Disease, 5th ed, WB Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/9\">",
"      Beppu S, Suzuki S, Matsuda H, et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/10\">",
"      Fenoglio JJ Jr, McAllister HA Jr, DeCastro CM, et al. Congenital bicuspid aortic valve after age 20. Am J Cardiol 1977; 39:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/11\">",
"      Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation 2005; 111:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/12\">",
"      Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol 2001; 88:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/13\">",
"      EDWARDS JE. The congenital bicuspid aortic valve. Circulation 1961; 23:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/14\">",
"      Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 1997; 30:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/15\">",
"      Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/16\">",
"      Nihoyannopoulos P, Karas S, Sapsford RN, et al. Accuracy of two-dimensional echocardiography in the diagnosis of aortic arch obstruction. J Am Coll Cardiol 1987; 10:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/17\">",
"      Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/18\">",
"      Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 1999; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/19\">",
"      Niwa K, Perloff JK, Bhuta SM, et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001; 103:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/20\">",
"      Keane MG, Wiegers SE, Plappert T, et al. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. Circulation 2000; 102:III35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/21\">",
"      Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/22\">",
"      Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol 2004; 43:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/23\">",
"      Roberts CS, Roberts WC. Dissection of the aorta associated with congenital malformation of the aortic valve. J Am Coll Cardiol 1991; 17:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/24\">",
"      Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/25\">",
"      von Kodolitsch Y, Aydin MA, Koschyk DH, et al. Predictors of aneurysmal formation after surgical correction of aortic coarctation. J Am Coll Cardiol 2002; 39:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/26\">",
"      Oliver JM, Alonso-Gonzalez R, Gonzalez AE, et al. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta. Am J Cardiol 2009; 104:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/27\">",
"      Bonderman D, Gharehbaghi-Schnell E, Wollenek G, et al. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. Circulation 1999; 99:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/28\">",
"      de Sa M, Moshkovitz Y, Butany J, David TE. Histologic abnormalities of the ascending aorta and pulmonary trunk in patients with bicuspid aortic valve disease: clinical relevance to the ross procedure. J Thorac Cardiovasc Surg 1999; 118:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/29\">",
"      Fedak PW, de Sa MP, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 2003; 126:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/30\">",
"      Nataatmadja M, West M, West J, et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003; 108 Suppl 1:II329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/31\">",
"      Roberts WC, Morrow AG, McIntosh CL, et al. Congenitally bicuspid aortic valve causing severe, pure aortic regurgitation without superimposed infective endocarditis. Analysis of 13 patients requiring aortic valve replacement. Am J Cardiol 1981; 47:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/32\">",
"      Sadee AS, Becker AE, Verheul HA, et al. Aortic valve regurgitation and the congenitally bicuspid aortic valve: a clinico-pathological correlation. Br Heart J 1992; 67:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/33\">",
"      Lambert EC, Menon VA, Wagner HR, Vlad P. Sudden unexpected death from cardiovascular disease in children. A cooperative international study. Am J Cardiol 1974; 34:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/34\">",
"      Keane JF, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 1993; 87:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/35\">",
"      Hsieh KS, Keane JF, Nadas AS, et al. Long-term follow-up of valvotomy before 1968 for congenital aortic stenosis. Am J Cardiol 1986; 58:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/36\">",
"      Bastianon V, Del Bolgia F, Boscioni M, et al. Altered cardiac repolarization during exercise in congenital aortic stenosis. Pediatr Cardiol 1993; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/37\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/38\">",
"      Mills P, Leech G, Davies M, Leathan A. The natural history of a non-stenotic bicuspid aortic valve. Br Heart J 1978; 40:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/39\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/40\">",
"      Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6169/abstract/41\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8157 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6169=[""].join("\n");
var outline_f6_1_6169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H412885\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF LEFT VENTRICULAR OUTFLOW OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Valvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Subvalvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Supravalvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BICUSPID AORTIC VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Course in unoperated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk factors for stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated cardiovascular anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sudden death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical and laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Echocardiographic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Evaluation for aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recommendations for monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H412885\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8157|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/62/16355\" title=\"diagnostic image 1\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8157|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/52/22351\" title=\"movie 1\">",
"      M-mode echocardiogram of AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/17/27921\" title=\"movie 2\">",
"      Bicuspid aortic valve short axis echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?20/47/21235\" title=\"movie 3\">",
"      TEE bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/11/43196\" title=\"table 1\">",
"      Causes LV outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 2\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/4/36939\" title=\"table 3A\">",
"      Echo asymptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/35/17979\" title=\"table 3B\">",
"      Echo symptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/39/19068\" title=\"table 4\">",
"      ACC AHA evaluate congenital AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/18/14635\" title=\"table 5\">",
"      ACC AHA echo aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24107\" title=\"table 6\">",
"      Bicuspid AV dilated asc aorta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_1_6170="Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)";
var content_f6_1_6170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Cem Akin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/1/6170/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/1/6170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis refers to a group of disorders characterized by excessive mast cell accumulation in one or multiple tissues. Mastocytosis is subdivided into two groups of disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous mastocytosis (CM) describes forms of mastocytosis that are limited to the skin.",
"     </li>",
"     <li>",
"      Systemic mastocytosis (SM) describes forms of mastocytosis in which mast cells infiltrate extracutaneous organs, with or without skin involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, classification, and clinical manifestations of cutaneous and systemic mastocytosis will be reviewed here. The evaluation, diagnosis, treatment, and prognosis of mastocytosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link\">",
"     \"Treatment and prognosis of systemic mastocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis, in all its forms, is a rare disorder; the exact incidence is unknown. Mastocytosis affects males and females in equal ratios.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, 80 percent of mastocytosis cases appear during the first year of life, and the majority is limited to the skin. Most eventually improve or resolve completely by adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults who develop mastocytosis more often have systemic forms of the disease, and these disorders tend to persist [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells contain a variety of vasoactive mediators and normally function to protect the body from microbial invaders and other insults by releasing these chemicals to generate inflammatory responses. Mediators released from mast cells include histamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , leukotrienes, prostaglandins, platelet activating factor, proteases, and cytokines, including tumor necrosis factor (TNF) (",
"    <a class=\"graphic graphic_table graphicRef52832 \" href=\"UTD.htm?39/20/40267\">",
"     table 1",
"    </a>",
"    ). The signs and symptoms associated with sudden and extensive mast cell mediator release are those associated with allergic and anaphylactic reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of mastocytosis result from both chronic and episodic mast cell mediator release. In addition, some advanced forms of mastocytosis involve signs and symptoms arising from tissue infiltration by mast cells, effects of local accumulations of these cells, and the presence of an associated non-mast cell clonal hematologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Molecular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of mastocytosis is incompletely understood. Stem cell factor (SCF), also called kit ligand, is a growth factor that is essential for normal development and expansion of mast cells from hematopoietic progenitors. Mast cells express a receptor for SCF on their surface, the receptor tyrosine kinase c-kit (CD 117 or c-kit receptor). Many of the molecular defects associated with mastocytosis involve gain of function mutations in KIT, the gene encoding the c-kit receptor. There are limited data that SCF overexpression may play a role in some cases.",
"   </p>",
"   <p>",
"    Most other hematopoietic cells express c-kit receptor early in their development and then lose it during maturation, becoming unresponsive to SCF. Only mast cells maintain c-kit receptor and remain responsive to SCF throughout the lifetime of the cell. Thus, abnormalities in SCF regulation or c-kit receptor permanently affect the growth, differentiation, apoptosis, and activation of mast cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mutations in KIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating mutations of KIT have been implicated in the pathogenesis of both cutaneous and systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. The precise mechanism by which KIT activating mutations enhance signaling is not fully characterized, but these defects lead to SCF-independent activation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/10\">",
"     10",
"    </a>",
"    ]. Clonal expansion and apoptotic defects of KIT mutated mast cells are thought to provide the basis for pathologic accumulation of mast cells in tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several KIT mutations have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common mutation detected in human mast cell disease occurs in the codon 816 and consists of the substitution of valine for aspartate (Asp816Val). Asp816Val is present in most patients with systemic mastocytosis and in some patients with different forms of cutaneous mastocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/12-16\">",
"       12-16",
"      </a>",
"      ]. This mutation results in a putative activating loop in the kinase domain. In transfection studies, it causes ligand-independent autophosphorylation of the c-kit receptor and induces constitutive activation of the Stat5-PI3K-Akt signaling cascade [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/17\">",
"       17",
"      </a>",
"      ]. Mast cell signal transduction is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link&amp;anchor=H16#H16\">",
"       \"Mast cells: Surface receptors and signal transduction\", section on 'Signal transduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another mutation found in a neoplastic mast cell line (HMC-1) is rare in human disease. It is located at codon 560, in the so-called juxtamembrane domain between transmembrane and intracellular kinase domains. This mutation results in the loss of helical structure, and also induces constitutive activation of c-kit kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/8,18\">",
"       8,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other rare KIT mutations have been reported in mastocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/9\">",
"       9",
"      </a>",
"      ]. Non-activating mutations have been reported in some children with cutaneous mastocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    KIT mutations are somatic mutations in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]; they are rarely found in germline cells and are not polymorphisms, but can be found in some hematopoietic progenitor cells and other mature hematopoietic lineages in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/20\">",
"     20",
"    </a>",
"    ]. Rare familial cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/21\">",
"     21",
"    </a>",
"    ], but it is not clear if all of these patients had KIT mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Ten pairs of monozygotic twins have been described in whom symptoms and onset of disease were concordant, although several other reports describe twins with discordant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, although mastocytosis may be present at birth, it is neither inherited nor passed down to offspring in the great majority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Increased expression of stem cell factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased expression of SCF, the ligand for c-kit receptor, has been linked to mastocytosis lesions in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/25\">",
"     25",
"    </a>",
"    ]. SCF was found free in the dermis and the extracellular spaces between keratinocytes in skin samples of adults and children with cutaneous forms of mastocytosis, suggesting the increased presence of soluble SCF. Local mast cell hyperplasia was linked to increased free SCF. In these cases, there was no elevation of SCF in the peripheral blood and the mRNA sequence was not mutated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study demonstrated no differences in SCF levels in peripheral blood and skin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/26\">",
"     26",
"    </a>",
"    ], so this abnormality appears to be variable.",
"   </p>",
"   <p>",
"    In other studies of patients with systemic mastocytosis, increased mast cell numbers could be attributable to autocrine secretion of SCF by mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. SCF was bound to highly immature non-metachromatic mast cells in the peripheral blood. Membrane&ndash;bound SCF was also demonstrated in mature spleen and skin mast cells, as well as in bone marrow mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutive expression of the stress-related survival factor heat-shock protein 32 (Hsp32) in a human mast cell tumor line is another finding that may prove relevant to the pathogenesis of systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/29\">",
"     29",
"    </a>",
"    ]. Unregulated expression of Hsp32 has also been implicated in chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/30\">",
"     30",
"    </a>",
"    ]. Mutations in TET2, a tumor suppressor gene, have been identified in about one-third of patients with systemic mastocytosis, although there was no correlation between these mutations and subtype of disease or prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/31\">",
"     31",
"    </a>",
"    ]. Elevated levels of soluble interleukin (IL)-5 receptor &alpha; have also been noted, raising the possibility that new therapeutics targeting this molecule may be useful in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus clinical classification was published by the World Health Organization (WHO) in 2001 and updated in 2008, which represents the currently accepted clinical approach to categorizing mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cutaneous mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mastocytosis (CM) describes forms of mastocytosis limited to the skin, in the absence of involvement of other organs. Skin lesions in cutaneous mastocytosis may be subdivided into subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urticaria pigmentosa (UP), also called maculopapular cutaneous mastocytosis, is the most commonly diagnosed form of CM. There are several subtypes of UP:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Typical UP (",
"      <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Plaque form (",
"      <a class=\"graphic graphic_picture graphicRef61345 \" href=\"UTD.htm?6/35/6704\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodular form",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Telangiectasia macularis eruptiva perstans (TMEP) (",
"      <a class=\"graphic graphic_picture graphicRef52501 \" href=\"UTD.htm?9/51/10034\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72163 \" href=\"UTD.htm?20/44/21190\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59118 \" href=\"UTD.htm?13/13/13522\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    UP and TMEP represent forms of cutaneous mastocytosis when identified in isolation; however, they may also be found in patients with systemic mastocytosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse cutaneous mastocytosis (DCM) is rare (",
"      <a class=\"graphic graphic_picture graphicRef68182 \" href=\"UTD.htm?4/62/5090\">",
"       picture 6",
"      </a>",
"      ). Bullous forms have been reported (",
"      <a class=\"graphic graphic_picture graphicRef52257 \" href=\"UTD.htm?43/7/44145\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63556 \" href=\"UTD.htm?0/46/738\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Solitary mastocytoma(s) of the skin is typically identified in infants and young children (",
"      <a class=\"graphic graphic_picture graphicRef50284 \" href=\"UTD.htm?43/20/44354\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76891 \" href=\"UTD.htm?29/50/30497\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mastocytosis (SM) is defined as involvement of an extracutaneous site, most commonly the bone marrow, and includes four distinct disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indolent systemic mastocytosis (ISM), is the most common form of systemic mastocytosis. As implied by the name, ISM follows a stable or slowly progressing clinical course and carries a good prognosis in most patients. Two rarer provisional subvariants are also classified under ISM:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Smoldering systemic mastocytosis (SSM): This describes patients with a high mast cell burden as evidenced by involvement of &gt;30 percent of the bone marrow space with mast cells and high tryptase levels &gt;200",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      liver or spleen enlargement without signs of hypersplenism or functional liver impairment, and subtle signs of myelodysplasia or myeloproliferation without overt diagnostic findings for myelodysplastic syndrome or myeloproliferative disorder.",
"     </li>",
"     <li>",
"      Isolated bone marrow mastocytosis (BMM): This describes patients with bone marrow involvement but without skin involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic mastocytosis with an associated hematologic non-mast cell lineage disorder",
"      <strong>",
"      </strong>",
"      (SM-AHNMD):",
"      <strong>",
"      </strong>",
"      The associated disorder may be myeloproliferative, myelodysplastic, or lymphoproliferative.",
"     </li>",
"     <li>",
"      Aggressive systemic mastocytosis (ASM): Patients with ASM have tissue dysfunction such as hepatic fibrosis and portal hypertension, malabsorption, or cytopenias due to aggressive tissue infiltration by mast cells.",
"     </li>",
"     <li>",
"      Mast cell leukemia (MCL): This is a rare category of SM characterized by presence of greater than 10 percent immature mast cells in the peripheral blood or greater than 20 percent immature mast cells in bone marrow smears in a nonspicular area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Solid mast cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of solid mast cell tumors, which are rare and are not categorized as either cutaneous or systemic mastocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mast cell sarcoma (MCS): These malignant tumors have been reported in the tibia, skull, and other bones [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extracutaneous mastocytoma: These benign tumors are composed of mature mast cells and are located in a tissue other than skin, such as the lung or skull, sometimes in older-aged patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of mastocytosis may be grouped as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin findings (which may be present in both cutaneous and systemic forms of mastocytosis).",
"     </li>",
"     <li>",
"      Symptoms arising from mediator release (which may be present in both cutaneous and systemic forms of mastocytosis, as well as solid mast cell tumors).",
"     </li>",
"     <li>",
"      Symptoms arising from (non-cutaneous) organ infiltration (which are only present in systemic forms of mastocytosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Darier's sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier's sign is defined as the development of urticaria and erythema (within about five minutes) of rubbing, scratching, or stroking skin or skin lesions that are heavily infiltrated with mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/40\">",
"     40",
"    </a>",
"    ]. This finding arises when physical irritation triggers the localized release of mast cell mediators. Darier's sign is present in various forms of mastocytosis involving the skin, including UP, diffuse cutaneous mastocytosis, and mastocytomas (although the latter should not be purposefully rubbed, as this can precipitate symptoms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Skin findings and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulations of mast cells in the skin may present as urticaria pigmentosa (eg, maculopapular CM), diffuse cutaneous mastocytosis, or cutaneous mastocytoma, as mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The most common complaint is pruritus, especially after exposure to a trigger such as physical irritation or heat [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients and caregivers may also report flushing or blister formation. Urticaria is uncommon and recurrent prominent urticaria should prompt consideration of other allergic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Urticaria pigmentosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria pigmentosa (UP) is the most common manifestation of mastocytosis in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/42\">",
"     42",
"    </a>",
"    ]. Lesions of UP are characterized by small yellow-tan to reddish&ndash;brown macules or slightly raised papules (",
"    <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"     picture 1",
"    </a>",
"    ). Nodules or plaque-like lesions may also occur (",
"    <a class=\"graphic graphic_picture graphicRef61345 \" href=\"UTD.htm?6/35/6704\">",
"     picture 2",
"    </a>",
"    ). The upper and lower extremities are most commonly affected, followed by the thorax and abdomen. In adults, the palms, soles, face, scalp, and other sun exposed areas generally remain free of lesions. In children, the face and scalp may be involved.",
"   </p>",
"   <p>",
"    Pruritus associated with urticaria pigmentosa may be exacerbated by changes in temperature, exercise, hot showers, local friction, ingestion of hot beverages, spicy food, ethanol, emotional stress, or certain drugs. Bullous eruptions with hemorrhage can also occur in children, a feature that is shared with diffuse cutaneous mastocytosis.",
"   </p>",
"   <p>",
"    As stated previously, UP can represent a form of cutaneous mastocytosis, or may be a cutaneous manifestation in patients with systemic mastocytosis. In those with systemic disease, UP is more typical of the less aggressive forms. Specifically, UP is found in over 90 percent of patients with systemic indolent mastocytosis, but in less than 50 percent of those with mastocytosis associated with a hematologic disorder (SM-AHNMD) or with ASM [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various KIT mutations have been identified in patients with UP, none of which predict an association with systemic disease. The Asp816Val mutation has been found in skin mast cells of adult patients with UP, and in some affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/15,43\">",
"     15,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Mutations in KIT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Telangiectasia macularis eruptiva perstans",
"      </strong>",
"      &mdash; Telangiectasia macularis eruptiva perstans (TMEP) is the least frequent form of cutaneous mastocytosis, accounting for less than 1 percent of cases. It occurs mainly in adults and is characterized by tan to brown macules with telangiectasias (",
"      <a class=\"graphic graphic_picture graphicRef52501 \" href=\"UTD.htm?9/51/10034\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72163 \" href=\"UTD.htm?20/44/21190\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59118 \" href=\"UTD.htm?13/13/13522\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/44\">",
"       44",
"      </a>",
"      ]. There is an increase in the mast cells around capillaries and venules of the superficial vascular plexus. Pruritus and blisters are not seen. Rarely, it is associated with systemic involvement.",
"      <br/>",
"      <br/>",
"      The diagnosis of TMEP should NOT be based on the findings in a skin biopsy alone without observation of the physical lesion, as mast cells can be found around blood vessels in healthy or inflamed skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mastocytomas of the skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary or multiple mastocytomas of the skin are less common than UP and usually present in childhood (",
"    <a class=\"graphic graphic_picture graphicRef50284 \" href=\"UTD.htm?43/20/44354\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76891 \" href=\"UTD.htm?29/50/30497\">",
"     picture 10",
"    </a>",
"    ). Spontaneous involution is frequently observed.",
"   </p>",
"   <p>",
"    Lesions are similar in quality to those of urticaria pigmentosa, but can be larger (up to several centimeters) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/45\">",
"     45",
"    </a>",
"    ]. Some mastocytomas have a yellow to orange coloration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/41\">",
"     41",
"    </a>",
"    ]. Bullae may be present, with typical localization in the extremities. Flushing may also occur, particularly after physical irritation of the tumor, so lesions should NOT be vigorously rubbed. Instead, the patient or caregiver can usually provide the history that flushing occurs if the lesions are disturbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diffuse cutaneous mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse cutaneous mastocytosis is the result of a diffuse mast cell infiltration in the dermis. Discrete lesions are not described. The skin appears either normal in color or possibly yellowish-brown, with increased thickness (",
"    <a class=\"graphic graphic_picture graphicRef68182 \" href=\"UTD.htm?4/62/5090\">",
"     picture 6",
"    </a>",
"    ). Involvement of the whole skin has been observed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous eruptions",
"      </strong>",
"      &mdash; Bullous eruptions with hemorrhage can occur in patients with diffuse cutaneous mastocytosis and urticaria pigmentosa (",
"      <a class=\"graphic graphic_picture graphicRef52257 \" href=\"UTD.htm?43/7/44145\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63556 \" href=\"UTD.htm?0/46/738\">",
"       picture 8",
"      </a>",
"      ). Eruptions can be spontaneous or triggered by infections or vaccinations. Blister fluid contains histamine, prostaglandins, and platelet activating factor. Blisters can be present at birth, and cutaneous mastocytosis should be considered in the differential of neonatal blistering disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"       \"Vesiculobullous and pustular lesions in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Symptoms arising from mediator release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell mediators induce vasodilation, hypotension, flushing, pruritus, syncope, abdominal pain, nausea, vomiting, diarrhea, fatigue, headache, cachexia, local anticoagulation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue remodeling and fibrosis (",
"    <a class=\"graphic graphic_table graphicRef52832 \" href=\"UTD.htm?39/20/40267\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with either CM or SM, release of mast cell mediators may occur in explosive episodes, presenting as apparent \"allergic\" reactions and anaphylaxis, or on a chronic basis, giving rise to problems such as chronic gastrointestinal complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Triggers for mediator release",
"    </span>",
"    &nbsp;&mdash;&nbsp;The release of mast cell mediators in patients with cutaneous and systemic mastocytosis may be precipitated by a variety of stimuli, although not all triggers cause mast cell degranulation in all patients. A careful history is often helpful in determining what can or cannot be tolerated by individual patients. Potential triggers include the following (",
"    <a class=\"graphic graphic_table graphicRef70309 \" href=\"UTD.htm?40/37/41563\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/49-54\">",
"     49-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications, including narcotics, opioids, NSAIDs, iodinated contrast agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and other antibiotics, and muscle relaxants used in anesthesia",
"     </li>",
"     <li>",
"      Physical factors, such as exercise, massage or friction applied to the skin, extremes of temperature, sudden temperature changes, and very spicy foods",
"     </li>",
"     <li>",
"      Surgical procedures or instrumentation (including biopsies or endoscopy)",
"     </li>",
"     <li>",
"      Alcohol ingestion",
"     </li>",
"     <li>",
"      Infections, including viral, bacterial, and parasitic",
"     </li>",
"     <li>",
"      Emotional stress",
"     </li>",
"     <li>",
"      Hymenoptera stings, either through non-allergic or IgE-mediated allergic mechanisms (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Concomitant allergic disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Toxic exposures, such as stings of jellyfish, snake bites, etc",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis can be observed in both cutaneous and systemic mastocytosis. Symptoms typically include flushing, syncope, gastrointestinal symptoms, and vascular collapse. Urticaria and angioedema occur less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/55\">",
"     55",
"    </a>",
"    ]. These reactions may result from either IgE-mediated allergy or non-specific activation of mast cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subset of patients with recurrent anaphylaxis, but without mastocytosis, has been reported to carry clonal markers of mast cell disease including D816V KIT mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anaphylaxis without identified IgE-mediated allergies appears to be particularly prevalent in males with indolent systemic mastocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic anaphylaxis to insect stings with negative skin and in vitro tests for venom-specific immunoglobulin E (IgE) has been described, and fatalities have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"       \"Fatal anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link\">",
"       \"Treatment and prognosis of systemic mastocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gastrointestinal complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal dysfunction caused by release of mast cell mediators can be observed in both cutaneous and systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/60\">",
"     60",
"    </a>",
"    ]. Gastrointestinal symptoms can be precipitated by the same triggers that cause systemic symptoms (",
"    <a class=\"graphic graphic_table graphicRef70309 \" href=\"UTD.htm?40/37/41563\">",
"     table 2",
"    </a>",
"    ). Signs and symptoms include abdominal pain, diarrhea, nausea, vomiting, peptic ulcer disease, and gastrointestinal bleeding.",
"   </p>",
"   <p>",
"    Abdominal pain and diarrhea were reported in up to 80 percent of patients with systemic mastocytosis, with duodenal ulceration and severe duodenitis in 30 to 50 percent of untreated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histamine and other mediators, released from local and distant mast cells, increase gastric acid secretion. Serum histamine concentrations may be elevated, particularly in the setting of ulcer disease, suggesting that circulating histamine contributes to basal acid hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diarrhea can result from increased motility induced by prostaglandin D2 (PGD2) secretion or from decreased rectal compliance and overactive rectal contractility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric manifestations, including depression, mood changes, lack of concentration, increased somnolence, irritability, and emotional instability, are frequently observed in patients with mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/49,62\">",
"     49,62",
"    </a>",
"    ]. These symptoms are sometimes referred to as \"mixed organic brain syndrome.\" These are typically ignored or undertreated before the diagnosis of mastocytosis is established. The precise cause of many of these manifestations is not known, although PGD2 is thought to increase somnolence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Musculoskeletal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse musculoskeletal pain of the long bones and a pain syndrome resembling fibromyalgia may be reported in patients with systemic mastocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19769724\">",
"    <span class=\"h4\">",
"     Osteopenia and osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients appears to be at increased risk of developing osteopenia and osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. This can be observed even in young adult men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Osteoporosis is fairly common in patients with indolent systemic mastocytosis (ISM) and may be due to effects of mast cell mediators such as histamine, tryptase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and cytokines (TNF, IL-6, TGF-beta) on bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. A bone densitometry is recommended to evaluate for osteoporosis in all patients with systemic mastocytosis.",
"   </p>",
"   <p>",
"    Patients with SM may also experience bone pain or fractures, especially of the vertebrae. Nerve damage can follow vertebral compression fractures, even in patients with ISM. Evaluation of these symptoms can reveal osteolytic, osteosclerotic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteopenic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. These presentations may be confused with metastatic malignancy. Skeletal scintigraphy and bone survey may be helpful in characterizing the extent of disease in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/72\">",
"     72",
"    </a>",
"    ]. The long bones and vertebrae are commonly affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Concomitant allergic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mastocytosis may have concomitant IgE-mediated allergic diseases, including allergic rhinitis, food and drug allergies, and Hymenoptera allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. They may also have asthma. The prevalence of allergic disorders in patients with mastocytosis (both cutaneous and systemic) appears to be similar to that of the general population (ie, between 20 and 30 percent in westernized nations) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/57,73,74\">",
"     57,73,74",
"    </a>",
"    ]. Total IgE levels are usually decreased in patients with mastocytosis, possibly due to binding to an increased number of mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mastocytosis are more susceptible to anaphylaxis during allergic reactions, particularly in response to Hymenoptera stings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/75\">",
"     75",
"    </a>",
"    ]. A prospective study found elevated baseline tryptase levels in 12 percent of patients with a history of systemic reactions to hymenoptera stings. Within this subset of patients with elevated baseline tryptase, 70 percent had anaphylactic reactions and 80 percent had diagnostic or subdiagnostic accumulations of aberrant mast cells in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Symptoms arising from organ infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proliferation of mast cells in specific organs can be seen in some forms of systemic mastocytosis. Non-cutaneous organs are not involved in cutaneous mastocytosis. The organ systems most often affected are the bone marrow, gastrointestinal tract, lymph nodes, liver, spleen, skeletal system, and genitourinary tract with the following clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/62,77,78\">",
"     62,77,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia and thrombocytopenia",
"     </li>",
"     <li>",
"      Hepatosplenomegaly, portal hypertension, and hypersplenism",
"     </li>",
"     <li>",
"      Malabsorption",
"     </li>",
"     <li>",
"      Lytic bone lesions and pathologic fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the respiratory and endocrine systems are seldom involved in patients with systemic mastocytosis, although patients with SM may have concomitant asthma at rates similar to the general population. The incidence of bacterial, fungal, or viral infections is not increased and patients are not immunocompromised unless there is an associated hematologic disorder affecting other cell lines (ie, neutrophils).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common hematologic abnormality is a mild to moderate anemia, which occurs in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/79\">",
"     79",
"    </a>",
"    ]. The etiology is probably multifactorial. Mast cells are not found in the circulation except in those with mast cell leukemia. In this disorder, greater than 10 percent or more of circulating nucleated cells may be mast cells.",
"   </p>",
"   <p>",
"    Eosinophilia is found in 25 percent of patients. In some patients, eosinophils exhibit the same phenotype as those in the hypereosinophilic syndrome or chronic eosinophilic leukemia (CEL) (ie, hypogranular and hypersegmented nuclei). Some patients with mastocytosis may have associated CEL (a clonal disorder), while others may have a reactive eosinophilia, possibly due to cytokine release [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Myeloproliferative HES variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A monocytosis can be found in patients with ASM or ASM-AHNMD, and is found in approximately one-half of patients with advanced mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/81\">",
"     81",
"    </a>",
"    ]. This may represent a sign of marrow dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myeloproliferative or myelodysplastic diseases are most commonly associated with SM-AHNMD, although lymphoproliferative diseases such as myeloma and lymphomas and secondary acute leukemias have also been reported. Most of these patients present with activating Asp816Val KIT mutations in the peripheral blood, indicating a multipotential hematopoietic clonal nature of the SM [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. Rare cases of systemic mastocytosis associated with myeloproliferative disorders exhibiting both c-kit D816V and JAK2 V617F mutations have been reported. Among the disorders that have been reported in association with systemic mastocytosis are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/82\">",
"     82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic myelomonocytic leukemia (CMML)",
"     </li>",
"     <li>",
"      Myelodysplastic syndromes (MDS)",
"     </li>",
"     <li>",
"      Unclassifiable myeloproliferative neoplasms (MPD)",
"     </li>",
"     <li>",
"      Hypereosinophilic syndrome",
"     </li>",
"     <li>",
"      Chronic eosinophilic leukemia",
"     </li>",
"     <li>",
"      Acute myeloid leukemia (especially that associated with t(8:21)(q22:q22))",
"     </li>",
"     <li>",
"      Plasma cell myeloma",
"     </li>",
"     <li>",
"      Hairy cell leukemia",
"     </li>",
"     <li>",
"      Polycythemia vera",
"     </li>",
"     <li>",
"      Hodgkin's and non-Hodgkin lymphoma",
"     </li>",
"     <li>",
"      Primary thrombocytopenia or thrombocythemia",
"     </li>",
"     <li>",
"      Chronic myeloid leukemia (CML)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excessive bleeding, which has been reported in some patients, may be due to the high levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    released from mast cells, and a prolonged bleeding time may be observed in skin areas infiltrated by mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. Another proposed mechanism involves proteolytic disruption of fibrinogen by tryptase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/87\">",
"     87",
"    </a>",
"    ]. Malabsorption of vitamin K may also contribute to a systemic bleeding diathesis. Abnormal bleeding has been observed in children with diffuse cutaneous mastocytosis, with one reported death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/88\">",
"     88",
"    </a>",
"    ]. However, in the authors&rsquo; experience, most patients with mastocytosis have normal coagulation studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Intestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease, steatorrhea, malabsorption, and hepatomegaly may occur when mast cells infiltrate the intestine or liver in aggressive systemic mastocytosis (ASM) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/27,89\">",
"     27,89",
"    </a>",
"    ]. Liver function tests may be elevated. Liver biopsy demonstrates an increased number of mast cells with eosinophilic infiltrates and extramedullary hematopoiesis, which is more prominent in ASM, systemic mastocytosis with an associated hematologic non-mast cell lineage disorder (SM-AHNMD), and mast cell leukemia (MCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/90\">",
"     90",
"    </a>",
"    ]. Portal hypertension and ascites may develop in these advanced categories of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Lymphoid tissues and spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph nodes and spleen are commonly infiltrated in all types of systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central and peripheral lymphadenopathy are noted in 20 to 60 percent of patients with indolent systemic mastocytosis (ISM), and in a higher proportion in those with SM-AHNMD, ASM, and MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?6/1/6170/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenomegaly is observed in 50 percent of patients with ISM, but in over 70 percent of those with SM-AHNMD, ASM, and MCL. A marked increased in weight (eg, 700 grams) may be seen. Hypersplenism (ie, nonimmune hemolytic anemia and other hematologic abnormalities) may cause hematologic abnormalities. Splenic enlargement can also cause left upper quadrant discomfort or external compression of other organs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis comprises a group of rare disorders of excessive mast cell proliferation and accumulation, which can be limited to the skin (cutaneous mastocytosis, CM) or involve bone marrow and other extracutaneous tissues (systemic mastocytosis, SM). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children are usually affected by cutaneous forms of mastocytosis. Most improve or resolve completely by adolescence. In contrast, adults more often present with systemic forms of mastocytosis and have persistent disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mast cell development is dependent upon stem cell factor and its receptor, c-kit. Activating mutations of KIT (the gene for the c-kit receptor protein) are strongly associated with both cutaneous and systemic forms of mastocytosis and thus have been implicated as the major contributor to the pathogenesis of mastocytosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous mastocytosis is further divided into three subtypes: maculopapular or urticaria pigmentosa, diffuse cutaneous mastocytosis, and solitary mastocytoma of the skin. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cutaneous mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic mastocytosis is divided into four distinct disorders: indolent systemic mastocytosis, systemic mastocytosis with an associated hematologic non-mast cell lineage disorder, aggressive systemic mastocytosis, and mast cell leukemia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systemic mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The many signs and symptoms of mastocytosis may be categorized into skin findings, symptoms due to release of mast cell mediators (",
"      <a class=\"graphic graphic_table graphicRef52832 \" href=\"UTD.htm?39/20/40267\">",
"       table 1",
"      </a>",
"      ), and symptoms arising from mast cell infiltration of organs other than the skin. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accumulations of mast cells in the skin can take various forms. Pruritus is the predominant symptom. The most common skin finding is urticaria pigmentosa (",
"      <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"       picture 1",
"      </a>",
"      ), which can be present in patients with either cutaneous or systemic mastocytosis. Other specific skin findings include solitary or multiple cutaneous mastocytomas (",
"      <a class=\"graphic graphic_picture graphicRef50284 \" href=\"UTD.htm?43/20/44354\">",
"       picture 9",
"      </a>",
"      ), diffuse cutaneous mastocytosis (",
"      <a class=\"graphic graphic_picture graphicRef68182 \" href=\"UTD.htm?4/62/5090\">",
"       picture 6",
"      </a>",
"      ), and telangiectasia macularis eruptiva perstans (TMEP) (",
"      <a class=\"graphic graphic_picture graphicRef59118 \" href=\"UTD.htm?13/13/13522\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Skin findings and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with both CM and SM, a variety of triggers can precipitate mast cell mediator release (",
"      <a class=\"graphic graphic_table graphicRef70309 \" href=\"UTD.htm?40/37/41563\">",
"       table 2",
"      </a>",
"      ). Release of mediators may occur in explosive episodes, presenting as apparent allergic reactions and anaphylaxis, or on a chronic basis, giving rise to problems such as chronic gastrointestinal complaints. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Symptoms arising from mediator release'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extracutaneous organ involvement is only present in systemic forms of mastocytosis. Depending on the organs involved, findings include steatorrhea, malabsorption, lymphadenopathy, splenomegaly, hematologic and liver abnormalities, and skeletal lesions. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Symptoms arising from organ infiltration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/1\">",
"      Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/2\">",
"      Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/3\">",
"      Kirshenbaum AS, Kettelhut BV, Metcalfe DD, Garriga MM. Mastocytosis in infants and children: recognition of patterns of skin disease. Allergy Proc 1989; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/4\">",
"      Kettelhut BV, Parker RI, Travis WD, Metcalfe DD. Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. A study of 17 patients. Am J Clin Pathol 1989; 91:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/5\">",
"      Akoglu G, Erkin G, Cakir B, et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol 2006; 20:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/6\">",
"      Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/7\">",
"      Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 1993; 142:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/8\">",
"      Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/9\">",
"      Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/10\">",
"      Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000; 14:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/11\">",
"      Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/12\">",
"      Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/13\">",
"      Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995; 92:10560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/14\">",
"      Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998; 83:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/15\">",
"      Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/16\">",
"      Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999; 96:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/17\">",
"      Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008; 112:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/18\">",
"      Hashimoto K, Tsujimura T, Moriyama Y, et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol 1996; 148:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/19\">",
"      Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002; 116:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/20\">",
"      Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002; 100:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/21\">",
"      Wasag B, Niedoszytko M, Piskorz A, et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011; 39:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/22\">",
"      Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy 1994; 73:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/23\">",
"      Fowler JF Jr, Parsley WM, Cotter PG. Familial urticaria pigmentosa. Arch Dermatol 1986; 122:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/24\">",
"      Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am 2000; 14:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/25\">",
"      Longley BJ Jr, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993; 328:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/26\">",
"      Brockow K, Akin C, Huber M, et al. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol 2002; 109:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/27\">",
"      Castells MC, Friend DS, Bunnell CA, et al. The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 1996; 98:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/28\">",
"      Akin C, Jaffe ES, Raffeld M, et al. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am J Clin Pathol 2002; 118:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/29\">",
"      Kondo R, Gleixner KV, Mayerhofer M, et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood 2007; 110:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/30\">",
"      Mayerhofer M, Florian S, Krauth MT, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 2004; 64:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/31\">",
"      Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/32\">",
"      Wilson TM, Maric I, Shukla J, et al. IL-5 receptor &alpha; levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol 2011; 128:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/33\">",
"      Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603.",
"     </a>",
"    </li>",
"    <li>",
"     Valent P, Horny LP, Li CY. Mastocytosis. In: World Health Organization classification of tumors. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues, Jaffe ES, Harris BL, Stein H, et al (Eds), IARC Press, 2001. p.291.",
"    </li>",
"    <li>",
"     Horny HP, Metcalfe DD, Bennett JM, et AL. Mastocytosis. In: World Health Organization Classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/36\">",
"      Brci�� L, Vuleti�� LB, Stepan J, et al. Mast-cell sarcoma of the tibia. J Clin Pathol 2007; 60:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/37\">",
"      Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 2003; 27:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/38\">",
"      Castells MC. Extracutaneous mastocytoma. J Allergy Clin Immunol 2006; 117:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/39\">",
"      Charrette EE, Mariano AV, Laforet EG. Solitary mast cell \"tumor\" of lung. Its place in the spectrum of mast cell disease. Arch Intern Med 1966; 118:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/40\">",
"      Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000; 14:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/41\">",
"      Vano-Galvan S, Alvarez-Twose I, De las Heras E, et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol 2011; 147:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/42\">",
"      CAPLAN RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963; 87:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/43\">",
"      Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/44\">",
"      Parkes Weber F, Rast H. Telangiectasia macularis eruptiva perstans- a telangiectasia and relatively pigmentless variety of urticaria pigmentosa of adults. Acta Derm Venereol (Stockh) 1935; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/45\">",
"      CHARGIN L, SACHS PM. Urticaria pigmentosa appearing as a solitary nodular lesion. AMA Arch Derm Syphilol 1954; 69:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/46\">",
"      Orkin M, Good RA, Clawson CC, et al. Bullous mastocytosis. Arch Dermatol 1970; 101:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/47\">",
"      Austen KF. Systemic mastocytosis. N Engl J Med 1992; 326:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/48\">",
"      Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997; 99:155.",
"     </a>",
"    </li>",
"    <li>",
"     Metcalfe DD. The mastocytosis syndrome. In: Fitzpatrick's dermatology in internal medicine, 5th ed, Freedburg IM, Eisen AZ, Wolff K, et aL (Eds), McGraw Hill, New York 1999. p.1902.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/50\">",
"      Ludolph-Hauser D, Ru&euml;ff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/51\">",
"      Koide T, Nakajima T, Makifuchi T, Fukuhara N. Systemic mastocytosis and recurrent anaphylactic shock. Lancet 2002; 359:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/52\">",
"      Kim DC, Horan R. Anaphylaxis to insect sting associated with urticaria pigmentosa. Allergy Asthma Proc 2003; 24:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/53\">",
"      Bridgman DE, Clarke R, Sadleir PH, et al. Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases. Anaesth Intensive Care 2013; 41:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/54\">",
"      Alvarez-Twose I, Bonadonna P, Matito A, et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol 2013; 131:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/55\">",
"      Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 2009; 39:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/56\">",
"      Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/57\">",
"      Gonz&aacute;lez de Olano D, de la Hoz Caballer B, N&uacute;&ntilde;ez L&oacute;pez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/58\">",
"      Kontou-Fili K. Patients with negative skin tests. Curr Opin Allergy Clin Immunol 2002; 2:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/59\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/60\">",
"      Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/61\">",
"      Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988; 95:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/62\">",
"      Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/63\">",
"      Kushnir-Sukhov NM, Brittain E, Reynolds JC, et al. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006; 139:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/64\">",
"      van der Veer E, van der Goot W, de Monchy JG, et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/65\">",
"      Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/66\">",
"      Lidor C, Frisch B, Gazit D, et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res 1990; 5:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/67\">",
"      Abramowitz JD, Weinerman SA. Osteoporosis as the sole manifestation of systemic mastocytosis in a young man. Endocr Pract 2012; 18:e158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/68\">",
"      Brumsen C, Papapoulos SE, Lentjes EG, et al. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002; 31:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/69\">",
"      Guillaume N, Desoutter J, Chandesris O, et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013; 126:75.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/70\">",
"      Rosenbaum RC, Frieri M, Metcalfe DD. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis. J Nucl Med 1984; 25:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/71\">",
"      Floman Y, Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J Spinal Disord 1991; 4:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/72\">",
"      Huang TY, Yam LT, Li CY. Radiological features of systemic mast-cell disease. Br J Radiol 1987; 60:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/73\">",
"      Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003; 48:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/74\">",
"      M&uuml;ller U, Helbling A, Hunziker T, et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/75\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/76\">",
"      Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/77\">",
"      Rogers MP, Bloomingdale K, Murawski BJ, et al. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986; 48:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/78\">",
"      Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002; 127:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/79\">",
"      Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/80\">",
"      Gotlib J, Akin C. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol 2012; 49:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/81\">",
"      Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990; 76:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/82\">",
"      Parker RI. Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/83\">",
"      Kauhanen P, Kovanen PT, Reunala T, Lassila R. Effects of skin mast cells on bleeding time and coagulation activation at the site of platelet plug formation. Thromb Haemost 1998; 79:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/84\">",
"      Koenig M, Morel J, Reynaud J, et al. An unusual cause of spontaneous bleeding in the intensive care unit - mastocytosis: a case report. Cases J 2008; 1:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/85\">",
"      Sucker C, Mansmann G, Steiner S, et al. Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost 2008; 14:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/86\">",
"      Arias M, Villalba C, Requena I, et al. Acute spinal epidural hematoma and systemic mastocytosis. Spine (Phila Pa 1976) 2004; 29:E161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/87\">",
"      Prieto-Garc&iacute;a A, Zheng D, Adachi R, et al. Mast cell restricted mouse and human tryptase&middot;heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen. J Biol Chem 2012; 287:7834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/88\">",
"      Murphy M, Walsh D, Drumm B, Watson R. Bullous mastocytosis: a fatal outcome. Pediatr Dermatol 1999; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/89\">",
"      Reisberg IR, Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 1987; 82:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/90\">",
"      Mican JM, Di Bisceglie AM, Fong TL, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/91\">",
"      Mekori YA. Lymphoid tissues and the immune system in mastocytosis. Hematol Oncol Clin North Am 2000; 14:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/1/6170/abstract/92\">",
"      Travis WD, Li CY. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol 1988; 1:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4786 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6170=[""].join("\n");
var outline_f6_1_6170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Molecular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mutations in KIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Increased expression of stem cell factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLASSIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Solid mast cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Darier's sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Skin findings and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Urticaria pigmentosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mastocytomas of the skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diffuse cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Symptoms arising from mediator release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Triggers for mediator release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gastrointestinal complaints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Musculoskeletal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19769724\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Concomitant allergic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Symptoms arising from organ infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Intestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Lymphoid tissues and spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4786|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/49/41746\" title=\"picture 1\">",
"      Urticaria pigmentosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/35/6704\" title=\"picture 2\">",
"      Masto cutaneous infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/51/10034\" title=\"picture 3\">",
"      TMEP I close up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/44/21190\" title=\"picture 4\">",
"      TMEP II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/13/13522\" title=\"picture 5\">",
"      TMEP III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/62/5090\" title=\"picture 6\">",
"      Diffuse cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44145\" title=\"picture 7\">",
"      Bullous eruption in SM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/46/738\" title=\"picture 8\">",
"      Infant with bullous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/20/44354\" title=\"picture 9\">",
"      Mastocytoma extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/50/30497\" title=\"picture 10\">",
"      Mastocytoma infant hand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/20/40267\" title=\"table 1\">",
"      Mast cell mediators in SM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/37/41563\" title=\"table 2\">",
"      Possible triggers of mast cell activation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_1_6171="Bisphosphonates in order of potency";
var content_f6_1_6171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bisphosphonates listed in order of increasing potency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Simple bisphosphonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etidronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiludronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clodronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nitrogen-containing bisphosphonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pamidronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alendronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neridronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibandronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risedronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zoledronic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6171=[""].join("\n");
var outline_f6_1_6171=null;
var title_f6_1_6172="Causes of Cushings syndrome";
var content_f6_1_6172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of causes of Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\" rowspan=\"1\">",
"        ACTH-dependent",
"Cushing's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cushing's disease",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ectopic ACTH syndrome",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ectopic CRH syndrome",
"       </td>",
"       <td>",
"        &lt;&lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\" rowspan=\"1\">",
"        ACTH-independent",
"Cushing's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenal adenoma",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenal carcinoma",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micronodular hyperplasia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Macronodular hyperplasia",
"       </td>",
"       <td>",
"        &lt;&lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\" rowspan=\"1\">",
"        Pseudo-Cushing's",
"syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major depressive disorder",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcoholism",
"       </td>",
"       <td>",
"        &lt;&lt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Relative prevalence of various causes of Cushing's syndrome in 630 patients (146 consecutive patients seen at Vanderbilt University Medical Center before 1993 and published reports describing 484 patients). The prevalence of pseudo-Cushing's syndrome depends upon the individual clinician's threshold of clinical suspicion; in our experience, it is very rare. The relative prevalence of various causes of Cushing's syndrome among children and adolescents may differ somewhat from that of adults. The ectopic ACTH syndrome, for example, is less common in children.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6172=[""].join("\n");
var outline_f6_1_6172=null;
var title_f6_1_6173="Laser treatment VAIN";
var content_f6_1_6173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laser treatment of vaginal intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients treated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurred after first treatment, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stafl",
"       </td>",
"       <td>",
"        1977",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        3-12 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petrelli",
"       </td>",
"       <td>",
"        1980",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2-12 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capen",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        4-28 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Townsend",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jobson",
"       </td>",
"       <td>",
"        1983",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        6-27 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Woodman",
"       </td>",
"       <td>",
"        1984",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        6-60 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Curtin",
"       </td>",
"       <td>",
"        1985",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        6-42 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lenchan",
"       </td>",
"       <td>",
"        1986",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        6-27 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stuart",
"       </td>",
"       <td>",
"        1988",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        6-38 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ireland",
"       </td>",
"       <td>",
"        1988",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        3-12 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krebs",
"       </td>",
"       <td>",
"        1989",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        12-84 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Audet-LaPointe",
"       </td>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        7-85 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hoffman",
"       </td>",
"       <td>",
"        1991",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        11-56 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diakomanolis",
"       </td>",
"       <td>",
"        1996",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        35-82 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supracordevole",
"       </td>",
"       <td>",
"        1998",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        3-12 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campagnutta",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        13-90 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dodge",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        &gt;7mo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6173=[""].join("\n");
var outline_f6_1_6173=null;
var title_f6_1_6174="Viral gastroenteritis signs";
var content_f6_1_6174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics of children hospitalized with acute gastroenteritis associated with rotavirus or with other causes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Clinical finding",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Rotavirus",
"infection (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Study 1*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Study 2&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Detected (N = 72)",
"       </td>",
"       <td class=\"subtitle3\">",
"        Not detected (N = 78)",
"       </td>",
"       <td class=\"subtitle3\">",
"        Detected (N = 242)",
"       </td>",
"       <td class=\"subtitle3\">",
"        Not detected (N = 590)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        93&bull;",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"       <td>",
"        96&bull;",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        88&bull;",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        37.9-39.0&ordm;C",
"       </td>",
"       <td class=\"sublist_other\">",
"        46",
"       </td>",
"       <td class=\"sublist_other\">",
"        29",
"       </td>",
"       <td class=\"sublist_other\">",
"        24",
"       </td>",
"       <td class=\"sublist_other\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;39&ordm;C",
"       </td>",
"       <td class=\"sublist_other\">",
"        31",
"       </td>",
"       <td class=\"sublist_other\">",
"        33",
"       </td>",
"       <td class=\"sublist_other\">",
"        45&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        None",
"       </td>",
"       <td class=\"sublist_other\">",
"        23",
"       </td>",
"       <td class=\"sublist_other\">",
"        38",
"       </td>",
"       <td class=\"sublist_other\">",
"        31",
"       </td>",
"       <td class=\"sublist_other\">",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dehydration",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        83&bull;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        40",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertonic",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        17",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isotonic",
"       </td>",
"       <td class=\"sublist_other\">",
"        95&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        77",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypotonic",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lethargy",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngeal erythema",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhinitis",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red tympanic membrane with loss of landmarks",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhonchi or wheezing",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable cervical lymph nodes",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        9&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0 to 6 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        22&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        47&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6 to 11 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        26",
"       </td>",
"       <td class=\"sublist_other\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        12 to 17 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        22",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        18 to 23 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        24 to 35 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        13",
"       </td>",
"       <td class=\"sublist_other\">",
"        9&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        36 to 47 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        48 to 59 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &bull; P value &lt;0.05 within that study.",
"    </div>",
"    <div class=\"reference\">",
"     * Data from Rodriguez WJ, Kim HW, Arrobio JO, et al, J Pediatr 1977; 91:188.",
"     <br>",
"      &Delta; Data from Staat MA, Azimi P, Berke T, et al, Pediatr Inf Dis J 2002; 21:221. Additional study months are included to complete one year of study.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6174=[""].join("\n");
var outline_f6_1_6174=null;
var title_f6_1_6175="Fracture scheme proximal fifth metatarsal";
var content_f6_1_6175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Schematic representation of fracture zones for proximal fifth metatarsal fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_1_6175=[""].join("\n");
var outline_f6_1_6175=null;
